

Curriculum Vitae Fortunato Ciardiello

Personal Information

E-mail fortunato.ciardiello@unicampania.it

Citizenship Italian

DOB 04 August 1960

Work Address Via Sergio Pansini 5, 80131 Napoli
Work Telephone 0039 0815666760
Fax 0039 0815666688

Position

Dec 2008 – present Full Professor of Medical Oncology;
Dec 2010 – present Director of Department of Clinical and Experimental medicine;
Jul 2012 – 2016 Member of Academic Senate of the University of the study of the Campania
“L.Vanvitelli”;
Nov 2010 – present Head, Division of Medical Oncology and Hematology;
Apr 2007 – present Head, Laboratory of Molecular targeted Cancer Therapies;
Scientific Member of the Ethics Committee for Clinical Research;
Responsible for Integrated Course in Medical Oncology and Hematology, Medical
School.

Work Experience

Jul 1986 – Dec 1990

Visiting Fellow - National Cancer Institute, Bethesda – USA

Business or sector Tumor Growth Factor Section, Laboratory of Tumor Immunology and
Biology

Dec 1990 - Oct 2002

Assistant Professor - Dipartimento di Endocrinologia e Oncologia Molecolare e
Clinica, Università di Napoli “Federico II”, Naples (Italy)

Nov 2002 – Nov 2008

Associate Professor - Dipartimento di Internistica Clinica e Sperimentale "F. Magrassi",
Università degli Studi della Campania "L. Vanvitelli", Naples (Italy).

Education and Training

Period	Jul 1984
Title	Medicine School MD degree - Università di Napoli "Federico II", Naples (Italy)
Period	Dec 1987
Title	Specialty in Oncology - Università di Napoli "Federico II", Naples (Italy)
Period	Jun 1992
Title	Ph.D degree in Molecular Biology and Pathology - Università di Napoli "Federico II", Naples (Italy)

Languages

Mother tongue(s) **Italian**

Other language(s) **English**

autoevaluation
European level ()*

English

Comprensione				Parlato				Scritto	
Listened		Readen		Interazione orale		Produzione orale			
C2	Utente avanzato	C2	Utente avanzato	C2	Utente avanzato	C2	Utente avanzato	C2	Utente avanzato

(*) [*Quadro comune europeo di riferimento per le lingue*](#)

ADDITIONAL INFORMATION

Honours and awards

November 2000: “Guido Venosta” Italian National Award for “Development of novel anticancer therapeutic approaches”, Fondazione Italiana per la Ricerca sul Cancro (FIRC), Milan, Italy.

October 2005: Pfizer Visiting Professor in Medical Oncology, Division of Medical Oncology; School of Medicine, University of Colorado Cancer Center, Aurora, Colorado, USA.

December 2013: Serono Symposia International Foundation “International Award in Oncology”.

Main Areas of Research Interest

Scientific Boards

- European Society of Medical Oncology (ESMO) Educational Committee Member (2007-2010);
- ESMO Executive Committee Member and Treasurer (2011-2013);
- ESMO Press and Media Working Group Chief (2011-2013);
- ESMO Executive Committee Member and President Elect (2014-2015);
- ESMO Executive Committee Member and President (2016-2017);
- Scientific Council Member of the Molecular Targeted Therapy of Cancer (MTTC) European Educational Initiative in Medical Oncology (2002-2012);
- Member of the Scientific Committee of the Italian Association for Cancer research (AIRC), the most important Charity supporting Cancer Research in Italy (2008-2013).

Editorial Boards of Scientific Journals

- Annals of Oncology
- Clinical Cancer Research
- Oncology Reports
- International Journal of Oncology
- Targeted Oncology
- Current Cancer Therapy Reviews

Scientific Societies Membership

- American Association for Cancer Research (AACR)
- American Society of Clinical Oncology (ASCO)
- Italian Association of Medical Oncology (AIOM)
- Italian Society of Cancerology (SIC)
- European Society of Medical Oncology (ESMO)

Participation to several clinical trials about Oncology as Principal Investigator, in compliance with GCP guidelines

PUBLICATIONS

PUBBLICAZIONI

1. GRAZIANI V, SCOGNAMIGLIO M, BELLI V, ESPOSITO A, D'ABROSCA B, CHAMBERY A, RUSSO R, PANELLA M, RUSSO A, CIARDIELLO F, TROIANI T, POTENZA N, FIORENTINO A. METABOLOMIC APPROACH FOR A RAPID IDENTIFICATION OF NATURAL PRODUCTS WITH CYTOTOXIC ACTIVITY AGAINST HUMAN COLORECTAL CANCER CELLS. *SCI REP.* 2018 MAR 28;8(1):5309. DOI: 10.1038/S41598-018-23704-9. PUBMED PMID: 29593231; PUBMED CENTRAL PMCID: PMC5871890
2. DELLA CORTE CM, CIARAMELLA V, CARDONE C, LA MONICA S, ALFIERI R, PETRONINI PG, MALAPELLE U, VIGLIAR E, PEPE F, TRONCONE G, CASTELLONE MD, TROIANI T, MARTINELLI E, CIARDIELLO F, MORGILLO F. ANTITUMOR EFFICACY OF DUAL BLOCKADE OF EGFR SIGNALING BY OSIMERTINIB IN COMBINATION WITH SELUMETINIB OR CETUXIMAB IN ACTIVATED EGFR HUMAN NSCLC TUMOR MODELS. *J THORAC ONCOL.* 2018 MAR 8. PII: S1556-0864(18)30181-3. DOI: 10.1016/J.JTHO.2018.02.025. [EPUB AHEAD OF PRINT] PUBMED PMID: 29526823.
3. PINTO C, DI BISCEGLIE M, DI FABIO F, BOCHICCHIO A, LATIANO T, CORDIO S, ROSATI G, ASCHELE C, MARINO A, BERGAMO F, BUSTREO S, FRASSINETI L, CIARDIELLO F, DAMATO A, GIAQUINTA S, BALDARI D, BONI L. PHASE II STUDY OF PREOPERATIVE TREATMENT WITH EXTERNAL RADIOTHERAPY PLUS PANITUMUMAB IN LOW-RISK, LOCALLY ADVANCED RECTAL CANCER (RAP STUDY/STAR-03). *ONCOLOGIST.* 2018 MAR 9. PII: THEONCOLOGIST.2017-0484. DOI: 10.1634/THEONCOLOGIST.2017-0484. [EPUB AHEAD OF PRINT] PUBMED PMID: 29523646.
4. DE PLACIDO S, GALLO C, DE LAURENTIIS M, BISAGNI G, ARPINO G, SAROBBA MG, RICCARDI F, RUSSO A, DEL MASTRO L, COGONI AA, COGNETTI F, GORI S, FOGLIETTA J, FRASSOLDATI A, AMOROSO D, LAUDADIO L, MOSCETTI L, MONTEMURRO F, VERUSIO C, BERNARDO A, LORUSSO V, GRAVINA A, MORETTI G, LAURIA R, LAI A, MOCERINO C, RIZZO S, NUZZO F, CARLINI P, PERRONE F; GIM INVESTIGATORS. ADJUVANT ANASTROZOLE VERSUS EXEMESTANE VERSUS LETROZOLE, UPFRONT OR AFTER 2 YEARS OF TAMOXIFEN, IN ENDOCRINE-SENSITIVE BREAST CANCER (FATA-GIM3): A RANDOMISED, PHASE 3 TRIAL. *LANCET ONCOL.* 2018 APR;19(4):474-485. DOI: 10.1016/S1470-2045(18)30116-5. EPUB 2018 FEB 23. ERRATUM IN: *LANCET ONCOL.* 2018 APR;19(4):E184. PUBMED PMID:29482983.
5. AMERI P, CANEPA M, ANKER MS, BELENKOV Y, BERGLER-KLEIN J, COHEN-SOLAL A, FARMAKIS D, LÓPEZ-FERNÁNDEZ T, LAINSCAK M, PUDIL R, RUSCHITSKA F, SEFEROVIC P, FILIPPATOS G, COATS A, SUTER T, VON HAEHLING S, CIARDIELLO F, DE BOER RA, LYON AR, TOCCHETTI CG; HEART FAILURE ASSOCIATION CARDIO-ONCOLOGY STUDY GROUP OF THE EUROPEAN SOCIETY OF CARDIOLOGY. CANCER DIAGNOSIS IN PATIENTS WITH HEART FAILURE: EPIDEMIOLOGY, CLINICAL IMPLICATIONS AND GAPS IN KNOWLEDGE. *EUR J HEART FAIL.* 2018 FEB 21. DOI: 10.1002/EJHF.1165. [EPUB AHEAD OF PRINT] REVIEW. PUBMED PMID: 29464808.
6. PRAGER GW, BRAGA S, BYSTRICKY B, QVORTRUP C, CRISCITIELLO C, ESIN E, SONKE GS, MARTÍNEZ GA, FRENEL JS, KARAMOUZIS M, STRIJBOS M, YAZICI O, BOSSI P, BANERJEE S, TROIANI T, ENIU A, CIARDIELLO F, TABERNERO J, ZIELINSKI CC, CASALI PG, CARDOSO F, DOUILLARD JY, JEZDIC S, MCGREGOR K, BRICALLI G, VYAS M, ILBAWI A. GLOBAL CANCER CONTROL: RESPONDING TO THE GROWING BURDEN, RISING COSTS AND INEQUALITIES IN ACCESS. *ESMO OPEN.* 2018 FEB 2;3(2):E000285. DOI: 10.1136/ESMOOPEN-2017-000285. ECOLLECTION 2018. PUBMED PMID: 29464109; PUBMED CENTRAL PMCID: PMC5812392.
7. DELLA CORTE CM, VISCARDI G, DI LIELLO R, FASANO M, MARTINELLI E, TROIANI T, CIARDIELLO F, MORGILLO F. ROLE AND TARGETING OF ANAPLASTIC LYMPHOMA KINASE IN CANCER. *MOL CANCER.* 2018 FEB 19;17(1):30. DOI: 10.1186/S12943-018-0776-2. REVIEW. PUBMED PMID: 29455642; PUBMED CENTRAL PMCID: PMC5817803.

8. MONTAGUT C, ARGILÉS G, CIARDIELLO F, POULSEN TT, DIENSTMANN R, KRAGH M, KOPETZ S, LINDSTED T, DING C, VIDAL J, CLAUSELL-TORMOS J, SIRAVEGNA G, SÁNCHEZ-MARTÍN FJ, KOEFOED K, PEDERSEN MW, GRANDAL MM, DVORKIN M, WYRWICZ L, ROVIRA A, CUBILLO A, SALAZAR R, DESSEIGNE F, NADAL C, ALBANELL J, ZAGONEL V, SIENA S, FUMI G, ROSPO G, NADLER P, HORAK ID, BARDELLI A, TABERNERO J. EFFICACY OF SYM004 IN PATIENTS WITH METASTATIC COLORECTAL CANCER WITH ACQUIRED RESISTANCE TO ANTI-EGFR THERAPY AND MOLECULARLY SELECTED BY CIRCULATING TUMOR DNA ANALYSES: A PHASE 2 RANDOMIZED CLINICAL TRIAL. *JAMA ONCOL*. 2018 FEB 8;E175245. DOI: 10.1001/JAMAONCOL.2017.5245 [EPUB AHEAD OF PRINT] PUBMED PMID: 29423521.
9. REGINELLI A, CLEMENTE A, CARDONE C, URRARO F, IZZO A, MARTINELLI E, TROIANI T, CIARDIELLO F, BRUNESE L, CAPPABIANCA S. COMPUTED TOMOGRAPHY DENSITOMETRIC STUDY OF ANTI-ANGIOGENIC EFFECT OF REGORAFENIB IN COLORECTAL CANCER LIVER METASTASIS. *FUTURE ONCOL*. 2018 FEB 13. DOI: 10.2217/FON-2017-0687. [EPUB AHEAD OF PRINT] PUBMED PMID: 29433345.
10. GRIDELLI C, BAAS P, BARLESI F, CIARDIELLO F, CRINÒ L, FELIP E, GADGEEL S, PAPANIMITRAKOPOULOU V, PAZ-ARES L, PLANCHARD D, PEROL M, HANNA N, SGAMBATO A, CASALUCE F, DE MARINIS F. SECOND-LINE TREATMENT OPTIONS IN NON-SMALL-CELL LUNG CANCER: REPORT FROM AN INTERNATIONAL EXPERTS PANEL MEETING OF THE ITALIAN ASSOCIATION OF THORACIC ONCOLOGY. *CLIN LUNG CANCER*. 2017 DEC 22. PII: S1525-7304(17)30349-2. DOI: 10.1016/J.CLLC.2017.12.010. [EPUB AHEAD OF PRINT] REVIEW. PUBMED PMID: 29396237.
11. MARTINELLI E, TROIANI T, SFORZA V, MARTINI G, CARDONE C, VITIELLO PP, CIARDIELLO D, RACHIGLIO AM, NORMANNO N, SARTORE-BIANCHI A, MARSONI S, BARDELLI A, SIENA S, CIARDIELLO F. SEQUENTIAL HER2 BLOCKADE AS EFFECTIVE THERAPY IN CHEMOREFRACTORY, HER2 GENE-AMPLIFIED, RAS WILD-TYPE, METASTATIC COLORECTAL CANCER: LEARNING FROM A CLINICAL CASE. *ESMO OPEN*. 2018 JAN 10;3(1):E000299. DOI: 10.1136/ESMOOPEN-2017-000299. ECOLLECTION 2018. PUBMED PMID: 29387480; PUBMED CENTRAL PMCID: PMC5786925.
12. VAN CUTSEM E, MAYER RJ, LAURENT S, WINKLER R, GRÁVALOS C, BENAVIDES M, LONGO-MUNOZ F, PORTALES F, CIARDIELLO F, SIENA S, YAMAGUCHI K, MURO K, DENDA T, TSUJI Y, MAKRIS L, LOEHRER P, LENZ HJ, OHTSU A; RECOURSE STUDY GROUP. THE SUBGROUPS OF THE PHASE III RECOURSE TRIAL OF TRIFLURIDINE/TIPIRACIL (TAS-102) VERSUS PLACEBO WITH BEST SUPPORTIVE CARE IN PATIENTS WITH METASTATIC COLORECTAL CANCER. *EUR J CANCER*. 2018 FEB;90:63-72. DOI: 10.1016/J.EJCA.2017.10.009. EPUB 2017 DEC 21. PUBMED PMID: 29274618.
13. NAPOLITANO S, CIARDIELLO F. NOVEL IN VITRO CANCER MODELS FOR OPTIMIZING ANTI-EGFR THERAPIES. *CLIN CANCER RES*. 2018 FEB 15;24(4):727-729. DOI: 10.1158/1078-0432.CCR-17-2937. EPUB 2017 DEC 8. PUBMED PMID: 29222163.
14. MARTINELLI E, SFORZA V, CARDONE C, CAPASSO A, NAPPI A, MARTINI G, NAPOLITANO S, RACHIGLIO AM, NORMANNO N, CAPPABIANCA S, REGINELLI A, BISCEGLIE MD, LATIANOT P, MAIELLO E, ORDITURA M, DE VITA F, MORGILLO F, CIARDIELLO F, TROIANI T. CLINICAL OUTCOME AND MOLECULAR CHARACTERISATION OF CHEMOREFRACTORY METASTATIC COLORECTAL CANCER PATIENTS WITH LONG-TERM EFFICACY OF REGORAFENIB TREATMENT. *ESMO OPEN*. 2017 JUL 29;2(3):E000177. DOI: 10.1136/ESMOOPEN-2017-000177. ECOLLECTION 2017. PUBMED PMID: 29211816; PUBMED CENTRAL PMCID: PMC5703385.
15. CIARDIELLO F, TABERNERO J. THE CANCER MOONSHOT FROM A EUROPEAN PERSPECTIVE. *LANCET ONCOL*. 2017 NOV;18(11):E626. DOI: 10.1016/S1470-2045(17)30798-2. EPUB 2017 OCT 31. PUBMED PMID: 29208380.
16. YOSHINO T, ARNOLD D, TANIGUCHI H, PENTHEROUDAKIS G, YAMAZAKI K, XU RH, KIM TW, ISMAIL F, TAN IB, YEH KH, GROTHEY A, ZHANG S, AHN JB, MASTURA MY, CHONG D, CHEN LT, KOPETZ S, EGUCHI-NAKAJIMA T, EBI H, OHTSU A, CERVANTES A, MURO K, TABERNERO J, MINAMI H, CIARDIELLO F, DOUILLARD JY. PAN-ASIAN ADAPTED ESMO CONSENSUS GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER: A JSMO-ESMO INITIATIVE ENDORSED BY CSCO, KACO, MOS, SSO AND TOS. *ANN ONCOL*. 2018 JAN 1;29(1):44-70. DOI: 10.1093/ANNONC/MDX738. PUBMED PMID: 29155929.
17. NAPOLITANO S, MARTINI G, MARTINELLI E, DELLA CORTE CM, MORGILLO F, BELLIV V, CARDONE C, MATRONE N, CIARDIELLO F, TROIANI T. ANTITUMOR EFFICACY OF TRIPLE MONOCLONAL ANTIBODY INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) WITH MM151 IN EGFR-DEPENDENT AND IN CETUXIMAB-RESISTANT HUMAN COLORECTAL CANCER CELLS. *ONCOTARGET*. 2017 AUG 2;8(47):82773-82783. DOI: 10.18632/ONCOTARGET.19797. ECOLLECTION 2017 OCT 10. PUBMED PMID: 29137301; PUBMED CENTRAL PMCID: PMC5669927.
18. MORGILLO F, DELLA CORTE CM, DIANA A, MAURO CD, CIARAMELLA V, BARRA G, BELLIV, FRANZESE E, BIANCO R, MAIELLO E, DE VITA F, CIARDIELLO F, ORDITURA M. PHOSPHATIDYLINOSITOL 3-KINASE

- (PI3KA)/AKT AXIS BLOCKADE WITH TASELISIB ORIPATASERTIB ENHANCES THE EFFICACY OF ANTI-MICROTUBULE DRUGS IN HUMAN BREASTCANCER CELLS. *ONCOTARGET*. 2017 AUG 22;8(44):76479-76491. DOI:10.18632/ONCOTARGET.20385. ECOLLECTION 2017 SEP 29. PUBMED PMID: 29100327; PUBMED CENTRAL PMCID: PMC5652721.
19. LATERZA MM, POMPELLA L, PETRILLO A, TIRINO G, PAPPALARDO A, ORDITURA M, TROIANI T, CIARDIELLO F, DI MARTINO N, DE VITA F. EFFICACY OF A TRIPLET AND DOUBLET-BASED CHEMOTHERAPY AS FIRST-LINE THERAPY IN PATIENTS WITH HER2-NEGATIVE METASTATIC GASTRIC CANCER: A RETROSPECTIVE ANALYSIS FROM THE CLINICAL PRACTICE. *MED ONCOL*. 2017 OCT 17;34(11):186. DOI: 10.1007/S12032-017-1046-7. PUBMED PMID:29043514.
 20. SFORZA V, MARTINELLI E, CARDONE C, MARTINI G, NAPOLITANO S, VITIELLO PP, VITALE P, ZANALETI N, REGINELLI A, BISCEGLIE MD, LATIANO TP, BOCHICCHIO AM, CECERE F, SELVAGGI F, CIARDIELLO F, TROIANI T. CLINICAL OUTCOME OF PATIENTS WITH CHEMOREFRACTORY METASTATIC COLORECTAL CANCER TREATED WITH TRIFLURIDINE/TIPIRACIL (TAS-102): A SINGLE ITALIAN INSTITUTION COMPASSIONATE USE PROGRAMME. *ESMO OPEN*. 2017 SEP 21;2(4):E000229. DOI: 10.1136/ESMOOPEN-2017-000229. ECOLLECTION 2017. PUBMED PMID: 29018575; PUBMED CENTRAL PMCID: PMC5623320.
 21. BELLI V, SFORZA V, CARDONE C, MARTINELLI E, BARRA G, MATRONE N, NAPOLITANO S, MORGILLO F, TUCCILLO C, FEDERICO A, DALLIO M, LOGUERCIO C, GRAVINA AG, DE PALMAR, CIARDIELLO F, TROIANI T. REGORAFENIB IN COMBINATION WITH SILYBIN AS A NOVEL POTENTIAL STRATEGY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER. *ONCOTARGET*. 2017 AUG 7;8(40):68305-68316. DOI: 10.18632/ONCOTARGET.20054. ECOLLECTION 2017 SEP 15. PUBMED PMID: 28978118; PUBMED CENTRAL PMCID: PMC5620258.
 22. NAPOLITANO S, MARTINI G, MARTINELLI E, BELLI V, PARASCANDOLO A, LAUKKANEN MO, SFORZA V, MORGILLO F, CIARDIELLO D, CIARDIELLO F, TROIANI T. THERAPEUTIC EFFICACY OF SYM004, A MIXTURE OF TWO ANTI-EGFR ANTIBODIES IN HUMAN COLORECTAL CANCER WITH ACQUIRED RESISTANCE TO CETUXIMAB AND MET ACTIVATION. *ONCOTARGET*. 2017 JUN 27;8(40):67592-67604. DOI: 10.18632/ONCOTARGET.18749. ECOLLECTION 2017 SEP 15. PUBMED PMID: 28978055; PUBMED CENTRAL PMCID: PMC5620195.
 23. NORMANNO N, ESPOSITO ABATE R, LAMBIASE M, FORGIONE L, CARDONE C, IANNACCONEA, SACCO A, RACHIGLIO AM, MARTINELLI E, RIZZI D, PISCONTI S, BIGLIETTO M, BORDONARO R, TROIANI T, LATIANO TP, GIULIANI F, LEO S, RINALDI A, MAIELLO E, CIARDIELLO F; CAPRI-GOIM INVESTIGATORS. RAS TESTING OF LIQUID BIOPSY CORRELATES WITH THE OUTCOME OF METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FIRST-LINE FOLFIRI PLUS CETUXIMAB IN THE CAPRI-GOIM TRIAL. *ANN ONCOL*. 2018 JAN 1;29(1):112-118. DOI: 10.1093/ANNONC/MDX417. PUBMED PMID: 28950295.
 24. ANTONIA SJ, VILLEGAS A, DANIEL D, VICENTE D, MURAKAMI S, HUI R, YOKOI T, CHIAPPORI A, LEE KH, DE WIT M, CHO BC, BOURHABA M, QUANTIN X, TOKITO T, MEKHAILT, PLANCHARD D, KIM YC, KARAPETIS CS, HIRET S, OSTOROS G, KUBOTA K, GRAY JE, PAZ-ARES L, DE CASTRO CARPEÑO J, WADSWORTH C, MELILLO G, JIANG H, HUANG Y, DENNIS PA, ÖZGÜROĞLU M; PACIFIC INVESTIGATORS. DURVALUMAB AFTER CHEMORADIOTHERAPY IN STAGE III NON-SMALL-CELL LUNG CANCER. *N ENGL J MED*. 2017 NOV 16;377(20):1919-1929. DOI: 10.1056/NEJMOA1709937. EPUB 2017 SEP 8. PUBMED PMID:28885881.
 25. MORGILLO F, AMENDOLA G, DELLA CORTE CM, GIACOMELLI C, BOTTA L, DI MARO S, MESSERE A, CIARAMELLA V, TALIANI S, MARINELLI L, TRINCAVELLI ML, MARTINI C, NOVELLINO E, CIARDIELLO F, COSCONATI S. DUAL MET AND SMO NEGATIVE MODULATOR OVERCOME RESISTANCE TO EGFR INHIBITORS IN HUMAN NONSMALL CELL LUNG CANCER. *J MED CHEM*. 2017 SEP 14;60(17):7447-7458. DOI: 10.1021/ACS.JMEDCHEM.7B00794. EPUB 2017 AUG 22. PUBMED PMID: 28787156.
 26. MARTINI G, TROIANI T, CARDONE C, VITIELLO P, SFORZA V, CIARDIELLO D, NAPOLITANO S, DELLA CORTE CM, MORGILLO F, RAUCCI A, CUOMO A, SELVAGGI F, CIARDIELLO F, MARTINELLI E. PRESENT AND FUTURE OF METASTATIC COLORECTAL CANCER TREATMENT: A REVIEW OF NEW CANDIDATE TARGETS. *WORLD J GASTROENTEROL*. 2017 JUL 14;23(26):4675-4688. DOI: 10.3748/WJG.V23.I26.4675. REVIEW. PUBMED PMID:28765689; PUBMED CENTRAL PMCID: PMC5514633.
 27. ORDITURA M, GRAVINA A, RICCARDI F, DIANA A, MOCERINO C, LEOPALDI L, FABOZZI A, GIORDANO G, NETTUNO R, INCORONATO P, BARZELLONI ML, CAPUTO R, PISANO A, GRIMALDI G, GENUA G, MONTESARCHIO V, BARBATO E, IODICE G, LIETO E, PROCACCINI E, MABILIA R, FEBBRARO A, LAURENTIIS M, CIARDIELLO F. ERIBULIN FOR METASTATIC BREAST CANCER (MBC) TREATMENT: A RETROSPECTIVE, MULTICENTER STUDY BASED IN CAMPANIA, SOUTH ITALY (ERI-001 TRIAL). *ESMO OPEN*. 2017 JUN 2;2(2):E000176. DOI: 10.1136/ESMOOPEN-2017-000176. ECOLLECTION 2017. PUBMED PMID: 28761747; PUBMED CENTRAL PMCID: PMC5519815.

28. MORGILLO F, FASANO M, DELLA CORTE CM, SASSO FC, PAPACCIO F, VISCARDI G, ESPOSITO G, DI LIELLO R, NORMANNO N, CAPUANO A, BERRINO L, VICIDOMINI G, FIORELLI A, SANTINI M, CIARDIELLO F. RESULTS OF THE SAFETY RUN-IN PART OF THE METAL (METFORMIN IN ADVANCED LUNG CANCER) STUDY: A MULTICENTRE, OPEN-LABEL PHASE-II STUDY OF METFORMIN WITH ERLOTINIB IN SECOND-LINE THERAPY OF PATIENTS WITH STAGE IV NON-SMALL-CELL LUNG CANCER. *ESMO OPEN*. 2017 MAY 2;2(2):E000132. DOI:10.1136/ESMOOPEN-2016-000132. ECOLLECTION 2017. PUBMED PMID: 28761738; PUBMED CENTRAL PMCID: PMC5519802.
29. DELLA CORTE CM, VISCARDI G, PAPACCIO F, ESPOSITO G, MARTINI G, CIARDIELLO D, MARTINELLI E, CIARDIELLO F, MORGILLO F. IMPLICATION OF THE HEDGEHOG PATHWAY IN HEPATOCELLULAR CARCINOMA. *WORLD J GASTROENTEROL*. 2017 JUN 28;23(24):4330-4340. DOI: 10.3748/WJG.V23.I24.4330. REVIEW. PUBMED PMID: 28706416; PUBMED CENTRAL PMCID: PMC5487497.
30. PETERS S, CAMIDGE DR, SHAW AT, GADGEEL S, AHN JS, KIM DW, OU SI, PÉROL M, DZIADZIUSZKO R, ROSELL R, ZEAITER A, MITRY E, GOLDING S, BALAS B, NOE J, MORCOS PN, MOK T; ALEX TRIAL INVESTIGATORS. ALECTINIB VERSUS CRIZOTINIB IN UNTREATED ALK-POSITIVE NON-SMALL-CELL LUNG CANCER. *N ENGL J MED*. 2017 AUG 31;377(9):829-838. DOI: 10.1056/NEJM0A1704795. EPUB 2017 JUN 6. PUBMED PMID: 28586279.
31. ARNOLD D, LUEZA B, DOUILLARD JY, PEETERS M, LENZ HJ, VENOOK A, HEINEMANN V, VAN CUTSEM E, PIGNON JP, TABERNEO J, CERVANTES A, CIARDIELLO F. PROGNOSTIC AND PREDICTIVE VALUE OF PRIMARY TUMOUR SIDE IN PATIENTS WITH RAS WILD-TYPE METASTATIC COLORECTAL CANCER TREATED WITH CHEMOTHERAPY AND EGFR DIRECTED ANTIBODIES IN SIX RANDOMIZED TRIALS. *ANN ONCOL*. 2017 AUG 1;28(8):1713-1729. DOI: 10.1093/ANNONC/MDX175. PUBMED PMID: 28407110.
32. DELLA CORTE CM, MALAPELLE U, VIGLIAR E, PEPE F, TRONCONE G, CIARAMELLA V, TROIANI T, MARTINELLI E, BELLI V, CIARDIELLO F, MORGILLO F. EFFICACY OF CONTINUOUS EGFR-INHIBITION AND ROLE OF HEDGEHOG IN EGFR ACQUIRED RESISTANCE IN HUMAN LUNG CANCER CELLS WITH ACTIVATING MUTATION OF EGFR. *ONCOTARGET*. 2017 APR 4;8(14):23020-23032. DOI: 10.18632/ONCOTARGET.15479. PUBMED PMID: 28416737 PUBMED CENTRAL PMCID: PMC5410282.
33. SRIVATSA S, PAUL MC, CARDONE C, HOLCMANN M, AMBERG N, PATHRIA P, DIAMANTI MA, LINDER M, TIMELTHALER G, DIENES HP, KENNER L, WRBA F, PRAGER GW, ROSE-JOHN S, EFERL R, LIGUORI G, BOTTI G, MARTINELLI E, GRETEN FR, CIARDIELLO F, SIBILIA M. EGFR IN TUMOR-ASSOCIATED MYELOID CELLS PROMOTES DEVELOPMENT OF COLORECTAL CANCER IN MICE AND ASSOCIATES WITH OUTCOMES OF PATIENTS. *GASTROENTEROLOGY*. 2017 JUL;153(1):178-190.E10. DOI: 10.1053/J.GASTRO.2017.03.053. EPUB 2017 APR 9. PMID: 28400195
34. E MARTINELLI, C CARDONE, T TROIANI, N NORMANNO, S PISCONTI, V SFORZA, AR BORDONARO, AM RACHIGLIO, M LAMBIASE, TP LATIANO, G MODONI, S CORDIO, F GIULIANI, M BIGLIETTO, V MONTESARCHIO, C BARONE, G TONINI, S CINIERI, A FEBBRARO, D RIZZI, F DEVITA, M ORDITURA, G COLUCCI, E MAIELLO, F CIARDIELLO. CLINICAL ACTIVITY AND TOLERABILITY OF FOLFIRI AND CETUXIMAB IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER IN THE CAPRI-GOIM FIRST-LINE TRIAL. DOI: 10.1136/ESMOOPEN-2016-000086 PUBLISHED 20 FEBRUARY 2017
35. ERIKA MARTINELLI, VINCENZO SFORZA, CLAUDIA CARDONE, ANNA CAPASSO, ANNA NAPPI, GIULIA MARTINI, STEFANIA NAPOLITANO, ANNA MARIA RACHIGLIO, NICOLA NORMANNO, SALVATORE CAPPABIANCA, ALFONSO REGINELLI, MAURIZIO DI BISCEGLIE, TIZIANA PIA LATIANO, EVARISTO MAIELLO, MICHELE ORDITURA, FERNANDO DE VITA, FLORIANA MORGILLO, FORTUNATO CIARDIELLO, TERESA TROIANI. CLINICAL OUTCOME AND MOLECULAR CHARACTERISATION OF CHEMOREFRACTORY METASTATIC COLORECTAL CANCER PATIENTS WITH LONG-TERM EFFICACY OF REGORAFENIB TREATMENT *ESMO OPEN* 2017;0:E000177. DOI:10.1136/ESMOOPEN-2017-000177
36. STEFANIA NAPOLITANO, GIULIA MARTINI, ERIKA MARTINELLI, VALENTINA BELLI, ALESSIA PARASCANDOLO, MIKKO O. LAUKKANEN, VINCENZO SFORZA, FLORIANA MORGILLO, DAVIDE CIARDIELLO, FORTUNATO CIARDIELLO, TERESA TROIANI. THERAPEUTIC EFFICACY OF SYM004, A MIXTURE OF TWO ANTI-EGFR ANTIBODIES IN HUMAN COLORECTAL CANCER WITH ACQUIRED RESISTANCE TO CETUXIMAB AND MET ACTIVATION. *ONCOTARGET* 2017, IN PRESS.
37. STEFANIA NAPOLITANO, GIULIA MARTINI, ERIKA MARTINELLI, CARMINIA MARIA DELLA CORTE, FLORIANA MORGILLO, VALENTINA BELLI, CLAUDIA CARDONE, NUNZIA MATRONE, FORTUNATO CIARDIELLO AND TERESA TROIANI. ANTITUMOR EFFICACY OF TRIPLE MONOCLONAL ANTIBODY

- INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) WITH MM151 IN EGFR-DEPENDENT AND IN CETUXIMAB-RESISTANT HUMAN COLORECTAL CANCER CELLS. *ONCOTARGET* 2017, IN PRESS
38. ARNOLD D, LUEZA B, DOUILLARD JY, PEETERS M, LENZ HJ, VENOOK A, HEINEMANN V, VAN CUTSEM E, PIGNON JP, TABERNERO J, CERVANTES A, CIARDIELLO F. PROGNOSTIC AND PREDICTIVE VALUE OF PRIMARY TUMOUR SIDE IN PATIENTS WITH RAS WILD-TYPE METASTATIC COLORECTAL CANCER TREATED WITH CHEMOTHERAPY AND EGFR DIRECTED ANTIBODIES IN SIX RANDOMISED TRIALS. *ANN ONCOL*. 2017 APR 12. DOI: 10.1093/ANNONC/MDX175. [EPUB AHEAD OF PRINT PMID: 28407110
 39. DELLA CORTE CM, MALAPELLE U, VIGLIAR E, PEPE F, TRONCONE G, CIARAMELLA V, TROIANI T, MARTINELLI E, BELLI V, CIARDIELLO F, MORGILLO F. EFFICACY OF CONTINUOUS EGFR-INHIBITION AND ROLE OF HEDGEHOG IN EGFR ACQUIRED RESISTANCE IN HUMAN LUNG CANCER CELLS WITH ACTIVATING MUTATION OF EGFR. *ONCOTARGET*. 2017 APR 4;8(14):23020-23032. DOI: 10.18632/ONCOTARGET.15479. PMID:28416737
 40. PETERS S, STAHEL RA, DAFNI U, PONCE AIX S, MASSUTÍ B, GAUTSCHI O, COATE L, LÓPEZ MARTÍN A, VAN HEEMST R, BERGHMANS T, MELDGAARD P, COBO DOLS M, GARDE NOGUERA J, CURIONI-FONTECEDRO A, RAUCH D, MARK MT, CUFFE S, BIESMA B, VAN HENTEN AM, JUAN VIDAL Ó, PALMERO SANCHEZ R, VILLA GUZMÁN JC, COLLADO MARTIN R, PERALTA S, INSA A, SUMMERS Y, LÁNG I, HORGAN A, CIARDIELLO F, DE HOSSON S, PIETERMAN R, GROEN HJ, VAN DEN BERG PM, ZIELINSKI CC, CHITTAZHATHU KURIAN KURUVILLA Y, GASCA-RUCHTI A, KASSAPIAN M, NOVELLO S, TORRI V, TSOURTI Z, GREGORC V, SMIT EF; EMPHASIS-LUNG COLLABORATIVE GROUP. RANDOMIZED PHASE III TRIAL OF ERLOTINIB VERSUS DOCETAXEL IN PATIENTS WITH ADVANCED SQUAMOUS CELL NON-SMALL CELL LUNG CANCER FAILING FIRST-LINE PLATINUM-BASED DOUBLET CHEMOTHERAPY STRATIFIED BY VERISTRAT GOOD VERSUS VERISTRAT POOR. THE EUROPEAN THORACIC ONCOLOGY PLATFORM (ETOP) EMPHASIS-LUNG TRIAL.
 41. *J THORAC ONCOL*. 2017 APR;12(4):752-762. DOI: 10.1016/J.JTHO.2016.12.017. EPUB 2016 DEC 23.
 42. KIM L, SAIEG M, DI MAIO M, GALLO C, BUTTS C, CIARDIELLO F, FELD R, CHENG D, GEBBIA V, BURGIO MA, ALAM Y, SIGNORIELLO S, ROSSI A, LEIGHL N, MAIONE P, MORABITO A, LIU G, TSAO MS, PERRONE F, GRIDELLI C. BIOMARKER ANALYSIS OF THE PHASE 3 TORCH TRIAL FOR FIRST LINE ERLOTINIB VERSUS CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS. *ONCOTARGET*. 2017 FEB 25. DOI: 10.18632/ONCOTARGET.15725. [EPUB AHEAD OF PRINT PMID 28427160
 43. MARTINELLI E, MORGILLO F, TROIANI T, CIARDIELLO F. CANCER RESISTANCE TO THERAPIES AGAINST THE EGFR-RAS-RAF PATHWAY: THE ROLE OF MEK. *CANCER TREAT REV*. 2017 FEB;53:61-69. DOI: 10.1016/J.CTRV.2016.12.001. EPUB 2016 DEC 30. REVIEW. PMID: 28073102
 44. FEDERICO A, BRANCACCIO G, DALLIO M, IODICE P, FABOZZI A, DEL PRETE S, CIARDIELLO F, LOGUERIO C, GAETA GB. REACTIVATION OF HEPATITIS B VIRUS IN CANCER PATIENTS TREATED WITH CHEMOTHERAPY FOR SOLID TUMORS. IS THE PROPHYLAXIS REALLY REQUIRED? *DIG LIVER DIS*. 2017 FEB;49(2):197-201. DOI: 10.1016/J.DLD.2016.11.004. EPUB 2016 NOV 16 PMID: 27899262
 45. FASANO M, FABOZZI A, GIORDANO G, VENTURINI F, AURILIO G, CANTILE F, FABOZZI T, RICCI V, SANTABARBARA G, MORGILLO F, CIARDIELLO F, DE VITA F. COMPLETE RESPONSE TO CAPECITABINE IN A FRAIL, ELDERLY PATIENT WITH METASTATIC COLORECTAL CANCER: A CASE REPORT. *ONCOL LETT*. 2017 FEB;13(2):979-983. DOI: 10.3892/OL.2016.5523. EPUB 2016 DEC 20 PMID: 28356988
 46. RITTMeyer A, BARLESI F, WATERKAMP D, PARK K, CIARDIELLO F, VON PAWEL J, GADGEEL SM, HIDA T, KOWALSKI DM, DOLS MC, CORTINOVIS DL, LEACH J, POLIKOFF J, BARRIOS C, KABBINAVAR F, FRONTERA OA, DE MARINIS F, TURNA H, LEE JS, BALLINGER M, KOWANETZ M, HE P, CHEN DS, SANDLER A, GANDARA DR; OAK STUDY GROUP. ATEZOLIZUMAB VERSUS DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED NON-SMALL-CELL LUNG CANCER (OAK): A PHASE 3, OPEN-LABEL, MULTICENTRE RANDOMISED CONTROLLED TRIAL. *LANCET*. 2017 JAN 21;389(10066):255-265. DOI: 10.1016/S0140-6736(16)32517-X. EPUB 2016 DEC 13. PMID: 27979383
 47. MORGAN G, LAMBERTINI M, KOURIE HR, AMARAL T, ARGILES G, BANERJEE S, CARDONE C, CORRAL J, DE MATTOS-ARRUDA L, ÖZTÜRK A, PETROVA M, POULSEN L, STRIJOS M, TYULYANDINA A, VIDRA R, CALIFANO R, DE AZAMBUJA E, GARRIDO LOPEZ P, GUARNERI V, RECK M, MOISEYENKO V, MARTINELLI E, DOUILLARD JY, STAHEL R, VOEST E, ARNOLD D, CARDOSO F, CASALI P, CERVANTES A, EGGERMONT AM, ENIU A, JASSEM J, PENTHEROUDAKIS G, PETERS S, MCGREGOR K, RAUH S, ZIELINSKI CC, CIARDIELLO F, TABERNERO J, PREUSSER M. CAREER OPPORTUNITIES AND BENEFITS FOR YOUNG ONCOLOGISTS IN THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO).ESMO

OPEN. 2016 DEC 7;1(6): E000107. DOI: 10.1136/ESMOOPEN-2016-000107. ECOLLECTION 2016. REVIEW. PMID: 28255451

48. PERRONE F, JOMMI C, DI MAIO M, GIMIGLIANO A, GRIDELLI C, PIGNATA S, CIARDIELLO F, NUZZO F, DE MATTEIS A, DEL MASTRO L, BRYCE J, DANIELE G, MORABITO A, PICCIRILLO MC, ROCCO G, GUIZZARO L, GALLO C. THE ASSOCIATION OF FINANCIAL DIFFICULTIES WITH CLINICAL OUTCOMES IN CANCER PATIENTS: SECONDARY ANALYSIS OF 16 ACADEMIC PROSPECTIVE CLINICAL TRIALS CONDUCTED IN ITALY. ANN ONCOL. 2016 DEC;27(12):2224-2229. DOI: 10.1093/ANNONC/MDW433. EPUB 2016 OCT 26. PMID: 27789469
49. FASANO M, DELLA CORTE CM, VICIDOMINI G, SCOTTI V, RAMBALDI PF, FIORELLI A, ACCARDO M, DE VITA F, SANTINI M, CIARDIELLO F, MORGILLO F. SMALL BOWEL METASTASIS FROM PANCREATIC CANCER IN A LONG-TERM SURVIVAL PATIENT WITH SYNCHRONOUS ADVANCED MALIGNANT PLEURAL MESOTHELIOMA: A CASE REPORT AND LITERATURE REVIEW. ONCOL LETT. 2016 DEC;12(6):4505-4509. DOI: 10.3892/OL.2016.5279. EPUB 2016 OCT 18. PMID 28105159
50. VAN KRIEKEN H, DEANS S, HALL JA, NORMANNO N, CIARDIELLO F, DOUILLARD JY. ESMO OPEN. 2016 NOV 18;1(5); E000114. QUALITY TO RELY ON: MEETING REPORT OF THE 5TH MEETING OF EXTERNAL QUALITY ASSESSMENT, NAPLES 2016. ECOLLECTION 2016. NO ABSTRACT AVAILABLE. PMID: 27933215
51. VOGEL A, CIARDIELLO F, HUBNER RA, BLANC JF, CARRATO A, YANG Y, PATEL DA, EKTARE V, DE JONG FA, GILL S. POST-GEMCITABINE THERAPY FOR PATIENTS WITH ADVANCED PANCREATIC CANCER - A COMPARATIVE REVIEW OF RANDOMIZED TRIALS EVALUATING OXALIPLATIN- AND/OR IRINOTECAN-CONTAINING REGIMENS. CANCER TREAT REV. 2016 NOV; 50:142-147. DOI: 10.1016/J.CTRV.2016.09.001. EPUB 2016 SEP 9. REVIEW. PMID: 27676174
52. RACHIGLIO AM, ESPOSITO ABATE R, SACCO A, PASQUALE R, FENIZIA F, LAMBIASE M, MORABITO A, MONTANINO A, ROCCO G, ROMANO C, NAPPI A, IAFFAIOLI RV, TATANGELO F, BOTTI G, CIARDIELLO F, MAIELLO MR, DE LUCA A, NORMANNO N. LIMITS AND POTENTIAL OF TARGETED SEQUENCING ANALYSIS OF LIQUID BIOPSY IN PATIENTS WITH LUNG AND COLON CARCINOMA. ONCOTARGET. 2016 OCT 11;7(41):66595-66605. DOI: 10.18632/ONCOTARGET.10704. PMID: 27448974
53. KÖHNE CH, POSTON G, FOLPRECHT G, CIARDIELLO F, RONGA P, BEIER F, VAN CUTSEM E. FOLFIRI PLUS CETUXIMAB IN PATIENTS WITH LIVER-LIMITED OR NON-LIVER-LIMITED RAS WILD-TYPE METASTATIC COLORECTAL CANCER: A RETROSPECTIVE SUBGROUP ANALYSIS OF THE CRYSTAL STUDY. EUR J SURG ONCOL. 2016 OCT;42(10):1540-7. DOI: 10.1016/J.EJSO.2016.05.038. EPUB 2016 JUN 23. PMID: 27575968
54. DE VITA F, VENTRIGLIA J, FEBBRARO A, LATERZA MM, FABOZZI A, SAVASTANO B, PETRILLO A, DIANA A, GIORDANO G, TROIANI T, CONZO G, GALIZIA G, CIARDIELLO F, ORDITURA M. NAB-PACLITAXEL AND GEMCITABINE IN METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC): FROM CLINICAL TRIALS TO CLINICAL PRACTICE. BMC CANCER. 2016 SEP 2;16(1):709. DOI: 10.1186/S12885-016-2671-9. PMID: 27590845
55. GRIDELLI C, ROSSI A, CIARDIELLO F, DE MARINIS F, CRINÒ L, MORABITO A, MORGILLO F, MONTANINO A, DANIELE G, PICCIRILLO MC, NORMANNO N, GALLO C, PERRONE F. BEVERLY: RATIONALE AND DESIGN OF A RANDOMIZED OPEN-LABEL PHASE III TRIAL COMPARING BEVACIZUMAB PLUS ERLOTINIB VERSUS ERLOTINIB ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH EGFR-MUTATED ADVANCED NONSQUAMOUS NON-SMALL-CELL LUNG CANCER. CLIN LUNG CANCER. 2016 SEP; 17(5):461-465. DOI: 10.1016/J.CLLC.2016.04.001. EPUB 2016 APR 22 PMID: 27209164
56. ESMO CONSENSUS GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER. VAN CUTSEM E, CERVANTES A, ADAM R, SOBRERO A, VAN KRIEKEN JH, ADERKA D, ARANDA AGUILAR E, BARDELLI A, BENSON A, BODOKY G, CIARDIELLO F, D'HOORE A, DIAZ-RUBIO E, DOUILLARD JY, DUCREUX M, FALCONE A, GROTHEY A, GRUENBERGER T, HAUSTERMANS K, HEINEMANN V, HOFF P, KÖHNE CH, LABIANCA R, LAURENT-PUIG P, MA B, MAUGHAN T, MURO K, NORMANNO N, ÖSTERLUND P, OYEN WJ, PAPAMICHAEL D, PENTHEROUDAKIS G, PFEIFFER P, PRICE TJ, PUNT C, RICKE J, ROTH A, SALAZAR R, SCHEITHAUER W, SCHMOLL HJ, TABERNERO J, TAÏEB J, TEJPAR S, WASAN H, YOSHINO T, ZAAANAN A, ARNOLD D. ANN ONCOL. 2016 AUG;27(8):1386-422. DOI: 10.1093/ANNONC/MDW235. EPUB 2016 JUL 5 PMID: 27380959

57. SFORZA V, MARTINELLI E, CIARDIELLO F, GAMBARDELLA V, NAPOLITANO S, MARTINI G, DELLA CORTE C, CARDONE C, FERRARA ML, REGINELLI A, LIGUORI G, BELLI G, TROIANI T. MECHANISMS OF RESISTANCE TO ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN METASTATIC COLORECTAL CANCER. *WORLD J GASTROENTEROL*. 2016 JUL 28;22(28):6345-61. DOI: 10.3748/WJG.V22.I28.6345. REVIEW PMID: 27605871
58. SEGELOV E, THAVANESWARAN S, WARING PM, DESAI J, ROBLEDO KP, GEBSKI VJ, ELEZ E, NOTT LM, KARAPETIS CS, LUNKE S, CHANTRILL LA, PAVLAKIS N, KHASRAW M, UNDERHILL C, CIARDIELLO F, JEFFORD M, WASAN H, HAYDON A, PRICE TJ, VAN HAZEL G, WILSON K, SIMES J, SHAPIRO JD. RESPONSE TO CETUXIMAB WITH OR WITHOUT IRINOTECAN IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER HARBORING THE KRAS G13D MUTATION: AUSTRALASIAN GASTRO-INTESTINAL TRIALS GROUP ICECREAM STUDY. *J CLIN ONCOL*. 2016 JUL 1;34(19):2258-64. DOI: 10.1200/JCO.2015.65.6843. EPUB 2016 APR 25 PMID: 27114605
59. DE MARINIS F, BRIA E, CIARDIELLO F, CRINÒ L, DOUILLARD JY, GRIESINGER F, LAMBRECHTS D, PEROL M, RAMALINGAM SS, SMIT EF, GRIDELLI C. INTERNATIONAL EXPERTS PANEL MEETING OF THE ITALIAN ASSOCIATION OF THORACIC ONCOLOGY ON ANTIANGIOGENETIC DRUGS FOR NON-SMALL CELL LUNG CANCER: REALITIES AND HOPES. *J THORAC ONCOL*. 2016 JUL;11(7):1153-69. DOI: 10.1016/J.JTHO.2016.03.015. EPUB 2016 APR 5.
60. CIARDIELLO F, NORMANNO N, MARTINELLI E, TROIANI T, PISCONTI S, CARDONE C, NAPPI A, BORDONARO AR, RACHIGLIO M, LAMBIASE M, LATIANO TP, MODONI G, CORDIO S, GIULIANI F, BIGLIETTO M, MONTESARCHIO V, BARONE C, TONINI G, CINIERI S, FEBBRARO A, RIZZI D, DE VITA F, ORDITURA M, COLUCCI G, MAIELLO E; CAPRI-GOIM INVESTIGATORS; CAPRI-GOIM INVESTIGATORS. CETUXIMAB CONTINUATION AFTER FIRST PROGRESSION IN METASTATIC COLORECTAL CANCER (CAPRI-GOIM): A RANDOMIZED PHASE II TRIAL OF FOLFOX PLUS CETUXIMAB VERSUS FOLFOX. *ANN ONCOL*. 2016 JUN;27(6):1055-61. DOI: 10.1093/ANNONC/MDW136. EPUB 2016 MAR 21.
61. SARTORE-BIANCHI A, TRUSOLINO L, MARTINO C, BENCARDINO K, LONARDI S, BERGAMO F, ZAGONEL V, LEONE F, DEPETRIS I, MARTINELLI E, TROIANI T, CIARDIELLO F, RACCA P, BERTOTTI A, SIRAVEGNA G, TORRI V, AMATU A, GHEZZI S, MARRAPESE G, PALMERI L, VALTORTA E, CASSINGENA A, LAURICELLA C, VANZULLI A, REGGE D, VERONESE S, COMOGLIO PM, BARDELLI A, MARSONI S, SIENA S. DUAL-TARGETED THERAPY WITH TRASTUZUMAB AND LAPATINIB IN TREATMENT-REFRACTORY, KRAS CODON 12/13 WILD-TYPE, HER2-POSITIVE METASTATIC COLORECTAL CANCER (HERACLES): A PROOF-OF-CONCEPT, MULTICENTRE, OPEN-LABEL, PHASE 2 TRIAL. *LANCET ONCOL*. 2016 JUN;17(6):738-46. DOI: 10.1016/S1470-2045(16)00150-9. EPUB 2016 APR 20 PMID: 27108243
62. SEGELOV E, WARING P, DESAI J, WILSON K, GEBSKI V, THAVANESWARAN S, ELEZ E, UNDERHILL C, PAVLAKIS N, CHANTRILL L, NOTT L, JEFFORD M, KHASRAW M, DAY F, WASAN H, CIARDIELLO F, KARAPETIS C, JOUBERT W, VAN HAZEL G, HAYDON A, PRICE T, TEJPAN S, TEBBUTT N, SHAPIRO J. ICECREAM: RANDOMISED PHASE II STUDY OF CETUXIMAB ALONE OR IN COMBINATION WITH IRINOTECAN IN PATIENTS WITH METASTATIC COLORECTAL CANCER WITH EITHER KRAS, NRAS, BRAF AND PI3KCA WILD TYPE, OR G13D MUTATED TUMOURS. *BMC CANCER*. 2016 MAY 31;16:339. DOI: 10.1186/S12885-016-2389-8 PMID: 27246726
63. ULLRICH A, CIARDIELLO F, BRICALLI G, CHERNY NI, ENIU A. ESMO AND WHO: 14 YEARS OF WORKING IN PARTNERSHIP ON CANCER CONTROL. *ESMO OPEN*. 2016 MAY 26;1(3):E000012. ECOLLECTION 2016. NO ABSTRACT AVAILABLE. PMID: 27843600
64. MECHANISMS OF RESISTANCE TO EGFR-TARGETED DRUGS: LUNG CANCER. *MORGILLO F, DELLA CORTE CM, FASANO M, CIARDIELLO F*. *ESMO OPEN*. 2016 MAY 11;1(3):E000060. ECOLLECTION 2016. REVIEW. PMID: 27843613
65. ORDITURA M, PETRILLO A, VENTRIGLIA J, DIANA A, LATERZA MM, FABOZZI A, SAVASTANO B, FRANZESE E, CONZO G, SANTINI L, CIARDIELLO F, DE VITA F. PANCREATIC NEUROENDOCRINE TUMORS: NOSOGRAPHY, MANAGEMENT AND TREATMENT. *INT J SURG*. 2016 APR;28 SUPPL 1:S156-62. DOI: 10.1016/J.IJSU.2015.12.052. EPUB 2015 DEC 18. REVIEW PMID: 26708853
66. TABERNERO J, CIARDIELLO F. BREXIT: A EUROPEAN PERSPECTIVE. *LANCET ONCOL*. 2016 MAY;17(5):558-9. DOI: 10.1016/S1470-2045(16)30062-6. EPUB 2016 APR 27. NO ABSTRACT AVAILABLE. PUBMED PMID: 27301028 IF 26.509

67. SEGELOV E, WARING P, DESAI J, WILSON K, GEBSKI V, THAVANESWARAN S, ELEZ E, UNDERHILL C, PAVLAKIS N, CHANTRILL L, NOTT L, JEFFORD M, KHASRAW M, DAY F, WASAN H, CIARDIELLO F, KARAPETIS C, JOUBERT W, VAN HAZEL G, HAYDON A, PRICE T, TEJPAR S, TEBBUTT N, SHAPIRO J. ICECREAM: RANDOMISED PHASE II STUDY OF CETUXIMAB ALONE OR IN COMBINATION WITH IRINOTECAN IN PATIENTS WITH METASTATIC COLORECTAL CANCER WITH EITHER KRAS, NRAS, BRAF AND PI3KCA WILD TYPE, OR G13D MUTATED TUMOURS. *BMC CANCER*. 2016 MAY 31;16(1):339. DOI: 10.1186/S12885-016-2389-8. PUBMED PMID:27246726 IF 3.265
68. GRIDELLI C, ROSSI A, CIARDIELLO F, DE MARINIS F, CRINÒ L, MORABITO A, MORGILLO F, MONTANINO A, DANIELE G, PICCIRILLO MC, NORMANNO N, GALLO C, PERRONE F. BEVERLY: RATIONALE AND DESIGN OF A RANDOMIZED OPEN-LABEL PHASE III TRIAL COMPARING BEVACIZUMAB PLUS ERLOTINIB VERSUS ERLOTINIB ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH EGFR-MUTATED ADVANCED NONSQUAMOUS NON-SMALL-CELL LUNG CANCER. *CLIN LUNG CANCER*. 2016 APR 22. PII: S1525-7304(16)30061-4. DOI: 10.1016/J.CLLC.2016.04.001. [EPUB AHEAD OF PRINT] PUBMED PMID:27209164 IF 3.030
69. CASALUCE F, SGAMBATO A, SACCO PC, PALAZZOLO G, MAIONE P, ROSSI A, CIARDIELLO F, GRIDELLI C. RESISTANCE TO CRIZOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH ALK REARRANGEMENT: MECHANISMS, TREATMENT STRATEGIES AND NEW TARGETED THERAPIES. *CURR CLIN PHARMACOL*. 2016 MAY 2. [EPUB AHEAD OF PRINT]PUBMED PMID:27138017 IF 2.374 CIT. 1
70. SEGELOV E, THAVANESWARAN S, WARING PM, DESAI J, ROBLEDO KP, GEBSKI VJ, ELEZ E, NOTT LM, KARAPETIS CS, LUNKE S, CHANTRILL LA, PAVLAKIS N, KHASRAW M, UNDERHILL C, CIARDIELLO F, JEFFORD M, WASAN H, HAYDON A, PRICE TJ, VAN HAZEL G, WILSON K, SIMES J, SHAPIRO JD. RESPONSE TO CETUXIMAB WITH OR WITHOUT IRINOTECAN IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER HARBORING THE KRAS G13D MUTATION: AUSTRALASIAN GASTRO-INTESTINAL TRIALS GROUP ICECREAM STUDY. *J CLIN ONCOL*. 2016 JUL 1;34(19):2258-64. DOI: 10.1200/JCO.2015.65.6843. EPUB 2016 APR 25.PUBMED PMID:27114605 IF 20.982
71. SARTORE-BIANCHI A, TRUSOLINO L, MARTINO C, BENCARDINO K, LONARDI S, BERGAMO F, ZAGONEL V, LEONE F, DEPETRIS I, MARTINELLI E, TROIANI T, CIARDIELLO F, RACCA P, BERTOTTI A, SIRAVEGNA G, TORRI V, AMATU A, GHEZZI S, MARRAPESE G, PALMERI L, VALTORTA E, CASSINGENA A, LAURICELLA C, VANZULLI A, REGGE D, VERONESE S, COMOGLIO PM, BARDELLI A, MARSONI S, SIENA S. DUAL-TARGETED THERAPY WITH TRASTUZUMAB AND LAPATINIB IN TREATMENT-REFRACTORY, KRAS CODON 12/13 WILD-TYPE, HER2-POSITIVE METASTATIC COLORECTAL CANCER (HERACLES): A PROOF-OF-CONCEPT, MULTICENTRE, OPEN-LABEL, PHASE 2 TRIAL. *LANCET ONCOL*. 2016 JUN;17(6):738-46. DOI: 10.1016/S1470-2045(16)00150-9. EPUB 2016 APR 20. PUBMED PMID:27108243 IF 26.509 CIT. 6
72. DE MARINIS F, BRIA E, CIARDIELLO F, CRINÒ L, DOUILLARD JY, GRIESINGER F, LAMBRECHTS D, PEROL M, RAMALINGAM SS, SMIT EF, GRIDELLI C. INTERNATIONAL EXPERTS PANEL MEETING OF THE ITALIAN ASSOCIATION OF THORACIC ONCOLOGY ON ANTIANGIOGENETIC DRUGS FOR NON-SMALL CELL LUNG CANCER: REALITIES AND HOPES. *J THORAC ONCOL*. 2016 JUL;11(7):1153-69. DOI: 10.1016/J.JTHO.2016.03.015. EPUB 2016 APR 5. PUBMED PMID:27063293 IF 5.040
73. CIARDIELLO F, NORMANNO N, MARTINELLI E, TROIANI T, PISCONTI S, CARDONE C, NAPPI A, BORDONARO AR, RACHIGLIO M, LAMBIASE M, LATIANO TP, MODONI G, CORDIO S, GIULIANI F, BIGLIETTO M, MONTESARCHIO V, BARONE C, TONINI G, CINIERI S, FEBBRARO A, RIZZI D, DE VITA F, ORDITURA M, COLUCCI G, MAIELLO E; CAPRI-GOIM INVESTIGATORS; CAPRI-GOIM INVESTIGATORS. CETUXIMAB CONTINUATION AFTER FIRST PROGRESSION IN METASTATIC COLORECTAL CANCER (CAPRI-GOIM): A RANDOMIZED PHASE II TRIAL OF FOLFOX PLUS CETUXIMAB VERSUS FOLFOX. *ANN ONCOL*. 2016 JUN;27(6):1055-61 DOI:10.1093/ANNONC/MDW136. EPUB 2016 MAR 21. PUBMED PMID: 27002107 IF 9.269
74. CIARDIELLO F, ADAMS R, TABERNERO J, SEUFFERLEIN T, TAIEB J, MOISEYENKO V, MA B, LOPEZ G, VANSTEENKISTE JF, ESSER R, TEJPAR S. AWARENESS, UNDERSTANDING, AND ADOPTION OF PRECISION MEDICINE TO DELIVER PERSONALIZED TREATMENT FOR PATIENTS WITH CANCER: A MULTINATIONAL SURVEY COMPARISON OF PHYSICIANS AND PATIENTS. *ONCOLOGIST*. 2016 MAR;21(3):292-300. DOI: 10.1634/THEONCOLOGIST.2015-0279. EPUB 2016 FEB 17. PUBMED PMID:26888693 IF 4.789 CIT.

75. ORDITURA M, PETRILLO A, VENTRIGLIA J, DIANA A, LATERZA MM, FABOZZI A, SAVASTANO B, FRANZESE E, CONZO G, SANTINI L, CIARDIELLO F, DE VITA F. PANCREATIC NEUROENDOCRINE TUMORS: NOSOGRAPHY, MANAGEMENT AND TREATMENT. INT J SURG. 2016 APR;28 SUPPL 1: S156-62. DOI: 10.1016/J.IJSU.2015.12.052. EPUB 2015 DEC 18. REVIEW.PUBMED PMID:26708853 IF 1.657
76. DELLA CORTE CM, CIARAMELLA V, DI MAURO C, CASTELLONE MD, PAPACCIO F, FASANO M, SASSO FC, MARTINELLI E, TROIANI T, DE VITA F, ORDITURA M, BIANCO R, CIARDIELLO F, MORGILLO F. METFORMIN INCREASES ANTITUMOR ACTIVITY OF MEK INHIBITORS THROUGH GLI1 DOWNREGULATION IN LKB1 POSITIVE HUMAN NSCLC CANCER CELLS. ONCOTARGET. 2016 JAN 26;7(4):4265-78. DOI: 10.18632/ONCOTARGET.6559. PUBMED PMID:26673006 IF 5.008 CIT. 1
77. CIARDIELLO F. MAINTENANCE THERAPY FOR METASTATIC COLORECTAL CANCER. LANCET ONCOL. 2015 NOV;16(15):1444-5. DOI: 10.1016/S1470-2045(15)00308-3. EPUB 2015 OCT 22. NO ABSTRACT AVAILABLE.PUBMED PMID:26474519 IF 26.509 CIT. 1
78. SALAZAR R, CIARDIELLO F. OPTIMIZING ANTI-EGFR THERAPY IN COLORECTAL CANCER. CLIN CANCER RES. 2015 DEC 15;21(24):5415-6. DOI: 10.1158/1078-0432.CCR-15-1768. EPUB 2015 OCT 13. PUBMED PMID:26463710 IF 8.738 CIT. 2
79. VALTORTA E, MARTINO C, SARTORE-BIANCHI A, PENAULT-LLOORCA F, VIALE G, RISIO M, RUGGE M, GRIGIONI W, BENCARDINO K, LONARDI S, ZAGONEL V, LEONE F, NOE J, CIARDIELLO F, PINTO C, LABIANCA R, MOSCONI S, GRAIFF C, APRILE G, FRAU B, GARUFI C, LOUPAKIS F, RACCA P, TONINI G, LAURICELLA C, VERONESE S, TRUINI M, SIENA S, MARSONI S, GAMBACORTA M. ASSESSMENT OF A HER2 SCORING SYSTEM FOR COLORECTAL CANCER: RESULTS FROM A VALIDATION STUDY. MOD PATHOL. 2015 NOV;28(11):1481-91. DOI: 10.1038/MODPATHOL.2015.98. EPUB 2015 OCT 9. PUBMED PMID:26449765 IF 5.485 CIT. 6
80. SGAMBATO A, CASALUCE F, SACCO PC, PALAZZOLO G, MAIONE P, ROSSI A, CIARDIELLO F, GRIDELLI C. ANTI PD-1 AND PDL-1 IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED NON- SMALL CELL LUNG CANCER (NSCLC): A REVIEW ON TOXICITY PROFILE AND ITS MANAGEMENT. CURR DRUG SAF. 2016;11(1):62-8. PUBMED PMID:26412670 IF 3.206 CIT. 1
81. VAN CUTSEM E, BEIER F, CIARDIELLO F. REPLY TO S. DEBSKA-SZMICH ET AL. J CLIN ONCOL. 2015 OCT 20;33(30):3518. DOI: 10.1200/JCO.2015.62.4619. EPUB 2015 AUG 24. NO ABSTRACT AVAILABLE. PUBMED PMID:26304910 IF 20.982 CIT.
82. DELLA CORTE CM, BELLEVICINE C, VICIDOMINI G, VITAGLIANO D, MALAPELLE U, ACCARDO M, FABOZZI A, FIORELLI A, FASANO M, PAPACCIO F, MARTINELLI E, TROIANI T, TRONCONE G, SANTINI M, BIANCO R, CIARDIELLO F, MORGILLO F. SMO GENE AMPLIFICATION AND ACTIVATION OF THE HEDGEHOG PATHWAY AS NOVEL MECHANISMS OF RESISTANCE TO ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR DRUGS IN HUMAN LUNG CANCER. CLIN CANCER RES. 2015 OCT 15;21(20):4686-97. DOI: 10.1158/1078-0432.CCR-14-3319. EPUB 2015 JUN 29. PUBMED PMID:26124204 IF 8.738 CIT. 6
83. FASANO M, DELLA CORTE CM, PAPACCIO F, CIARDIELLO F, MORGILLO F. PULMONARY LARGE-CELL NEUROENDOCRINE CARCINOMA: FROM EPIDEMIOLOGY TO THERAPY. J THORAC ONCOL. 2015 AUG;10(8):1133-41. DOI: 10.1097/JTO.0000000000000589. PUBMED PMID: 26039012 IF 5.040 CIT. 9
84. MCLELLAN B, CIARDIELLO F, LACOUTURE ME, SEGAERT S, VAN CUTSEM E. REGORAFENIB-ASSOCIATED HAND-FOOT SKIN REACTION: PRACTICAL ADVICE ON DIAGNOSIS, PREVENTION, AND MANAGEMENT. ANN ONCOL. 2015 OCT;26(10):2017-26. DOI: 10.1093/ANNONC/MDV244. EPUB 2015 JUN 1. REVIEW. PUBMED PMID:26034039 IF 9.269 CIT. 6
85. TROIANI T, NAPOLITANO S, MARTINI G, MARTINELLI E, CARDONE C, NORMANNO N, VITAGLIANO D, MORGILLO F, FENZIA F, LAMBIASE M, FORMISANO L, BIANCO R, CIARDIELLO D, CIARDIELLO F. MAINTENANCE TREATMENT WITH CETUXIMAB AND BAY86-9766 INCREASES ANTITUMOR EFFICACY OF IRINOTECAN PLUS CETUXIMAB IN HUMAN COLORECTAL CANCER XENOGRAFT MODELS. CLIN CANCER RES. 2015 SEP 15;21(18):4153-64. DOI: 10.1158/1078-0432.CCR-15-0211. EPUB 2015 MAY 27. PUBMED PMID: 26019172 IF 8.738 CIT. 2
86. MACARULLA T, CERVANTES A, TABERNERO J, ROSELLÓ S, VAN CUTSEM E, TEJPAR S, PRENEN H, MARTINELLI E, TROIANI T, LAFFRANCHI B, JEGO V, VON RICHTER O, CIARDIELLO F. PHASE I STUDY OF FOLFIRI PLUS PIMASERTIB AS SECOND-LINE TREATMENT FOR KRAS-MUTATED METASTATIC

COLORECTAL CANCER. BR J CANCER. 2015 JUN 9;112(12):1874-81. DOI: 10.1038/BJC.2015.144. EPUB 2015 MAY 19. PUBMED PMID: 25989270 IF 5.569 CIT. 4

87. MARTINELLI E, MARTINI G, CARDONE C, TROIANI T, LIGUORI G, VITAGLIANO D, NAPOLITANO S, MORGILLO F, RINALDI B, MELILLO RM, LIOTTI F, NAPPI A, BIANCO R, BERRINO L, CIUFFREDA LP, CIARDIELLO D, IAFFAIOLI V, BOTTI G, FERRAIOLO F, CIARDIELLO F. AXL IS AN ONCOTARGET IN HUMAN COLORECTAL CANCER. ONCOTARGET. 2015 SEP 15;6(27):23281-96. PUBMED PMID:25966280 IF 5.008 CIT. 3
88. BOKEMEYER C, KÖHNE CH, CIARDIELLO F, LENZ HJ, HEINEMANN V, KLINKHARDT U, BEIER F, DUECKER K, VAN KRIEKEN JH, TEJPAR S. FOLFOX4 PLUS CETUXIMAB TREATMENT AND RAS MUTATIONS IN COLORECTAL CANCER. EUR J CANCER. 2015 JUL;51(10):1243-52. DOI: 10.1016/J.EJCA.2015.04.007. EPUB 2015 APR 30. PUBMED PMID:25937522 IF 6.163 CIT. 18
89. ORDITURA M, GALIZIA G, LIETO E, DE VITA F, CIARDIELLO F. TREATMENT OF ESOPHAGOGASTRIC JUNCTION CARCINOMA: AN UNSOLVED DEBATE. WORLD J GASTROENTEROL. 2015 APR 21;21(15):4427-31. DOI: 10.3748/WJG.V21.I15.4427. REVIEW.PUBMED PMID:25914451 IF 2.787 CIT. 2
90. GRIDELLI C, BALDUCCI L, CIARDIELLO F, DI MAIO M, FELIP E, LANGER C, LILENBAUM RC, PERRONE F, SENAN S, DE MARINIS F. TREATMENT OF ELDERLY PATIENTS WITH NON-SMALL-CELL LUNG CANCER: RESULTS OF AN INTERNATIONAL EXPERT PANEL MEETING OF THE ITALIAN ASSOCIATION OF THORACIC ONCOLOGY. CLIN LUNG CANCER. 2015 SEP;16(5):325-33. DOI: 10.1016/J.CLLC.2015.02.006. EPUB 2015 MAR 7. REVIEW. PUBMED PMID:25862554 IF 3.030 CIT. 9
91. NORMANNO N, RACHIGLIO AM, LAMBIASE M, MARTINELLI E, FENIZIA F, ESPOSITO C, ROMA C, TROIANI T, RIZZI D, TATANGELO F, BOTTI G, MAIELLO E, COLUCCI G, CIARDIELLO F; CAPRI-GOIM INVESTIGATORS. HETEROGENEITY OF KRAS, NRAS, BRAF AND PIK3CA MUTATIONS IN METASTATIC COLORECTAL CANCER AND POTENTIAL EFFECTS ON THERAPY IN THE CAPRI GOIM TRIAL. ANN ONCOL. 2015 AUG;26(8):1710-4. DOI: 10.1093/ANNONC/MDV176. EPUB 2015 APR 7. PUBMED PMID: 25851630 IF 9.269 CIT. 17
92. NAPOLITANO S, MARTINI G, RINALDI B, MARTINELLI E, DONNIACUO M, BERRINO L, VITAGLIANO D, MORGILLO F, BARRA G, DE PALMA R, MEROLLA F, CIARDIELLO F, TROIANI T. PRIMARY AND ACQUIRED RESISTANCE OF COLORECTAL CANCER TO ANTI-EGFR MONOCLONAL ANTIBODY CAN BE OVERCOME BY COMBINED TREATMENT OF REGORAFENIB WITH CETUXIMAB. CLIN CANCER RES. 2015 JUL 1;21(13):2975-83. DOI: 10.1158/1078-0432.CCR-15-0020. EPUB 2015 APR 2. PUBMED PMID: 25838391 IF 8.738 CIT. 7
93. ARGILÉS G, SAUNDERS MP, RIVERA F, SOBRERO A, BENSON A 3RD, GUILLÉN PONCE C, CASCINU S, VAN CUTSEM E, MACPHERSON IR, STRUMBERG D, KÖHNE CH, ZALCBERG J, WAGNER A, LUIGI GAROSI V, GRUNERT J, TABERNERO J, CIARDIELLO F. REGORAFENIB PLUS MODIFIED FOLFOX6 AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: A PHASE II TRIAL. EUR J CANCER. 2015 MAY;51(8):942-9. DOI: 10.1016/J.EJCA.2015.02.013. EPUB 2015 MAR 25. PUBMED PMID: 25818084 IF 6.163 CIT. 7
94. FEDERICO A, ORDITURA M, COTTICELLI G, DE SIO I, ROMANO M, GRAVINA AG, DALLIO M, FABOZZI A, CIARDIELLO F, LOGUERCIO C, DE VITA F. SAFETY AND EFFICACY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND CHILD-PUGH A OR B CIRRHOSIS. ONCOL LETT. 2015 APR;9(4):1628-1632. EPUB 2015 FEB 12. PUBMED PMID: 25789012 IF 1.482 CIT. 6
95. DI MAIO M, GALLO C, LEIGHL NB, PICCIRILLO MC, DANIELE G, NUZZO F, GRIDELLI C, GEBBIA V, CIARDIELLO F, DE PLACIDO S, CERIBELLI A, FAVARETTO AG, DE MATTEIS A, FELD R, BUTTS C, BRYCE J, SIGNORIELLO S, MORABITO A, ROCCO G, PERRONE F. SYMPTOMATIC TOXICITIES EXPERIENCED DURING ANTICANCER TREATMENT: AGREEMENT BETWEEN PATIENT AND PHYSICIAN REPORTING IN THREE RANDOMIZED TRIALS. J CLIN ONCOL. 2015 MAR 10;33(8):910-5. DOI: 10.1200/JCO.2014.57.9334. EPUB 2015 JAN 26. PUBMED PMID: 25624439 IF 20.982 CIT. 43
96. VAN CUTSEM E, LENZ HJ, KÖHNE CH, HEINEMANN V, TEJPAR S, MELEZÍNEK I, BEIER F, STROH C, ROUGIER P, VAN KRIEKEN JH, CIARDIELLO F. FLUOROURACIL, LEUCOVORIN, AND IRINOTECAN PLUS CETUXIMAB TREATMENT AND RAS MUTATIONS IN COLORECTAL CANCER. J CLIN ONCOL. 2015 MAR 1;33(7):692-700. DOI: 10.1200/JCO.2014.59.4812. EPUB 2015 JAN 20. PUBMED PMID: 25605843 IF 20.982 CIT. 100

97. STAHEL R, BOGAERTS J, CIARDIELLO F, DE RUYSSCHER D, DUBSKY P, DUCREUX M, FINN S, LAURENT-PUIG P, PETERS S, PICCART M, SMIT E, SOTIRIOU C, TEJPAR S, VAN CUTSEM E, TABERNERO J. OPTIMISING TRANSLATIONAL ONCOLOGY IN CLINICAL PRACTICE: STRATEGIES TO ACCELERATE PROGRESS IN DRUG DEVELOPMENT. *CANCER TREAT REV*. 2014 DEC 16. PII: S0305-7372(14)00209-6. DOI: 10.1016/J.CTRV.2014.12.004. [EPUB AHEAD OF PRINT] REVIEW. PUBMED PMID: 25533737. IF 7.983 CIT. 13
98. DE VITA F, DI MARTINO N, FABOZZI A, LATERZA MM, VENTRIGLIA J, SAVASTANO B, PETRILLO A, GAMBARDELLA V, SFORZA V, MARANO L, AURICCHIO A, GALIZIA G, CIARDIELLO F, ORDITURA M. CLINICAL MANAGEMENT OF ADVANCED GASTRIC CANCER: THE ROLE OF NEW MOLECULAR DRUGS. *WORLD J GASTROENTEROL*. 2014 OCT 28;20(40):14537-58. DOI: 10.3748/WJG.V20.I40.14537. PUBMED PMID: 25356019; PUBMED CENTRAL PMCID: PMC4209522. IF 2.787 CIT. 18
99. CASALUCE F, SGAMBATO A, SACCO PC, PALAZZOLO G, MAIONE P, ROSSI A, CIARDIELLO F, GRIDELLI C. EMERGING DRUGS TARGETING PD-1 AND PD-L1: REALITY OR HOPE? EXPERT OPIN EMERG DRUGS. 2014 DEC;19(4):557-69. DOI: 10.1517/14728214.2014.964682. EPUB 2014 SEP 25. PUBMED PMID: 25253438. IF 2.120 CIT. 4
100. FASANO M, DELLA CORTE CM, CAPUANO A, SASSO FC, PAPACCIO F, BERRINO L, CIARDIELLO F, MORGILLO F. A MULTICENTER, OPEN-LABEL PHASE II STUDY OF METFORMIN WITH ERLOTINIB IN SECOND-LINE THERAPY OF STAGE IV NON-SMALL-CELL LUNG CANCER PATIENTS: TREATMENT RATIONALE AND PROTOCOL DYNAMICS OF THE METAL TRIAL. *CLIN LUNG CANCER*. 2015 JAN;16(1):57-9. DOI: 10.1016/J.CLCC.2014.06.010. EPUB 2014 AUG 17. PUBMED PMID: 25242667. IF 3.030 CIT. 6
101. FABERI A, MARIANELLA RM, FUSELLI F, LA MANTIA A, CIARDIELLO F, MONTESANO C, MASCINI M, SERGI M, COMPAGNONE D. FATTY ACID COMPOSITION AND $\Delta^{13}C$ OF BULK AND INDIVIDUAL FATTY ACIDS AS MARKER FOR AUTHENTICATING ITALIAN PDO/PGI EXTRA VIRGIN OLIVE OILS BY MEANS OF ISOTOPIC RATIO MASS SPECTROMETRY. *J MASS SPECTROM*. 2014 SEP;49(9):840-9. DOI: 10.1002/JMS.3399. PUBMED PMID: 25230181. IF 2.541 CIT. 3
102. CHENG AL, LI J, VAID AK, MA BB, TEH C, AHN JB, BELLO M, CHAROENTUM C, CHEN LT, DE LIMA LOPES G JR, HO GF, KONG HL, LAM KO, LIU TS, PARK YS, SRIURANPONG V, SUDOYO AW, WANG JY, ZHANG J, ZHANG SZ, CIARDIELLO F, KÖHNE CH, SHAW M, KIM TW. ADAPTATION OF INTERNATIONAL GUIDELINES FOR METASTATIC COLORECTAL CANCER: AN ASIAN CONSENSUS. *CLIN COLORECTAL CANCER*. 2014 SEP;13(3):145-55. DOI: 10.1016/J.CLCC.2014.06.004. EPUB 2014 JUN 26. PUBMED PMID: 25209093. IF 3.090 CIT. 4
103. D'AMATO C, ROSA R, MARCIANO R, D'AMATO V, FORMISANO L, NAPPI L, RAIMONDO L, DI MAURO C, SERVETTO A, FULCINITI F, CIPOLLETTA A, BIANCO C, CIARDIELLO F, VENEZIANI BM, DE PLACIDO S, BIANCO R. INHIBITION OF HEDGEHOG SIGNALLING BY NVP-LDE225 (ERISMODEGIB) INTERFERES WITH GROWTH AND INVASION OF HUMAN RENAL CELL CARCINOMA CELLS. *BR J CANCER*. 2014 SEP 9;111(6):1168-79. DOI: 10.1038/BJC.2014.421. EPUB 2014 AUG 5. PUBMED PMID: 25093491. IF 5.569 CIT. 7
104. POPESCU R, CIARDIELLO F, STAHEL R; ESMO EXECUTIVE BOARD. REPLY TO THE LETTER TO THE EDITOR 'STILL A LONG WAY TO GO TO ACHIEVE MULTIDISCIPLINARITY FOR THE BENEFIT OF PATIENTS: COMMENTARY ON THE ESMO POSITION PAPER' BY VALENTINI ET AL. *ANN ONCOL*. 2014 SEP;25(9):1865. DOI: 10.1093/ANNONC/MDU246. EPUB 2014 JUL 15. PUBMED PMID: 25028706. IF 9.269 CIT. 1
105. CREE IA, DEANS Z, LIGTENBERG MJ, NORMANNO N, EDSJÖ A, ROULEAU E, SOLÉ F, THUNNISSEN E, TIMENS W, SCHUURING E, DEQUEKER E, MURRAY S, DIETEL M, GROENEN P, VAN KRIEKEN JH; EUROPEAN SOCIETY OF PATHOLOGY TASK FORCE ON QUALITY ASSURANCE IN MOLECULAR PATHOLOGY; ROYAL COLLEGE OF PATHOLOGISTS. GUIDANCE FOR LABORATORIES PERFORMING MOLECULAR PATHOLOGY FOR CANCER PATIENTS. *J CLIN PATHOL*. 2014 NOV;67(11):923-31. DOI: 10.1136/JCLINPATH-2014-202404. EPUB 2014 JUL 10. PUBMED PMID: 25012948; PUBMED CENTRAL PMCID: PMC4215286. IF 2.912 CIT. 15
106. GEVA R, VECCHIONE L, KALOGERAS KT, VITTRUP JENSEN B, LENZ HJ, YOSHINO T, PAEZ D, MONTAGUT C, SOUGLAKOS J, CAPPUZZO F, CERVANTES A, FRATTINI M, FOUNTZILAS G, JOHANSEN JS, HØGDALL EV, ZHANG W, YANG D, YAMAZAKI K, NISHINA T, PAPAMICHAEL D, VINCENZI B, MACARULLA T, LOUPAKIS F, DE SCHUTTER J, SPINDLER KL, PFEIFFER P, CIARDIELLO F, PIESSEVAUX H, TEJPAR S. FCGR POLYMORPHISMS AND CETUXIMAB EFFICACY IN CHEMOREFRACTORY METASTATIC COLORECTAL CANCER: AN INTERNATIONAL CONSORTIUM STUDY. *GUT*. 2014 JUL 10.

PII: GUTJNL-2014-307234. DOI: 10.1136/GUTJNL-2014-307234. [EPUB AHEAD OF PRINT] PUBMED PMID: 25011934. IF 14.921 CIT.8

- 107.SGAMBATO A, CASALUCE F, MAIONE P, ROSSI A, CIARDIELLO F, GRIDELLI C. CETUXIMAB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): THE SHOWDOWN? J THORAC DIS. 2014 JUN;6(6):578-80. DOI: 10.3978/J.ISSN.2072-1439.2014.06.14. PUBMED PMID: 24976974; PUBMED CENTRAL PMCID: PMC4073354. IF 5.040 CIT. 9
- 108.CIARDIELLO F, ARNOLD D, CASALI PG, CERVANTES A, DOUILLARD JY, EGGERMONT A, ENIU A, MCGREGOR K, PETERS S, PICCART M, POPESCU R, VAN CUTSEM E, ZIELINSKI C, STAHEL R. DELIVERING PRECISION MEDICINE IN ONCOLOGY TODAY AND IN FUTURE-THE PROMISE AND CHALLENGES OF PERSONALISED CANCER MEDICINE: A POSITION PAPER BY THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO). ANN ONCOL. 2014 SEP;25(9):1673-8. DOI: 10.1093/ANNONC/MDU217. EPUB 2014 JUN 20. PUBMED PMID: 24950979. IF 9.269 CIT. 31
- 109.CIARDIELLO F, NORMANNO N, MAIELLO E, MARTINELLI E, TROIANI T, PISCONTI S, GIULIANI F, BARONE C, CARTENÌ G, RACHIGLIO AM, MONTESARCHIO V, TONINI G, RIZZI D, CINIERI S, BORDONARO R, FEBBRARO A, DE VITA F, ORDITURA M, FENZIA F, LAMBIASE M, RINALDI A, TATANGELO F, BOTTI G, COLUCCI G. CLINICAL ACTIVITY OF FOLFIRI PLUS CETUXIMAB ACCORDING TO EXTENDED GENE MUTATION STATUS BY NEXT-GENERATION SEQUENCING: FINDINGS FROM THE CAPRI-GOIM TRIAL. ANN ONCOL. 2014 SEP;25(9):1756-61. DOI: 10.1093/ANNONC/MDU230. EPUB 2014 JUN 18. PUBMED PMID: 24942275. IF 9.269 CIT. 28
- 110.ORDITURA M, GALIZIA G, DI MARTINO N, ANCONA E, CASTORO C, PACELLI R, MORGILLO F, ROSSETTI S, GAMBARDELLA V, FARELLA A, LATERZA MM, RUOL A, FABOZZI A, NAPOLITANO V, IOVINO F, LIETO E, FEI L, CONZO G, CIARDIELLO F, DE VITA F. EFFECT OF PREOPERATIVE CHEMORADIOTHERAPY ON OUTCOME OF PATIENTS WITH LOCALLY ADVANCED ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA-A PILOT STUDY. CURR ONCOL. 2014 JUN;21(3):125-33. DOI: 10.3747/CO.21.1570. PUBMED PMID: 24940093; PUBMED CENTRAL PMCID: PMC4059797. IF 1.829 CIT. 5
- 111.ROSSI A, MAIONE P, SACCO PC, SGAMBATO A, CASALUCE F, FERRARA ML, PALAZZOLO G, CIARDIELLO F, GRIDELLI C. ALK INHIBITORS AND ADVANCED NON-SMALL CELL LUNG CANCER (REVIEW). INT J ONCOL. 2014 AUG;45(2):499-508. DOI: 10.3892/IJO.2014.2475. EPUB 2014 MAY 29. PUBMED PMID: 24889366. IF 3.018 CIT. 16
- 112.TROIANI T, NAPOLITANO S, VITAGLIANO D, MORGILLO F, CAPASSO A, SFORZA V, NAPPI A, CIARDIELLO D, CIARDIELLO F, MARTINELLI E. PRIMARY AND ACQUIRED RESISTANCE OF COLORECTAL CANCER CELLS TO ANTI-EGFR ANTIBODIES CONVERGE ON MEK/ERK PATHWAY ACTIVATION AND CAN BE OVERCOME BY COMBINED MEK/EGFR INHIBITION. CLIN CANCER RES. 2014 JUL 15;20(14):3775-86. DOI: 10.1158/1078-0432.CCR-13-2181. EPUB 2014 MAY 8. PUBMED PMID: 24812410. IF 8.738 CIT. 23
- 113.GRIDELLI C, NOVELLO S, ZILEMBO N, LUCIANI A, FAVARETTO AG, DE MARINIS F, GENESTRETI G, CRINÒ L, GROSSI F, CAFFO O, FERRAÙ F, CRUCIANI G, BRANDES AA, GALETTA D, BARNI S, FASOLA G, CERA G, FERRARI S, IANNAONE C, CIARDIELLO F. PHASE II RANDOMIZED STUDY OF VANDETANIB PLUS GEMCITABINE OR GEMCITABINE PLUS PLACEBO AS FIRST-LINE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER IN ELDERLY PATIENTS. J THORAC ONCOL. 2014 MAY;9(5):733-7. DOI: 10.1097/JTO.000000000000120. PUBMED PMID: 24722160. IF 5.040 CIT. 10
- 114.FASANO M, DELLA CORTE CM, CALIFANO R, CAPUANO A, TROIANI T, MARTINELLI E, CIARDIELLO F, MORGILLO F. TYPE III OR ALLOSTERIC KINASE INHIBITORS FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER. EXPERT OPIN INVESTIG DRUGS. 2014 JUN;23(6):809-21. DOI: 10.1517/13543784.2014.902934. EPUB 2014 MAR 28. PUBMED PMID: 24673358. IF 2.120 CIT. 93
- 115.ORDITURA M, GALIZIA G, SFORZA V, GAMBARDELLA V, FABOZZI A, LATERZA MM, ANDREOZZI F, VENTRIGLIA J, SAVASTANO B, MABILIA A, LIETO E, CIARDIELLO F, DE VITA F. TREATMENT OF GASTRIC CANCER. WORLD J GASTROENTEROL. 2014 FEB 21;20(7):1635-49. DOI: 10.3748/WJG.V20.17.1635. REVIEW. PUBMED PMID: 24587643; PUBMED CENTRAL PMCID: PMC3930964. IF 2.787 CIT.
- 116.GRIDELLI C, DE MARINIS F, CAPPUZZO F, DI MAIO M, HIRSCH FR, MOK T, MORGILLO F, ROSELL R, SPIGEL DR, YANG JC, CIARDIELLO F. TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION OR ALK GENE REARRANGEMENT: RESULTS OF AN INTERNATIONAL EXPERT PANEL MEETING OF THE ITALIAN ASSOCIATION OF

THORACIC ONCOLOGY. CLIN LUNG CANCER. 2014 MAY;15(3):173-81. DOI: 10.1016/J.CLLC.2013.12.002. EPUB 2013 DEC 27. REVIEW. PUBMED PMID: 24486058. IF 3.030 CIT. 31

117. GRIDELLI C, ROSSI A, DI MAIO M, LEO S, FILIPAZZI V, FAVARETTO AG, BURGIO MA, CINIERI S, BIANCO R, CIARDIELLO F, CAVANNA L, BORDONARO R, COSTANZO R, SANDOMENICO C, GALLO C, PERRONE F, MORABITO A. RATIONALE AND DESIGN OF MILES-3 AND MILES-4 STUDIES: TWO RANDOMIZED PHASE 3 TRIALS COMPARING SINGLE-AGENT CHEMOTHERAPY VERSUS CISPLATIN-BASED DOUBLET IN ELDERLY PATIENTS WITH ADVANCED NON--SMALL-CELL LUNG CANCER. CLIN LUNG CANCER. 2014 MAR;15(2):166-70. DOI: 10.1016/J.CLLC.2013.11.011. EPUB 2013 NOV 20. PUBMED PMID: 24418693. IF 3.030 CIT. 12
118. ESPOSITO K, CIARDIELLO F, GIUGLIANO D. UNHEALTHY DIETS: A COMMON SOIL FOR THE ASSOCIATION OF METABOLIC SYNDROME AND CANCER. ENDOCRINE. 2014 MAY;46(1):39-42. DOI: 10.1007/S12020-013-0151-4. EPUB 2014 JAN 10. PUBMED PMID: 24408049. 3.279 CIT. 5
119. POPESCU RA, SCHÄFER R, CALIFANO R, ECKERT R, COLEMAN R, DOUILLARD JY, CERVANTES A, CASALI PG, SESSA C, VAN CUTSEM E, DE VRIES E, PAVLIDIS N, FUMASOLI K, WÖRMANN B, SAMONIGG H, CASCINU S, CRUZ HERNÁNDEZ JJ, HOWARD AJ, CIARDIELLO F, STAHEL RA, PICCART M. THE CURRENT AND FUTURE ROLE OF THE MEDICAL ONCOLOGIST IN THE PROFESSIONAL CARE FOR CANCER PATIENTS: A POSITION PAPER BY THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO). ANN ONCOL. 2014 JAN;25(1):9-15. DOI: 10.1093/ANNONC/MDT522. EPUB 2013 DEC 13. ERRATUM IN: ANN ONCOL. 2014 APR;25(4):916. PUBMED PMID: 24335854. IF 9.269 CIT. 19
120. BUTTS C, SOCINSKI MA, MITCHELL PL, THATCHER N, HAVEL L, KRZAKOWSKI M, NAWROCKI S, CIULEANU TE, BOSQUÉE L, TRIGO JM, SPIRA A, TREMBLAY L, NYMAN J, RAMLAU R, WICKART-JOHANSSON G, ELLIS P, GLADKOV O, PEREIRA JR, EBERHARDT WE, HELWIG C, SCHRÖDER A, SHEPHERD FA; START TRIAL TEAM. TECEMOTIDE (L-BLP25) VERSUS PLACEBO AFTER CHEMORADIOTHERAPY FOR STAGE III NON-SMALL-CELL LUNG CANCER (START): A RANDOMISED, DOUBLE-BLIND, PHASE 3 TRIAL. LANCET ONCOL. 2014 JAN;15(1):59-68. DOI: 10.1016/S1470-2045(13)70510-2. EPUB 2013 DEC 9. PUBMED PMID: 24331154. IF 26.509 CIT. 141
121. GALIZIA G, DE VITA F, LIETO E, ZAMBOLI A, MORGILLO F, CASTELLANO P, MABILIA A, AURICCHIO A, RENDA A, CIARDIELLO F, ORDITURA M. CONVERSION CHEMOTHERAPY FOLLOWED BY HEPATIC RESECTION IN COLORECTAL CANCER WITH INITIALLY UNRESECTABLE LIVER-LIMITED METASTASES. ONCOL REP. 2013 DEC;30(6):2992-8. DOI: 10.3892/OR.2013.2795. EPUB 2013 OCT 11. PUBMED PMID: 24126855. IF 2.486 CIT. 4
122. TROIANI T, MARTINELLI E, NAPOLITANO S, VITAGLIANO D, CIUFFREDA LP, COSTANTINO S, MORGILLO F, CAPASSO A, SFORZA V, NAPPI A, DE PALMA R, D'AIUTO E, BERRINO L, BIANCO R, CIARDIELLO F. INCREASED TGF- α AS A MECHANISM OF ACQUIRED RESISTANCE TO THE ANTI-EGFR INHIBITOR CETUXIMAB THROUGH EGFR-MET INTERACTION AND ACTIVATION OF MET SIGNALING IN COLON CANCER CELLS. CLIN CANCER RES. 2013 DEC 15;19(24):6751-65. DOI: 10.1158/1078-0432.CCR-13-0423. EPUB 2013 OCT 11. PUBMED PMID: 24122793. IF 8.738 CIT. 49
123. ORDITURA M, GALIZIA G, FABOZZI A, LIETO E, GAMBARDELLA V, MORGILLO F, DEL GENIO GM, FEI L, DI MARTINO N, RENDA A, CIARDIELLO F, DE VITA F. PREOPERATIVE TREATMENT OF LOCALLY ADVANCED ESOPHAGEAL CARCINOMA (REVIEW). INT J ONCOL. 2013 DEC;43(6):1745-53. DOI: 10.3892/IJO.2013.2118. EPUB 2013 OCT 2. REVIEW. PUBMED PMID: 24100679. IF 3.018 CIT. 4
124. ESPOSITO C, RACHIGLIO AM, LA PORTA ML, SACCO A, ROMA C, IANNACCONE A, TATANGELO F, FORGIONE L, PASQUALE R, BARBARO A, BOTTI G, CIARDIELLO F, NORMANNO N. THE S492R EGFR ECTODOMAIN MUTATION IS NEVER DETECTED IN KRAS WILD-TYPE COLORECTAL CARCINOMA BEFORE EXPOSURE TO EGFR MONOCLONAL ANTIBODIES. CANCER BIOL THER. 2013 DEC;14(12):1143-6. DOI: 10.4161/CBT.26340. EPUB 2013 SEP 23. PUBMED PMID: 24025416; PUBMED CENTRAL PMCID: PMC3912037. IF 2.921 CIT. 17
125. TROIANI T, MARTINELLI E, NAPOLITANO S, MORGILLO F, BELLI G, CIOFFI L, CIARDIELLO F. MOLECULAR ASPECTS OF RESISTANCE TO BIOLOGICAL AND NON-BIOLOGICAL DRUGS AND STRATEGIES TO OVERCOME RESISTANCE IN COLORECTAL CANCER. CURR MED CHEM. 2014;21(14):1639-53. REVIEW. PUBMED PMID: 23992332. IF 3.455 CIT. 10
126. MORGILLO F, SASSO FC, DELLA CORTE CM, FESTINO L, MANZO A, MARTINELLI E, TROIANI T, CAPUANO A, CIARDIELLO F. METFORMIN IN LUNG CANCER: RATIONALE FOR A COMBINATION

- THERAPY. EXPERT OPIN INVESTIG DRUGS. 2013 NOV;22(11):1401-9. DOI: 10.1517/13543784.2013.828691. EPUB 2013 AUG 12. REVIEW. PUBMED PMID: 23937224. IF 4.408 CIT. 5
- 127.GRIDELLI C, PETERS S, SGAMBATO A, CASALUCE F, ADJEI AA, CIARDIELLO F. ALK INHIBITORS IN THE TREATMENT OF ADVANCED NSCLC. CANCER TREAT REV. 2014 MAR;40(2):300-6. DOI: 10.1016/J.CTRV.2013.07.002. EPUB 2013 AUG 7. REVIEW. PUBMED PMID: 23931927. IF 7.983 CIT. 67
- 128.MORGILLO F, DE VITA F, ANTONIOL G, ORDITURA M, AURIEMMA PP, DIADEMA MR, LIETO E, SAVASTANO B, FESTINO L, LATERZA MM, FABOZZI A, VENTRIGLIA J, PETRILLO A, CIARDIELLO F, BARBARISI A, IOVINO F. SERUM INSULIN-LIKE GROWTH FACTOR 1 CORRELATES WITH THE RISK OF NODAL METASTASIS IN ENDOCRINE-POSITIVE BREAST CANCER. CURR ONCOL. 2013 AUG;20(4): E283-8. DOI: 10.3747/CO.20.1380. PUBMED PMID: 23904766; PUBMED CENTRAL PMCID: PMC3728056. IF 1.829 CIT. 11
- 129.SGAMBATO A, CASALUCE F, MAIONE P, ROSSI A, SACCO PC, PANZONE F, CIARDIELLO F, GRIDELLI C. MEDICAL TREATMENT OF SMALL CELL LUNG CANCER: STATE OF THE ART AND NEW DEVELOPMENT. EXPERT OPIN PHARMACOTHER. 2013 OCT;14(15):2019-31. DOI: 10.1517/14656566.2013.823401. EPUB 2013 AUG 1. REVIEW. PUBMED PMID: 23901936. IF 3.543 CIT. 17
- 130.MORGILLO F, SASSO FC, DELLA CORTE CM, VITAGLIANO D, D'AIUTO E, TROIANI T, MARTINELLI E, DE VITA F, ORDITURA M, DE PALMA R, CIARDIELLO F. SYNERGISTIC EFFECTS OF METFORMIN TREATMENT IN COMBINATION WITH GEFITINIB, A SELECTIVE EGFR TYROSINE KINASE INHIBITOR, IN LKB1 WILD-TYPE NSCLC CELL LINES. CLIN CANCER RES. 2013 JUL 1;19(13):3508-19. DOI: 10.1158/1078-0432.CCR-12-2777. EPUB 2013 MAY 21. PUBMED PMID: 23695170. IF 8.738 CIT. 34
- 131.VAN CUTSEM E, BORRÀS JM, CASTELLS A, CIARDIELLO F, DUCREUX M, HAQ A, SCHMOLL HJ, TABERNERO J. IMPROVING OUTCOMES IN COLORECTAL CANCER: WHERE DO WE GO FROM HERE? EUR J CANCER. 2013 JUL;49(11):2476-85. DOI: 10.1016/J.EJCA.2013.03.026. EPUB 2013 APR 30. REVIEW. PUBMED PMID: 23642327. IF 6.163 CIT. 21
- 132.MARTINELLI E, TROIANI T, D'AIUTO E, MORGILLO F, VITAGLIANO D, CAPASSO A, COSTANTINO S, CIUFFREDA LP, MEROLLA F, VECCHIONE L, DE VRIENDT V, TEJPAR S, NAPPI A, SFORZA V, MARTINI G, BERRINO L, DE PALMA R, CIARDIELLO F. ANTITUMOR ACTIVITY OF PIMASERTIB, A SELECTIVE MEK 1/2 INHIBITOR, IN COMBINATION WITH PI3K/MTOR INHIBITORS OR WITH MULTI-TARGETED KINASE INHIBITORS IN PIMASERTIB-RESISTANT HUMAN LUNG AND COLORECTAL CANCER CELLS. INT J CANCER. 2013 NOV;133(9):2089-101. DOI: 10.1002/IJC.28236. EPUB 2013 MAY 29. PUBMED PMID: 23629727. IF 5.531 CIT. 38
- 133.VAN KRIEKEN JH, SIEBERS AG, NORMANNO N; QUALITY ASSURANCE FOR MOLECULAR PATHOLOGY GROUP. EUROPEAN CONSENSUS CONFERENCE FOR EXTERNAL QUALITY ASSESSMENT IN MOLECULAR PATHOLOGY. ANN ONCOL. 2013 AUG;24(8):1958-63. DOI: 10.1093/ANNONC/MDT153. EPUB 2013 APR 23. REVIEW. PUBMED PMID: 23613479. IF 9.269 CIT. 22
- 134.FESTINO L, FABOZZI A, MANZO A, GAMBARDELLA V, MARTINELLI E, TROIANI T, DE VITA F, ORDITURA M, CIARDIELLO F, MORGILLO F. CRITICAL APPRAISAL OF THE USE OF REGORAFENIB IN THE MANAGEMENT OF COLORECTAL CANCER. CANCER MANAG RES. 2013 APR 12; 5:49-55. DOI: 10.2147/CMAR.S34281. PRINT 2013. PUBMED PMID: 23610528; PUBMED CENTRAL PMCID: PMC3628528. IF 4.790 CIT. 14
- 135.LORDICK F, KANG YK, CHUNG HC, SALMAN P, OH SC, BODOKY G, KURTEVA G, VOLOVAT C, MOISEYENKO VM, GORBUNOVA V, PARK JO, SAWAKI A, CELIK I, GÖTTE H, MELEZÍNKOVÁ H, MOEHLER M; ARBEITSGEMEINSCHAFT INTERNISTISCHE ONKOLOGIE AND EXPAND INVESTIGATORS. CAPECITABINE AND CISPLATIN WITH OR WITHOUT CETUXIMAB FOR PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED GASTRIC CANCER (EXPAND): A RANDOMISED, OPEN-LABEL PHASE 3 TRIAL. LANCET ONCOL. 2013 MAY;14(6):490-9. DOI: 10.1016/S1470-2045(13)70102-5. EPUB 2013 APR 15. PUBMED PMID: 23594786. IF 26.509 CIT. 330
- 136.PASSARO A, FASANO M, BRIA E, MORGILLO F, CANTILE F, ALESINI D, PELLEGRINO A, CORTESI E, CIARDIELLO F. DELIVERY OPTIMIZATION OF ERLOTINIB ACCORDING TO TOXICITY: MAY CLINICAL PRACTICE GO BEYOND RESEARCH? LUNG CANCER. 2013 JUN;80(3):352-3. DOI: 10.1016/J.LUNGCAN.2013.01.023. EPUB 2013 FEB 26. PUBMED PMID: 23453130. IF 3.767
- 137.CASALUCE F, SGAMBATO A, MAIONE P, CIARDIELLO F, GRIDELLI C. EMERGING MITOTIC INHIBITORS FOR NON-SMALL CELL CARCINOMA. EXPERT OPIN EMERG DRUGS. 2013 MAR;18(1):97-107. DOI: 10.1517/14728214.2013.777426. REVIEW. PUBMED PMID: 23448156. IF 2.120 CIT. 10

138. GRIDELLI C, GALLO C, BUTTS CA, CIARDIELLO F, FELD R, PERRONE F. REPLY TO V. LORUSSO ET AL. *J CLIN ONCOL*. 2013 JAN 10;31(2):289-9. PUBMED PMID: 23413460. IF 20.982
139. CASALUCE F, SGAMBATO A, MAIONE P, ROSSI A, FERRARA C, NAPOLITANO A, PALAZZOLO G, CIARDIELLO F, GRIDELLI C. ALK INHIBITORS: A NEW TARGETED THERAPY IN THE TREATMENT OF ADVANCED NSCLC. *TARGET ONCOL*. 2013 MAR;8(1):55-67. DOI: 10.1007/S11523-012-0250-9. EPUB 2013 JAN 17. REVIEW. PUBMED PMID: 23325296. IF 3.197 CIT. 43
140. TROIANI T, MARTINELLI E, MORGILLO F, CAPASSO A, NAPPI A, SFORZA V, CIARDIELLO F. TARGETED APPROACH TO METASTATIC COLORECTAL CANCER: WHAT COMES BEYOND EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND BEVACIZUMAB? *THER ADV MED ONCOL*. 2013 JAN;5(1):51-72. DOI: 10.1177/1758834012462462. PUBMED PMID: 23323147; PUBMED CENTRAL PMCID: PMC3539274. IF 2.486 CIT. 5
141. TROIANI T, ZAPPAVIGNA S, MARTINELLI E, ADDEO SR, STIUSO P, CIARDIELLO F, CARAGLIA M. OPTIMIZING TREATMENT OF METASTATIC COLORECTAL CANCER PATIENTS WITH ANTI-EGFR ANTIBODIES: OVERCOMING THE MECHANISMS OF CANCER CELL RESISTANCE. *EXPERT OPIN BIOL THER*. 2013 FEB;13(2):241-55. DOI: 10.1517/14712598.2012.756469. EPUB 2013 JAN 3. REVIEW. PUBMED PMID: 23281932. IF 3.478 CIT. 40
142. LICITRA L, STÖRKEL S, KERR KM, VAN CUTSEM E, PIRKER R, HIRSCH FR, VERMORKEN JB, VON HEYDEBRECK A, ESSER R, CELIK I, CIARDIELLO F. PREDICTIVE VALUE OF EPIDERMAL GROWTH FACTOR RECEPTOR EXPRESSION FOR FIRST-LINE CHEMOTHERAPY PLUS CETUXIMAB IN PATIENTS WITH HEAD AND NECK AND COLORECTAL CANCER: ANALYSIS OF DATA FROM THE EXTREME AND CRYSTAL STUDIES. *EUR J CANCER*. 2013 APR;49(6):1161-8. DOI: 10.1016/J.EJCA.2012.11.018. EPUB 2012 DEC 19. PUBMED PMID: 23265711. IF 6.163 CIT. 64
143. VAN KRIEKEN JH, NORMANNO N, BLACKHALL F, BOONE E, BOTTI G, CARNEIRO F, CELIK I, CIARDIELLO F, CREE IA, DEANS ZC, EDSJÖ A, GROENEN PJ, KAMARAINEN O, KREIPE HH, LIGTENBERG MJ, MARCHETTI A, MURRAY S, OPDAM FJ, PATTERSON SD, PATTON S, PINTO C, ROULEAU E, SCHUURING E, STERCK S, TARON M, TEJPAR S, TIMENS W, THUNNISSEN E, VAN DE VEN PM, SIEBERS AG, DEQUEKER E. GUIDELINE ON THE REQUIREMENTS OF EXTERNAL QUALITY ASSESSMENT PROGRAMS IN MOLECULAR PATHOLOGY. *VIRCHOWS ARCH*. 2013 JAN;462(1):27-37. DOI: 10.1007/S00428-012-1354-4. EPUB 2012 DEC 19. PUBMED PMID: 23250354. IF 2.651 CIT. 30
144. MARTINELLI E, TROIANI T, MORGILLO F, ORDITURA M, DE VITA F, BELLI G, CIARDIELLO F. EMERGING VEGF-RECEPTOR INHIBITORS FOR COLORECTAL CANCER. *EXPERT OPIN EMERG DRUGS*. 2013 MAR;18(1):25-37. DOI: 10.1517/14728214.2013.749856. EPUB 2012 DEC 6. REVIEW. PUBMED PMID: 23216053. IF 2.120 CIT. 17
145. GROTHEY A, VAN CUTSEM E, SOBRERO A, SIENA S, FALCONE A, YCHOU M, HUMBLET Y, BOUCHÉ O, MINEUR L, BARONE C, ADENIS A, TABERNERO J, YOSHINO T, LENZ HJ, GOLDBERG RM, SARGENT DJ, CIHON F, CUPIT L, WAGNER A, LAURENT D; CORRECT STUDY GROUP. REGORAFENIB MONOTHERAPY FOR PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (CORRECT): AN INTERNATIONAL, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL. *LANCET*. 2013 JAN 26;381(9863):303-12. DOI: 10.1016/S0140-6736(12)61900-X. EPUB 2012 NOV 22. PUBMED PMID: 23177514. IF 44.002 CIT. 5
146. DI MAIO M, LEIGHL NB, GALLO C, FELD R, CIARDIELLO F, BUTTS C, MAIONE P, GEBBIA V, MORGILLO F, WIERZBICKI R, FAVARETTO A, ALAM Y, CINIERI S, SIENA S, BIANCO R, RICCARDI F, SPATAFORA M, RAVAIOLI A, FELLETTI R, FREGONI V, GENESTRETI G, ROSSI A, MANCUSO G, FASANO M, MORABITO A, TSAO MS, SIGNORIELLO S, PERRONE F, GRIDELLI C; TORCH INVESTIGATORS. QUALITY OF LIFE ANALYSIS OF TORCH, A RANDOMIZED TRIAL TESTING FIRST-LINE ERLOTINIB FOLLOWED BY SECOND-LINE CISPLATIN/GEMCITABINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER. *J THORAC ONCOL*. 2012 DEC;7(12):1830-44. DOI: 10.1097/JTO.0B013E318275B327. PUBMED PMID: 23154555. IF 5.040 CIT. 9
147. SCHMOLL HJ, VAN CUTSEM E, STEIN A, VALENTINI V, GLIMELIUS B, HAUSTERMANS K, NORDLINGER B, VAN DE VELDE CJ, BALMANA J, REGULA J, NAGTEGAAL ID, BEETS-TAN RG, ARNOLD D, CIARDIELLO F, HOFF P, KERR D, KÖHNE CH, LABIANCA R, PRICE T, SCHEITHAUER W, SOBRERO A, TABERNERO J, ADERKA D, BARROSO S, BODOKY G, DOUILLARD JY, EL GHAZALY H, GALLARDO J, GARIN A, GLYNNE-JONES R, JORDAN K, MESHCHERYAKOV A, PAPAMICHAIL D, PFEIFFER P, SOUGLAKOS I, TURHAL S, CERVANTES A. ESMO CONSENSUS GUIDELINES FOR MANAGEMENT OF

PATIENTS WITH COLON AND RECTAL CANCER. A PERSONALIZED APPROACH TO CLINICAL DECISION MAKING. ANN ONCOL. 2012 OCT;23(10):2479-516. PUBMED PMID: 23012255. IF 9.269 CIT. 547

148. NORMANNO N, RACHIGLIO A, ROMA C, CIARDIELLO F, PINTO C. COMMENT ON 'A COMPARISON OF THREE METHODS FOR DETECTING KRAS MUTATIONS IN FORMALIN-FIXED COLORECTAL CANCER SPECIMENS'. BR J CANCER. 2012 NOV 6;107(10):1791-2; AUTHOR REPLY 1793-4. DOI: 10.1038/BJC.2012.431. EPUB 2012 SEP 25. PUBMED PMID: 23011482; PUBMED CENTRAL PMCID: PMC3493862. IF 5.569 CIT. 1
149. SGAMBATO A, CASALUCE F, MAIONE P, ROSSI A, ROSSI E, NAPOLITANO A, PALAZZOLO G, BARESCHINO MA, SCHETTINO C, SACCO PC, CIARDIELLO F, GRIDELLI C. THE C-MET INHIBITORS: A NEW CLASS OF DRUGS IN THE BATTLE AGAINST ADVANCED NONSMALL-CELL LUNG CANCER. CURR PHARM DES. 2012;18(37):6155-68. REVIEW. PUBMED PMID: 22873759. IF 3.052 CIT.12
150. GRIDELLI C, CIARDIELLO F, GALLO C, FELD R, BUTTS C, GEBBIA V, MAIONE P, MORGILLO F, GENESTRETI G, FAVARETTO A, LEIGHL N, WIERZBICKI R, CINIERI S, ALAM Y, SIENA S, TORTORA G, FELLETTI R, RICCARDI F, MANCUSO G, ROSSI A, CANTILE F, TSAO MS, SAIEG M, DA CUNHA SANTOS G, PICCIRILLO MC, DI MAIO M, MORABITO A, PERRONE F. FIRST-LINE ERLOTINIB FOLLOWED BY SECOND-LINE CISPLATIN-GEMCITABINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER: THE TORCH RANDOMIZED TRIAL. J CLIN ONCOL. 2012 AUG 20;30(24):3002-11. DOI: 10.1200/JCO.2011.41.2056. EPUB 2012 JUL 9. PUBMED PMID: 22778317. IF 20.982 CIT. 157
151. VAN CUTSEM E, TEJPAN S, VANBECKEVOORT D, PEETERS M, HUMBLET Y, GELDERBLOM H, VERMORKEN JB, VIRET F, GLIMELIUS B, GALLERANI E, HENDLISZ A, CATS A, MOEHLER M, SAGAERT X, VLASSAK S, SCHLICHTING M, CIARDIELLO F. INTRAPATIENT CETUXIMAB DOSE ESCALATION IN METASTATIC COLORECTAL CANCER ACCORDING TO THE GRADE OF EARLY SKIN REACTIONS: THE RANDOMIZED EVEREST STUDY. J CLIN ONCOL. 2012 AUG 10;30(23):2861-8. DOI: 10.1200/JCO.2011.40.9243. EPUB 2012 JUL 2. PUBMED PMID: 22753904. IF 20.982 CIT. 17
152. TROIANI T, MARTINELLI E, ORDITURA M, DE VITA F, CIARDIELLO F, MORGILLO F. BEYOND BEVACIZUMAB: NEW ANTI-VEGF STRATEGIES IN COLORECTAL CANCER. EXPERT OPIN INVESTIG DRUGS. 2012 JUL;21(7):949-59. DOI: 10.1517/13543784.2012.689287. EPUB 2012 MAY 22. REVIEW. PUBMED PMID: 22612461. IF 4.408 CIT. 27
153. CIARDIELLO F, NORMANNO N. HER2 SIGNALING AND RESISTANCE TO THE ANTI-EGFR MONOCLONAL ANTIBODY CETUXIMAB: A FURTHER STEP TOWARD PERSONALIZED MEDICINE FOR PATIENTS WITH COLORECTAL CANCER. CANCER DISCOV. 2011 NOV;1(6):472-4. DOI: 10.1158/2159-8290.CD-11-0261. PUBMED PMID: 22586650. IF 19.783 CIT. 12
154. TROIANI T, VECCHIONE L, MARTINELLI E, CAPASSO A, COSTANTINO S, CIUFFREDA LP, MORGILLO F, VITAGLIANO D, D'AIUTO E, DE PALMA R, TEJPAN S, VAN CUTSEM E, DE LORENZI M, CARAGLIA M, BERRINO L, CIARDIELLO F. INTRINSIC RESISTANCE TO SELUMETINIB, A SELECTIVE INHIBITOR OF MEK1/2, BY CAMP-DEPENDENT PROTEIN KINASE A ACTIVATION IN HUMAN LUNG AND COLORECTAL CANCER CELLS. BR J CANCER. 2012 MAY 8;106(10):1648-59. DOI: 10.1038/BJC.2012.129. PUBMED PMID: 22569000; PUBMED CENTRAL PMCID: PMC3349172. IF 5.569 CIT. 27
155. TROIANI T, MARTINELLI E, CAPASSO A, MORGILLO F, ORDITURA M, DE VITA F, CIARDIELLO F. TARGETING EGFR IN PANCREATIC CANCER TREATMENT. CURR DRUG TARGETS. 2012 JUN;13(6):802-10. REVIEW. PUBMED PMID: 22458527. IF 3.029 CIT. 55
156. BOKEMEYER C, VAN CUTSEM E, ROUGIER P, CIARDIELLO F, HEEGER S, SCHLICHTING M, CELIK I, KÖHNE CH. ADDITION OF CETUXIMAB TO CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR KRAS WILD-TYPE METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF THE CRYSTAL AND OPUS RANDOMISED CLINICAL TRIALS. EUR J CANCER. 2012 JUL;48(10):1466-75. DOI: 10.1016/J.EJCA.2012.02.057. EPUB 2012 MAR 23. PUBMED PMID: 22446022. IF 6.163 CIT. 309
157. DE VITA F, GIULIANI F, SILVESTRI N, ROSSETTI S, PIZZOLORUSSO A, SANTABARBARA G, GALIZIA G, COLUCCI G, CIARDIELLO F, ORDITURA M. CURRENT STATUS OF TARGETED THERAPIES IN ADVANCED GASTRIC CANCER. EXPERT OPIN THER TARGETS. 2012 APR;16 SUPPL 2: S29-34. DOI: 10.1517/14728222.2011.652616. EPUB 2012 MAR 23. REVIEW. PUBMED PMID: 22443228. IF 4.798 CIT. 38
158. GRIDELLI C, DE MARINIS F, DI MAIO M, ARDIZZONI A, BELANI CP, CAPPUZZO F, CIARDIELLO F, FIDIAS P, PAZ-ARES L, PERRONE F, PIRKER R, DE PETRIS L, STAHEL R. MAINTENANCE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER: RESULTS OF AN INTERNATIONAL EXPERT PANEL MEETING OF THE ITALIAN ASSOCIATION OF THORACIC ONCOLOGY. LUNG CANCER. 2012

- JUN;76(3):269-79. DOI: 10.1016/J.LUNGCAN.2011.12.011. EPUB 2012 JAN 21. REVIEW. PUBMED PMID: 22266040. IF 3.767 CIT. 15
159. NORMANNO N, PINTO C, CASTIGLIONE F, BARDELLI A, GAMBACORTA M, BOTTI G, NAPPI O, SIENA S, CIARDIELLO F, TADDEI G, MARCHETTI A. KRAS MUTATIONS TESTING IN COLORECTAL CARCINOMA PATIENTS IN ITALY: FROM GUIDELINES TO EXTERNAL QUALITY ASSESSMENT. PLOS ONE. 2011;6(12): E29146. DOI: 10.1371/JOURNAL.PONE.0029146. EPUB 2011 DEC 21. PUBMED PMID: 22216189; PUBMED CENTRAL PMCID: PMC3244430. IF 3.057 CIT. 25
160. MORGILLO F, MARTINELLI E, TROIANI T, ORDITURA M, DE VITA F, CIARDIELLO F. ANTITUMOR ACTIVITY OF SORAFENIB IN HUMAN CANCER CELL LINES WITH ACQUIRED RESISTANCE TO EGFR AND VEGFR TYROSINE KINASE INHIBITORS. PLOS ONE. 2011;6(12): E28841. DOI: 10.1371/JOURNAL.PONE.0028841. EPUB 2011 DEC 9. PUBMED PMID: 22174910; PUBMED CENTRAL PMCID: PMC3235154. IF 3.057 CIT. 24
161. MORELLI MP, TENTLER JJ, KULIKOWSKI GN, TAN AC, BRADSHAW-PIERCE EL, PITTS TM, BROWN AM, NALLAPAREDDY S, ARCAROLI JJ, SERKOVA NJ, HIDALGO M, CIARDIELLO F, ECKHARDT SG. PRECLINICAL ACTIVITY OF THE RATIONAL COMBINATION OF SELUMETINIB (AZD6244) IN COMBINATION WITH VORINOSTAT IN KRAS-MUTANT COLORECTAL CANCER MODELS. CLIN CANCER RES. 2012 FEB 15;18(4):1051-62. DOI: 10.1158/1078-0432.CCR-11-1507. EPUB 2011 DEC 15. PUBMED PMID: 22173548; PUBMED CENTRAL PMCID: PMC3876277. IF 8.738 CIT. 17
162. BARESCHINO MA, SCETTINO C, COLANTUONI G, ROSSI E, ROSSI A, MAIONE P, CIARDIELLO F, GRIDELLI C. THE ROLE OF ANTIANGIOGENETIC AGENTS IN THE TREATMENT OF BREAST CANCER. CURR MED CHEM. 2011;18(33):5022-32. REVIEW. PUBMED PMID: 22050750. IF 3.455 CIT. 70
163. GRIDELLI C, STAHEL R, BESSE B, CIARDIELLO F, FELIP E, GASPARINI S, GRAZIANO P, ROSSI A, DE MARINIS F. TREATMENT DECISION-MAKING FOR ADVANCED NON-SMALL CELL LUNG CANCER AND DIFFERENCES AMONG EUROPEAN COUNTRIES: 1ST AIOT-ETOP MEETING. LUNG CANCER. 2011 DEC;74(3):544-8. DOI: 10.1016/J.LUNGCAN.2011.08.013. EPUB 2011 SEP 28. PUBMED PMID: 21958448. IF 3.767 CIT. 1
164. VECCHIONE L, JACOBS B, NORMANNO N, CIARDIELLO F, TEJPAR S. EGFR-TARGETED THERAPY. EXP CELL RES. 2011 NOV 15;317(19):2765-71. DOI: 10.1016/J.YEXCR.2011.08.021. EPUB 2011 SEP 7. REVIEW. PUBMED PMID: 21925171. IF 3.378 CIT. 67
165. ORDITURA M, GALIZIA G, MORGILLO F, MARTINELLI E, LIETO E, VITIELLO F, DI MARTINO N, PACELLI R, RENDA A, CIARDIELLO F, DE VITA F. COMPLETE RESPONSE TO PREOPERATIVE CHEMORADIATION AND SURVIVAL IN ESOPHAGEAL CANCER: A POOLED ANALYSIS OF THREE SINGLE-INSTITUTION PHASE II TRIALS. DIS ESOPHAGUS. 2012 FEB;25(2):130-6. DOI: 10.1111/J.1442-2050.2011.01220. X. EPUB 2011 JUL 15. PUBMED PMID: 21762278. IF 2.146 CIT. 2
166. MORGILLO F, CASCONI T, D'AIUTO E, MARTINELLI E, TROIANI T, SAINTIGNY P, DE PALMA R, HEYMACH JV, BERRINO L, TUCCILLO C, CIARDIELLO F. ANTITUMOUR EFFICACY OF MEK INHIBITORS IN HUMAN LUNG CANCER CELLS AND THEIR DERIVATIVES WITH ACQUIRED RESISTANCE TO DIFFERENT TYROSINE KINASE INHIBITORS. BR J CANCER. 2011 JUL 26;105(3):382-92. DOI: 10.1038/BJC.2011.244. EPUB 2011 JUL 12. PUBMED PMID: 21750552; PUBMED CENTRAL PMCID: PMC3172903. IF 5.569 CIT. 33
167. STAHEL R, THATCHER N, FRÜH M, LE PÉCHOUX C, POSTMUS PE, SORENSEN JB, FELIP E; PANEL MEMBERS. 1ST ESMO CONSENSUS CONFERENCE IN LUNG CANCER; LUGANO 2010: SMALL-CELL LUNG CANCER. ANN ONCOL. 2011 SEP;22(9):1973-80. DOI: 10.1093/ANNONC/MDR313. EPUB 2011 JUL 4. PUBMED PMID: 21727198. IF 9.269 CIT. 24
168. CIARDIELLO F, TEJPAR S, NORMANNO N, MERCADANTE D, TEAGUE T, WOHLSCHLEGEL B, VAN CUTSEM E. UPTAKE OF KRAS MUTATION TESTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER IN EUROPE, LATIN AMERICA AND ASIA. TARGET ONCOL. 2011 SEP;6(3):133-45. DOI: 10.1007/S11523-011-0181-X. EPUB 2011 JUN 1. PUBMED PMID: 21630045. IF 3.197 CIT. 34
169. FELIP E, GRIDELLI C, BAAS P, ROSELL R, STAHEL R; PANEL MEMBERS. METASTATIC NON-SMALL-CELL LUNG CANCER: CONSENSUS ON PATHOLOGY AND MOLECULAR TESTS, FIRST-LINE, SECOND-LINE, AND THIRD-LINE THERAPY: 1ST ESMO CONSENSUS CONFERENCE IN LUNG CANCER; LUGANO 2010. ANN ONCOL. 2011 JUL;22(7):1507-19. DOI: 10.1093/ANNONC/MDR150. EPUB 2011 MAY 2. PUBMED PMID: 21536661. IF 9.269 CIT. 108

170. VAN CUTSEM E, KÖHNE CH, LÁNG I, FOLPRECHT G, NOWACKI MP, CASCINU S, SHCHEPOTIN I, MAUREL J, CUNNINGHAM D, TEJPAR S, SCHLICHTING M, ZUBEL A, CELIK I, ROUGIER P, CIARDIELLO F. CETUXIMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER: UPDATED ANALYSIS OF OVERALL SURVIVAL ACCORDING TO TUMOR KRAS AND BRAF MUTATION STATUS. *J CLIN ONCOL*. 2011 MAY 20;29(15):2011-9. DOI: 10.1200/JCO.2010.33.5091. EPUB 2011 APR 18. PUBMED PMID: 21502544. IF 20.982 CIT. 1090
171. ANDOLFO I, PETROSINO G, VECCHIONE L, DE ANTONELLIS P, CAPASSO M, MONTANARO D, GEMEI M, TRONCONE G, IOLASCON A, ORDITURA M, CIARDIELLO F, DE VITA F, ZOLLO M. DETECTION OF ERBB2 COPY NUMBER VARIATIONS IN PLASMA OF PATIENTS WITH ESOPHAGEAL CARCINOMA. *BMC CANCER*. 2011 APR 11; 11:126. DOI: 10.1186/1471-2407-11-126. PUBMED PMID: 21481261; PUBMED CENTRAL PMCID: PMC3094322. IF 3.265 CIT. 11
172. CASONE T, HERYNK MH, XU L, DU Z, KADARA H, NILSSON MB, OBORN CJ, PARK YY, EREZ B, JACOBY JJ, LEE JS, LIN HY, CIARDIELLO F, HERBST RS, LANGLEY RR, HEYMACH JV. UPREGULATED STROMAL EGFR AND VASCULAR REMODELING IN MOUSE XENOGRAFT MODELS OF ANGIOGENESIS INHIBITOR-RESISTANT HUMAN LUNG ADENOCARCINOMA. *J CLIN INVEST*. 2011 APR;121(4):1313-28. DOI: 10.1172/JCI42405. EPUB 2011 MAR 23. PUBMED PMID: 21436589; PUBMED CENTRAL PMCID: PMC3070607. IF 12.575 CIT. 91
173. DE VITA F, ORDITURA M, MARTINELLI E, VECCHIONE L, INNOCENTI R, SILENI VC, PINTO C, DI MAIO M, FARELLA A, TROIANI T, MORGILLO F, NAPOLITANO V, ANCONA E, DI MARTINO N, RUOL A, GALIZIA G, DEL GENIO A, CIARDIELLO F. A MULTICENTER PHASE II STUDY OF INDUCTION CHEMOTHERAPY WITH FOLFOX-4 AND CETUXIMAB FOLLOWED BY RADIATION AND CETUXIMAB IN LOCALLY ADVANCED OESOPHAGEAL CANCER. *BR J CANCER*. 2011 FEB 1;104(3):427-32. DOI: 10.1038/SJ.BJC.6606093. EPUB 2011 JAN 18. PUBMED PMID: 21245865; PUBMED CENTRAL PMCID: PMC3049578. IF 5.569 CIT. 45
174. GRIDELLI C, MORGILLO F, FAVARETTO A, DE MARINIS F, CHELLA A, CERE A G, MATTIOLI R, TORTORA G, ROSSI A, FASANO M, PASELLO G, RICCIARDI S, MAIONE P, DI MAIO M, CIARDIELLO F. SORAFENIB IN COMBINATION WITH ERLOTINIB OR WITH GEMCITABINE IN ELDERLY PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: A RANDOMIZED PHASE II STUDY. *ANN ONCOL*. 2011 JUL;22(7):1528-34. DOI: 10.1093/ANNONC/MDQ630. EPUB 2011 JAN 6. PUBMED PMID: 21212155. IF 9.269 CIT. 44
175. FIORELLI A, VICIDOMINI G, DI DOMENICO M, NAPOLITANO F, MESSINA G, MORGILLO F, CIARDIELLO F, SANTINI M. VASCULAR ENDOTHELIAL GROWTH FACTOR IN PLEURAL FLUID FOR DIFFERENTIAL DIAGNOSIS OF BENIGN AND MALIGNANT ORIGIN AND ITS CLINICAL APPLICATIONS. *INTERACT CARDIOVASC THORAC SURG*. 2011 MAR;12(3):420-4. DOI: 10.1510/ICVTS.2010.250357. EPUB 2010 DEC 20. PUBMED PMID: 21172937. IF 1.329 CIT. 27
176. CIARDIELLO F, JEZDIC S. NEW INSIGHTS ON PERSONALIZED CANCER TREATMENTS: A REPORT FROM THE ESMO CONGRESS. *EXPERT REV ANTICANCER THER*. 2011 JAN;11(1):21-3. DOI: 10.1586/ERA.10.212. PUBMED PMID: 21166507. IF 2.094 CIT. 6
177. DE ROOCK W, DE VRIENDT V, NORMANNO N, CIARDIELLO F, TEJPAR S. KRAS, BRAF, PIK3CA, AND PTEN MUTATIONS: IMPLICATIONS FOR TARGETED THERAPIES IN METASTATIC COLORECTAL CANCER. *LANCET ONCOL*. 2011 JUN;12(6):594-603. DOI: 10.1016/S1470-2045(10)70209-6. EPUB 2010 DEC 14. REVIEW. PUBMED PMID: 21163703. IF 26.509 CIT. 278
178. ZWIERZINA H, BARDELLI A, CIARDIELLO F, GARIBOLDI M, HÅKANSSON L, LAMBRECHTS D, LIND GE, LOEFFLER-RAGG J, SCHMOLL H, SIENA S, TABERNERO J, VAN CUTSEM E. MOLECULARLY TARGETED THERAPIES FOR COLORECTAL CANCER: STRATEGIES FOR IMPLEMENTING TRANSLATIONAL RESEARCH IN CLINICAL TRIALS. *CURR OPIN MOL THER*. 2010 DEC;12(6):703-11. REVIEW. PUBMED PMID: 21154162. IF 4.023
179. DE VITA F, GIULIANI F, SILVESTRI N, CATALANO G, CIARDIELLO F, ORDITURA M. HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN GASTRIC CANCER: A NEW THERAPEUTIC TARGET. *CANCER TREAT REV*. 2010 NOV;36 SUPPL 3: S11-5. DOI: 10.1016/S0305-7372(10)70014-1. REVIEW. PUBMED PMID: 21129604. IF 7.983 CIT. 74
180. VITAGLIANO D, DE FALCO V, TAMBURRINO A, COLUZZI S, TRONCONE G, CHIAPPETTA G, CIARDIELLO F, TORTORA G, FAGIN JA, RYAN AJ, CARLOMAGNO F, SANTORO M. THE TYROSINE

KINASE INHIBITOR ZD6474 BLOCKS PROLIFERATION OF RET MUTANT MEDULLARY THYROID CARCINOMA CELLS. ENDOCR RELAT CANCER. 2010 NOV 30;18(1):1-11. DOI: 10.1677/ERC-09-0292. PRINT 2011 FEB. PUBMED PMID: 20943719. IF 4.472 CIT. 49

181. MARTINELLI E, TROIANI T, MORGILLO F, RODOLICO G, VITAGLIANO D, MORELLI MP, TUCCILLO C, VECCHIONE L, CAPASSO A, ORDITURA M, DE VITA F, ECKHARDT SG, SANTORO M, BERRINO L, CIARDIELLO F. SYNERGISTIC ANTITUMOR ACTIVITY OF SORAFENIB IN COMBINATION WITH EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN COLORECTAL AND LUNG CANCER CELLS. CLIN CANCER RES. 2010 OCT 15;16(20):4990-5001. DOI: 10.1158/1078-0432.CCR-10-0923. EPUB 2010 SEP 1. PUBMED PMID: 20810384. IF 8.738 CIT.52
182. CAROTENUTO P, ROMA C, RACHIGLIO AM, TATANGELO F, PINTO C, CIARDIELLO F, NAPPI O, IAFFAIOLI RV, BOTTI G, NORMANNO N. DETECTION OF KRAS MUTATIONS IN COLORECTAL CARCINOMA PATIENTS WITH AN INTEGRATED PCR/SEQUENCING AND REAL-TIME PCR APPROACH. PHARMACOGENOMICS. 2010 AUG;11(8):1169-79. DOI: 10.2217/PGS.10.86. PUBMED PMID: 20712532. IF 3.784 CIT. 36
183. MORGILLO F, D'AIUTO E, TROIANI T, MARTINELLI E, CASCONI T, DE PALMA R, ORDITURA M, DE VITA F, CIARDIELLO F. ANTITUMOR ACTIVITY OF BORTEZOMIB IN HUMAN CANCER CELLS WITH ACQUIRED RESISTANCE TO ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS. LUNG CANCER. 2011 MAR;71(3):283-90. DOI: 10.1016/J.LUNGCAN.2010.06.005. PUBMED PMID: 20619923. IF 3.767 CIT. 31
184. DE ROOCK W, CLAES B, BERNASCONI D, DE SCHUTTER J, BIESMANS B, FOUNTZILAS G, KALOGERAS KT, KOTOULA V, PAPAMICHAEL D, LAURENT-PUIG P, PENAULT-LLORCA F, ROUGIER P, VINCENZI B, SANTINI D, TONINI G, CAPPUZZO F, FRATTINI M, MOLINARI F, SALETTI P, DE DOSSO S, MARTINI M, BARDELLI A, SIENA S, SARTORE-BIANCHI A, TABERNERO J, MACARULLA T, DI FIORE F, GANGLOFF AO, CIARDIELLO F, PFEIFFER P, QVORTRUP C, HANSEN TP, VAN CUTSEM E, PIESSEVAUX H, LAMBRECHTS D, DELORENZI M, TEJPAR S. EFFECTS OF KRAS, BRAF, NRAS, AND PIK3CA MUTATIONS ON THE EFFICACY OF CETUXIMAB PLUS CHEMOTHERAPY IN CHEMOTHERAPY-REFRACTORY METASTATIC COLORECTAL CANCER: A RETROSPECTIVE CONSORTIUM ANALYSIS. LANCET ONCOL. 2010 AUG;11(8):753-62. DOI: 10.1016/S1470-2045(10)70130-3. EPUB 2010 JUL 8. PUBMED PMID: 20619739. IF 26.509 CIT. 1137
185. VAN CUTSEM E, DICATO M, ARBER N, BERLIN J, CERVANTES A, CIARDIELLO F, DE GRAMONT A, DIAZ-RUBIO E, DUCREUX M, GEVA R, GLIMELIUS B, GLYNNE JONES R, GROTHEY A, GRUENBERGER T, HALLER D, HAUSTERMANS K, LABIANCA R, LENZ HJ, MINSKY B, NORDLINGER B, OHTSU A, PAVLIDIS N, ROUGIER P, SCHMIEGEL W, VAN DE VELDE C, SCHMOLL HJ, SOBRERO A, TABERNERO J. MOLECULAR MARKERS AND BIOLOGICAL TARGETED THERAPIES IN METASTATIC COLORECTAL CANCER: EXPERT OPINION AND RECOMMENDATIONS DERIVED FROM THE 11TH ESMO/WORLD CONGRESS ON GASTROINTESTINAL CANCER, BARCELONA, 2009. ANN ONCOL. 2010 JUN;21 SUPPL 6:VII-10. DOI: 10.1093/ANNONC/MDQ273. PUBMED PMID: 20534623. IF 9.269 CIT. 44
186. ORDITURA M, GALIZIA G, NAPOLITANO V, MARTINELLI E, PACELLI R, LIETO E, AURILIO G, VECCHIONE L, MORGILLO F, CATALANO G, CIARDIELLO F, DEL GENIO A, DI MARTINO N, DE VITA F. WEEKLY CHEMOTHERAPY WITH CISPLATIN AND PACLITAXEL AND CONCURRENT RADIATION THERAPY AS PREOPERATIVE TREATMENT IN LOCALLY ADVANCED ESOPHAGEAL CANCER: A PHASE II STUDY. CANCER INVEST. 2010 OCT;28(8):820-7. DOI: 10.3109/07357901003630926. PUBMED PMID: 20482249. IF 2.231 CIT. 28
187. VAN CUTSEM E, CIARDIELLO F. THE SEARCH FOR OPTIMAL RESPONSE PREDICTION IN CANCER LEADS TO A PERSONALIZED APPROACH. TARGET ONCOL. 2010 MAR;5(1):3-4. DOI: 10.1007/S11523-010-0139-4. EPUB 2010 MAR 28. PUBMED PMID: 20349283. IF 3.197 CIT. 12
188. NORMANNO N, TEJPAR S, CIARDIELLO F. RE: BIOMARKERS PREDICTING CLINICAL OUTCOME OF EPIDERMAL GROWTH FACTOR RECEPTOR-TARGETED THERAPY IN METASTATIC COLORECTAL CANCER. J NATL CANCER INST. 2010 APR 21;102(8):573; AUTHOR REPLY 573-5. DOI: 10.1093/JNCI/DJQ064. EPUB 2010 MAR 19. PUBMED PMID: 20305131. IF 14.697 CIT. 1
189. ORDITURA M, DE VITA F, MUTO P, VITIELLO F, MURINO P, LIETO E, VECCHIONE L, ROMANO A, MARTINELLI E, RENDA A, FERRARACCIO F, DEL GENIO A, CIARDIELLO F, GALIZIA G. ADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH STAGE III OR IV RADICALLY RESECTED GASTRIC CANCER: A PILOT STUDY. ARCH SURG. 2010 MAR;145(3):233-8. DOI: 10.1001/ARCHSURG.2010.2. PUBMED PMID: 20231623. IF 4.926 CIT. 21

190. TABERNERO J, CERVANTES A, RIVERA F, MARTINELLI E, ROJO F, VON HEYDEBRECK A, MACARULLA T, RODRIGUEZ-BRAUN E, EUGENIA VEGA-VILLEGAS M, SENGER S, RAMOS FJ, ROSELLÓ S, CELIK I, STROH C, BASELGA J, CIARDIELLO F. PHARMACOGENOMIC AND PHARMACOPROTEOMIC STUDIES OF CETUXIMAB IN METASTATIC COLORECTAL CANCER: BIOMARKER ANALYSIS OF A PHASE I DOSE-ESCALATION STUDY. *J CLIN ONCOL*. 2010 MAR 1;28(7):1181-9. DOI: 10.1200/JCO.2009.22.6043. EPUB 2010 JAN 25. PUBMED PMID: 20100964. IF 20.982 CIT. 101
191. AURILIO G, RICCI V, DE VITA F, FASANO M, FAZIO N, ORDITURA M, FUNICELLI L, DE LUCA G, IASEVOLI D, IOVINO F, CIARDIELLO F, CONZO G, NOLÈ F, LAMENDOLA M. A POSSIBLE CONNECTIVE TISSUE PRIMARY LYMPHOEPITHELIOMA-LIKE CARCINOMA (LELC). *ECANCERMEDICALSCIENCE*. 2010; 4:197. DOI: 10.3332/ECANCER.2010.197. EPUB 2010 DEC 22. PUBMED PMID: 22276042; PUBMED CENTRAL PMCID: PMC3234019. IF 1.120 CIT. 5
192. TABERNERO J, CIARDIELLO F, RIVERA F, RODRIGUEZ-BRAUN E, RAMOS FJ, MARTINELLI E, VEGA-VILLEGAS ME, ROSELLÓ S, LIEBSCHER S, KISKER O, MACARULLA T, BASELGA J, CERVANTES A. CETUXIMAB ADMINISTERED ONCE EVERY SECOND WEEK TO PATIENTS WITH METASTATIC COLORECTAL CANCER: A TWO-PART PHARMACOKINETIC/PHARMACODYNAMIC PHASE I DOSE-ESCALATION STUDY. *ANN ONCOL*. 2010 JUL;21(7):1537-45. DOI: 10.1093/ANNONC/MDP549. EPUB 2009 NOV 25. PUBMED PMID: 19940007. IF 9.269 CIT. 46
193. CIARDIELLO F, TEJPAR S, PAPAMICHAEL D. IMPLICATIONS OF KRAS MUTATION STATUS FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER. *TARGET ONCOL*. 2009 DEC;4(4):311-22. DOI: 10.1007/S11523-009-0129-6. EPUB 2009 NOV 14. PUBMED PMID: 19915942. IF 3.197 CIT. 3
194. MORELLI MP, BROWN AM, PITTS TM, TENTLER JJ, CIARDIELLO F, RYAN A, JÜRGENSMEIER JM, ECKHARDT SG. TARGETING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 AND -3 WITH CEDIRANIB (AZD2171): EFFECTS ON MIGRATION AND INVASION OF GASTROINTESTINAL CANCER CELL LINES. *MOL CANCER THER*. 2009 SEP;8(9):2546-58. DOI: 10.1158/1535-7163.MCT-09-0380. EPUB 2009 SEP 15. PUBMED PMID: 19755510; PUBMED CENTRAL PMCID: PMC2819052. IF 5.579
195. MARTINELLI E, DE PALMA R, ORDITURA M, DE VITA F, CIARDIELLO F. ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODIES IN CANCER THERAPY. *CLIN EXP IMMUNOL*. 2009 OCT;158(1):1-9. DOI: 10.1111/J.1365-2249.2009.03992. X. REVIEW. PUBMED PMID: 19737224; PUBMED CENTRAL PMCID: PMC2759052. IF 3.148 CIT. 141
196. NORMANNO N, TEJPAR S, MORGILLO F, DE LUCA A, VAN CUTSEM E, CIARDIELLO F. IMPLICATIONS FOR KRAS STATUS AND EGFR-TARGETED THERAPIES IN METASTATIC CRC. *NAT REV CLIN ONCOL*. 2009 SEP;6(9):519-27. DOI: 10.1038/NRCLINONC.2009.111. EPUB 2009 JUL 28. REVIEW. PUBMED PMID: 19636327. IF 18.786 CIT. 275
197. SCHETTINO C, BARESCHINO MA, ROSSI A, MAIONE P, CASTALDO V, MAZZEO N, SACCO PC, FERRARA ML, PALAZZOLO G, CIARDIELLO F, GRIDELLI C. THE POTENTIAL ROLE OF BEVACIZUMAB IN EARLY STAGES AND LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER. *THER ADV MED ONCOL*. 2009 JUL;1(1):5-13. DOI: 10.1177/1758834009338635. PUBMED PMID: 21789109; PUBMED CENTRAL PMCID: PMC3125989. IF 3.938 CIT. 1
198. VECCHIONE L, ORDITURA M, CIARDIELLO F, DE VITA F. NOVEL INVESTIGATIONAL DRUGS FOR GASTRIC CANCER. *EXPERT OPIN INVESTIG DRUGS*. 2009 JUL;18(7):945-55. DOI: 10.1517/13543780902969455. REVIEW. PUBMED PMID: 19466878. IF 4.408 CIT. 22
199. SCHETTINO C, BARESCHINO MA, MAIONE P, ROSSI A, CIARDIELLO F, GRIDELLI C. THE POTENTIAL ROLE OF PHARMACOGENOMIC AND GENOMIC IN THE ADJUVANT TREATMENT OF EARLY STAGE NON SMALL CELL LUNG CANCER. *CURR GENOMICS*. 2008 JUN;9(4):252-62. DOI: 10.2174/138920208784533665. PUBMED PMID: 19452042; PUBMED CENTRAL PMCID: PMC2682934. IF 2.430 CIT. 25
200. MORGILLO F, CANTILE F, FASANO M, TROIANI T, MARTINELLI E, CIARDIELLO F. RESISTANCE MECHANISMS OF TUMOUR CELLS TO EGFR INHIBITORS. *CLIN TRANSL ONCOL*. 2009 MAY;11(5):270-5. REVIEW. PUBMED PMID: 19451059. IF 2.075 CIT. 19
201. GRIDELLI C, MORABITO A, GEBBIA V, MENCOBONI M, CARROZZA F, VIGANÒ MG, VERUSIO C, BOLLINA R, MATTIOLI R, VALERIO MR, VALMADRE G, MAIONE P, ROSSI A, CASCONI T, MORGILLO F, DI MAIO M, PICCIRILLO MC, GALLO C, PERRONE F, CIARDIELLO F. CETUXIMAB AND GEMCITABINE IN ELDERLY OR ADULT PS2 PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: THE CETUXIMAB IN ADVANCED LUNG CANCER (CALC1-E AND CALC1-PS2) RANDOMIZED PHASE II

- TRIALS. LUNG CANCER. 2010 JAN;67 (1):86-92. DOI: 10.1016/J.LUNGCAN.2009.03.021. EPUB. PUBMED PMID: 19380175. IF 3.767 CIT. 40
202. ORDITURA M, DE VITA F, GALIZIA G, LIETO E, VECCHIONE L, VITIELLO F, MARTINELLI E, CIARDIELLO F. CORRELATION BETWEEN EFFICACY AND SKIN RASH OCCURRENCE FOLLOWING TREATMENT WITH THE EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR CETUXIMAB: A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS. ONCOL REP. 2009 APR; 21(4):1023-8. PUBMED PMID: 19288004. IF 2.486 CIT. 36
203. GRIDELLI C, MAIONE P, ROSSI A, FERRARA ML, BARESCINO MA, SCETTINO C, SACCOPC, CIARDIELLO F. POTENTIAL TREATMENT OPTIONS AFTER FIRST-LINE CHEMOTHERAPY FOR ADVANCED NSCLC: MAINTENANCE TREATMENT OR EARLY SECOND-LINE? ONCOLOGIST. 2009 FEB;14 (2):137-47. DOI: 10.1634/THEONCOLOGIST.2008-0152. EPUB 2009 FEB 3. PUBMED PMID: 19190239. IF 4.789 CIT. 63
204. DE VITA F, VECCHIONE L, GALIZIA G, DI MARTINO N, FABOZZI T, CATALANO G, CIARDIELLO F, ORDITURA M. PERSPECTIVES IN ADJUVANT THERAPY OF GASTRIC CANCER. ONCOLOGY. 2009; CA77 SUPPL 1:38-42. DOI: 10.1159/000258494. EPUB 2010 FEB 2. REVIEW. PUBMED PMID: 20130430. IF 2.152 CIT. 15
205. BIANCO R, ROSA R, DAMIANO V, DANIELE G, GELARDI T, GAROFALO S, TARALLO V, DE FALCO S, MELISI D, BENELLI R, ALBINI A, RYAN A, CIARDIELLO F, TORTORA G. VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 CONTRIBUTES TO RESISTANCE TO ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR DRUGS IN HUMAN CANCER CELLS. CLIN CANCER RES. 2008 AUG 15;14(16):5069-80. DOI: 10.1158/1078-0432.CCR-07-4905. EPUB 2008 AUG 11. PUBMED PMID: 18694994. IF 8.738 CIT. 120
206. GELARDI T, CAPUTO R, DAMIANO V, DANIELE G, PEPE S, CIARDIELLO F, LAHN M, BIANCO R, TORTORA G. ENZASTAURIN INHIBITS TUMOURS SENSITIVE AND RESISTANT TO ANTI-EGFR DRUGS. BR J CANCER. 2008 AUG 5;99(3):473-80. DOI: 10.1038/SJ.BJC.6604493. PUBMED PMID: 18665191; PUBMED CENTRAL PMCID: PMC2527788. IF 5.569 CIT. 18
207. GRIDELLI C, BUTTS C, CIARDIELLO F, FELD R, GALLO C, PERRONE F. AN INTERNATIONAL, MULTICENTER, RANDOMIZED PHASE III STUDY OF FIRST-LINE ERLOTINIB FOLLOWED BY SECOND-LINE CISPLATIN/GEMCITABINE VERSUS FIRST-LINE CISPLATIN/GEMCITABINE FOLLOWED BY SECOND-LINE ERLOTINIB IN ADVANCED NON-SMALL-CELL LUNG CANCER: TREATMENT RATIONALE AND PROTOCOL DYNAMICS OF THE TORCH TRIAL. CLIN LUNG CANCER. 2008 JUL;9(4):235-8. DOI: 10.3816/CLC.2008. N.037. PUBMED PMID: 18650174. IF 3.030 CIT.36
208. TORTORA G, CIARDIELLO F, GASPARINI G. COMBINED TARGETING OF EGFR-DEPENDENT AND VEGF-DEPENDENT PATHWAYS: RATIONALE, PRECLINICAL STUDIES AND CLINICAL APPLICATIONS. NAT CLIN PRACT ONCOL. 2008 SEP;5(9):521-30. DOI: 10.1038/NCPCONC1161. EPUB 2008 JUL 1. REVIEW. PUBMED PMID: 18594498. IF 9.113 CIT. 90
209. MORGILLO F, MARTINELLI E, TROIANI T, LAUS G, PEPE S, GRIDELLI C, CIARDIELLO F. SEQUENCE-DEPENDENT, SYNERGISTIC ANTIPROLIFERATIVE AND PROAPOPTOTIC EFFECTS OF THE COMBINATION OF CYTOTOXIC DRUGS AND ENZASTAURIN, A PROTEIN KINASE CBETA INHIBITOR, IN NON-SMALL CELL LUNG CANCER CELLS. MOL CANCER THER. 2008 JUN;7(6):1698-707. DOI: 10.1158/1535-7163.MCT-07-0547. PUBMED PMID: 18566241. IF 5.579 CIT. 34
210. TROIANI T, SCETTINO C, MARTINELLI E, MORGILLO F, TORTORA G, CIARDIELLO F. THE USE OF XENOGRAFT MODELS FOR THE SELECTION OF CANCER TREATMENTS WITH THE EGFR AS AN EXAMPLE. CRIT REV ONCOL HEMATOL. 2008 MAR;65(3):200-11. REVIEW. PUBMED PMID: 18389522. IF 5.039 CIT. 57
211. CASCONI T, MORELLI MP, MORGILLO F, KIM WY, RODOLICO G, PEPE S, TORTORA G, BERRINO L, LEE HY, HEYMACH JV, CIARDIELLO F. SYNERGISTIC ANTI-PROLIFERATIVE AND PRO-APOPTOTIC ACTIVITY OF COMBINED THERAPY WITH BORTEZOMIB, A PROTEASOME INHIBITOR, WITH ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) DRUGS IN HUMAN CANCER CELLS. J CELL PHYSIOL. 2008 SEP;216(3):698-707. DOI: 10.1002/JCP.21444. ERRATUM IN: J CELL PHYSIOL. 2008 OCT;217(1):290. TORTORA, GIAMPAOLO [ADDED]. PUBMED PMID: 18381602. IF 4.155 CIT. 31
212. GRIDELLI C, ARDIZZONI A, CIARDIELLO F, HANNA N, HEYMACH JV, PERRONE F, ROSELL R, SHEPHERD FA, THATCHER N, VANSTEENKISTE J, DE PETRIS L, DI MAIO M, DE MARINIS F. SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER. J THORAC ONCOL. 2008 APR;3(4):430-40. DOI: 10.1097/JTO.0B013E318168C815. PUBMED PMID: 18379366. IF 5.040 CIT. 86

213. SCHETTINO C, BARESCHINO MA, RICCI V, CIARDIELLO F. ERLOTINIB: AN EGF RECEPTOR TYROSINE KINASE INHIBITOR IN NON-SMALL-CELL LUNG CANCER TREATMENT. *EXPERT REV RESPIR MED*. 2008 APR;2(2):167-78. DOI: 10.1586/17476348.2.2.167. PUBMED PMID: 20477246. IF 2.176 CIT. 15
214. CIARDIELLO F, TORTORA G. EGFR ANTAGONISTS IN CANCER TREATMENT. *N ENGL J MED*. 2008 MAR 13;358(11):1160-74. DOI: 10.1056/NEJMRA0707704. REVIEW. ERRATUM IN: *N ENGL J MED*. 2009 APR 9;360(15):1579. PUBMED PMID: 18337605. IF 59.558 CIT. 1494
215. BIANCO R, GAROFALO S, ROSA R, DAMIANO V, GELARDI T, DANIELE G, MARCIANO R, CIARDIELLO F, TORTORA G. INHIBITION OF MTOR PATHWAY BY EVEROLIMUS COOPERATES WITH EGFR INHIBITORS IN HUMAN TUMOURS SENSITIVE AND RESISTANT TO ANTI-EGFR DRUGS. *BR J CANCER*. 2008 MAR 11;98(5):923-30. DOI: 10.1038/SJ.BJC.6604269. EPUB 2008 MAR 4. PUBMED PMID: 18319715; PUBMED CENTRAL PMCID: PMC2266842. IF 5.569 CIT. 141
216. IOVINO F, FERRARACCIO F, ORDITURA M, ANTONIOL G, MORGILLO F, CASONE T, DIADEMA MR, AURILIO G, SANTABARBARA G, RUGGIERO R, BELLI C, IRLANDESE E, FASANO M, CIARDIELLO F, PROCACCINI E, LO SCHIAVO F, CATALANO G, DE VITA F. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) LEVELS CORRELATE WITH TUMOR VEGF AND P53 OVEREXPRESSION IN ENDOCRINE POSITIVE PRIMARY BREAST CANCER. *CANCER INVEST*. 2008 APR-MAY;26(3):250-5. DOI: 10.1080/07357900701560612. PUBMED PMID: 18317965. IF 2.231 CIT.25
217. GRIDELLI C, ROSSI A, MORGILLO F, BARESCHINO MA, MAIONE P, DI MAIO M, CIARDIELLO F. A RANDOMIZED PHASE II STUDY OF PEMETREXED OR RAD001 AS SECOND-LINE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER IN ELDERLY PATIENTS: TREATMENT RATIONALE AND PROTOCOL DYNAMICS. *CLIN LUNG CANCER*. 2007 NOV;8(9):568-71. DOI: 10.3816/CLC.200.N.045. PUBMED PMID: 18186963. IF 3.030 CIT. 73
218. VENEZIANI BM, CRINITI V, CAVALIERE C, CORVIGNO S, NARDONE A, PICARELLI S, TORTORA G, CIARDIELLO F, LIMITE G, DE PLACIDO S. IN VITRO EXPANSION OF HUMAN BREAST CANCER EPITHELIAL AND MESENCHYMAL STROMAL CELLS: OPTIMIZATION OF A COCULTURE MODEL FOR PERSONALIZED THERAPY APPROACHES. *MOL CANCER THER*. 2007 DEC;6(12 PT 1):3091-100. PUBMED PMID: 18089705. IF 5.579 CIT. 8
219. BIANCO R, DAMIANO V, GELARDI T, DANIELE G, CIARDIELLO F, TORTORA G. RATIONAL COMBINATION OF TARGETED THERAPIES AS A STRATEGY TO OVERCOME THE MECHANISMS OF RESISTANCE TO INHIBITORS OF EGFR SIGNALING. *CURR PHARM DES*. 2007;13(33):3358-67. REVIEW. PUBMED PMID: 18045190. IF 3.052 CIT. 37
220. TABERNERO J, VAN CUTSEM E, DÍAZ-RUBIO E, CERVANTES A, HUMBLET Y, ANDRÉ T, VAN LAETHEM JL, SOULIÉ P, CASADO E, VERSLYPE C, VALERA JS, TORTORA G, CIARDIELLO F, KISKER O, DE GRAMONT A. PHASE II TRIAL OF CETUXIMAB IN COMBINATION WITH FLUOROURACIL, LEUCOVORIN, AND OXALIPLATIN IN THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER. *J CLIN ONCOL*. 2007 NOV 20;25(33):5225-32. PUBMED PMID: 18024868. IF 20.982 CIT. 310
221. TROIANI T, SERKOVA NJ, GUSTAFSON DL, HENTHORN TK, LOCKERBIE O, MERZ A, LONG M, MORROW M, CIARDIELLO F, ECKHARDT SG. INVESTIGATION OF TWO DOSING SCHEDULES OF VANDETANIB (ZD6474), AN INHIBITOR OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING, IN COMBINATION WITH IRINOTECAN IN A HUMAN COLON CANCER XENOGRAFT MODEL. *CLIN CANCER RES*. 2007 NOV 1;13(21):6450-8. PUBMED PMID: 17975157. IF 8.738 CIT. 36
222. CAPPUZZO F, FINOCCHIARO G, ROSSI E, JÄNNE PA, CARNAGHI C, CALANDRI C, BENCARDINO K, LIGORIO C, CIARDIELLO F, PRESSIANI T, DESTRO A, RONCALLI M, CRINO L, FRANKLIN WA, SANTORO A, VARELLA-GARCIA M. EGFR FISH ASSAY PREDICTS FOR RESPONSE TO CETUXIMAB IN CHEMOTHERAPY REFRACTORY COLORECTAL CANCER PATIENTS. *ANN ONCOL*. 2008 APR;19(4):717-23. EPUB 2007 OCT 31. PUBMED PMID: 17974556. IF 9.269 CIT. 191
223. BARESCHINO MA, SCHETTINO C, TROIANI T, MARTINELLI E, MORGILLO F, CIARDIELLO F. ERLOTINIB IN CANCER TREATMENT. *ANN ONCOL*. 2007 JUN;18 SUPPL 6:VI35-41. REVIEW. PUBMED PMID: 17591829. IF 9.269 CIT. 71

224. ORDITURA M, MARTINELLI E, GALIZIA G, VITIELLO F, FASANO M, MUTO P, CIARDIELLO F, DE VITA F. CHEMORADIOTHERAPY AS ADJUVANT TREATMENT OF GASTRIC CANCER. ANN ONCOL. 2007 JUN;18 SUPPL 6:VI133-5. REVIEW. PUBMED PMID: 17591807. IF 9.269 CIT. 18
225. DE VITA F, GIULIANI F, GALIZIA G, BELLI C, AURILIO G, SANTABARBARA G, CIARDIELLO F, CATALANO G, ORDITURA M. NEO-ADJUVANT AND ADJUVANT CHEMOTHERAPY OF GASTRIC CANCER. ANN ONCOL. 2007 JUN;18 SUPPL 6:VI120-3. REVIEW. PUBMED PMID: 17591804. IF 9.269 CIT. 58
226. FEDERICO A, MORGILLO F, TUCCILLO C, CIARDIELLO F, LOGUERCIO C. CHRONIC INFLAMMATION AND OXIDATIVE STRESS IN HUMAN CARCINOGENESIS. INT J CANCER. 2007 DEC 1;121(11):2381-6. REVIEW. PUBMED PMID: 17893868. IF 5.531 CIT. 540
227. GRIDELLI C, BARESCINO MA, SCETTINO C, ROSSI A, MAIONE P, CIARDIELLO F. ERLOTINIB IN NON-SMALL CELL LUNG CANCER TREATMENT: CURRENT STATUS AND FUTURE DEVELOPMENT. ONCOLOGIST. 2007 JUL;12(7):840-9. REVIEW. PUBMED PMID: 17673615. IF 4.789 CIT. 86
228. DAMIANO V, CAPUTO R, GAROFALO S, BIANCO R, ROSA R, MEROLA G, GELARDI T, RACIOPPI L, FONTANINI G, DE PLACIDO S, KANDIMALLA ER, AGRAWAL S, CIARDIELLO F, TORTORA G. TLR9 AGONIST ACTS BY DIFFERENT MECHANISMS SYNERGIZING WITH BEVACIZUMAB IN SENSITIVE AND CETUXIMAB-RESISTANT COLON CANCER XENOGRAFTS. PROC NATL ACAD SCI U S A. 2007 JUL 24;104(30):12468-73. EPUB 2007 JUL 16. PUBMED PMID: 17636117; PUBMED CENTRAL PMCID: PMC1920540. IF 9.674 CIT. 45
229. MORGILLO F, BARESCINO MA, BIANCO R, TORTORA G, CIARDIELLO F. PRIMARY AND ACQUIRED RESISTANCE TO ANTI-EGFR TARGETED DRUGS IN CANCER THERAPY. DIFFERENTIATION. 2007 NOV;75(9):788-99. EPUB 2007 JUL 2. REVIEW. PUBMED PMID: 17608727. IF 2.461 CIT. 75
230. BIANCO R, GELARDI T, DAMIANO V, CIARDIELLO F, TORTORA G. RATIONAL BASES FOR THE DEVELOPMENT OF EGFR INHIBITORS FOR CANCER TREATMENT. INT J BIOCHEM CELL BIOL. 2007;39(7-8):1416-31. EPUB 2007 MAY 21. REVIEW. PUBMED PMID: 17596994. IF 3.905 CIT. 98
231. GRIDELLI C, ROSSI A, MONGILLO F, BARESCINO M, MAIONE P, CIARDIELLO F. A RANDOMIZED PHASE II STUDY OF SORAFENIB/GEMCITABINE OR SORAFENIB/ERLOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER IN ELDERLY PATIENTS OR PATIENTS WITH A PERFORMANCE STATUS OF 2: TREATMENT RATIONALE AND PROTOCOL DYNAMICS. CLIN LUNG CANCER. 2007 MAY;8(6):396-8. PUBMED PMID: 17562243. IF 3.030 CIT. 28
232. CAPPUZZO F, LIGORIO C, JÄNNE PA, TOSCHI L, ROSSI E, TRISOLINI R, PAIOLI D, HOLMES AJ, MAGRINI E, FINOCCHIARO G, BARTOLINI S, CANCELLIERI A, CIARDIELLO F, PATELLI M, CRINO L, VARELLA-GARCIA M. PROSPECTIVE STUDY OF GEFITINIB IN EPIDERMAL GROWTH FACTOR RECEPTOR FLUORESCENCE IN SITU HYBRIDIZATION-POSITIVE/PHOSPHO-AKT-POSITIVE OR NEVER SMOKER PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: THE ONCOBELL TRIAL. J CLIN ONCOL. 2007 JUN 1;25(16):2248-55. PUBMED PMID: 17538169. IF 20.982 CIT. 224
233. GALIZIA G, LIETO E, DE VITA F, ORDITURA M, CASTELLANO P, TROIANI T, IMPERATORE V, CIARDIELLO F. CETUXIMAB, A CHIMERIC HUMAN MOUSE ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY, IN THE TREATMENT OF HUMAN COLORECTAL CANCER. ONCOGENE. 2007 MAY 28;26(25):3654-60. REVIEW. PUBMED PMID: 17530019. IF 7.932 CIT. 102
234. DE VITA F, GIULIANI F, ORDITURA M, MAIELLO E, GALIZIA G, DI MARTINO N, MONTEMURRO F, CARTENÌ G, MANZIONE L, ROMITO S, GEBBIA V, CIARDIELLO F, CATALANO G, COLUCCI G; GRUPPO ONCOLOGICO ITALIA MERIDIONALE. ADJUVANT CHEMOTHERAPY WITH EPIRUBICIN, LEUCOVORIN, 5-FLUOROURACIL AND ETOPOSIDE REGIMEN IN RESECTED GASTRIC CANCER PATIENTS: A RANDOMIZED PHASE III TRIAL BY THE GRUPPO ONCOLOGICO ITALIA MERIDIONALE (GOIM 9602 STUDY). ANN ONCOL. 2007 AUG;18(8):1354-8. EPUB 2007 MAY 24. PUBMED PMID: 17525087. IF 9.269 CIT. 79
235. TORTORA G, GELARDI T, CIARDIELLO F, BIANCO R. THE RATIONALE FOR THE COMBINATION OF SELECTIVE EGFR INHIBITORS WITH CYTOTOXIC DRUGS AND RADIOTHERAPY. INT J BIOL MARKERS. 2007 JAN-MAR;22(1 SUPPL 4):S47-52. REVIEW. PUBMED PMID: 17520581. IF 1.217 CIT. 23
236. GRIDELLI C, GALLO C, CERIBELLI A, GEBBIA V, GAMUCCI T, CIARDIELLO F, CAROZZA F, FAVARETTO A, DANIELE B, GALETTA D, BARBERA S, ROSETTI F, ROSSI A, MAIONE P, COGNETTI F, TESTA A, DI MAIO M, MORABITO A, PERRONE F; GECO INVESTIGATORS. FACTORIAL PHASE III RANDOMISED

- TRIAL OF ROFECOXIB AND PROLONGED CONSTANT INFUSION OF GEMCITABINE IN ADVANCED NON-SMALL-CELL LUNG CANCER: THE GEMCITABINE-COXIB IN NSCLC (GECO) STUDY. LANCET ONCOL. 2007 JUN;8(6):500-12. PUBMED PMID: 17513173. IF 26.509 CIT. 63
237. TORTORA G, BIANCO R, DANIELE G, CIARDIELLO F, MCCUBREY JA, RICCIARDI MR, CIUFFREDA L, COGNETTI F, TAFURI A, MILELLA M. OVERCOMING RESISTANCE TO MOLECULARLY TARGETED ANTICANCER THERAPIES: RATIONAL DRUG COMBINATIONS BASED ON EGFR AND MAPK INHIBITION FOR SOLID TUMOURS AND HAEMATOLOGIC MALIGNANCIES. DRUG RESIST UPDAT. 2007 JUN;10(3):81-100. EPUB 2007 MAY 7. REVIEW. PUBMED PMID: 17482503; PUBMED CENTRAL PMCID: PMC2548422. IF 7.950 CIT. 74
238. MORGILLO F, KIM WY, KIM ES, CIARDIELLO F, HONG WK, LEE HY. IMPLICATION OF THE INSULIN-LIKE GROWTH FACTOR-IR PATHWAY IN THE RESISTANCE OF NON-SMALL CELL LUNG CANCER CELLS TO TREATMENT WITH GEFITINIB. CLIN CANCER RES. 2007 MAY 1;13(9):2795-803. PUBMED PMID: 17473213. IF 8.738 CIT. 259
239. BARESCHINO MA, MORGILLO F, CIARDIELLO F. COMBINATION OF STANDARD CHEMOTHERAPY AND TARGETED AGENTS. J THORAC ONCOL. 2007 MAY;2(5 SUPPL):S19-23. REVIEW. PUBMED PMID: 17457224. IF 5.040 CIT. 2
240. ORDITURA M, LIETO E, FERRARACCIO F, DE CATALDIS G, TROIANI T, CASTELLANO P, CATALANO G, CIARDIELLO F, GALIZIA G, DE VITA F. HEPATOID CARCINOMA COLLIDING WITH A LIPOSARCOMA OF THE LEFT COLON SEROSA PRESENTING AS AN ABDOMINAL MASS. WORLD J SURG ONCOL. 2007 APR 22; 5:42. PUBMED PMID: 17448253; PUBMED CENTRAL PMCID: PMC1866233. IF 1.286
241. CASCONI T, MARTINELLI E, MORELLI MP, MORGILLO F, TROIANI T, CIARDIELLO F. EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN NON-SMALL-CELL LUNG CANCER. EXPERT OPIN DRUG DISCOV. 2007 MAR;2(3):335-48. DOI: 10.1517/17460441.2.3.335. PUBMED PMID: 23484645. IF 3.484 CIT. 4
242. CASCONI T, GRIDELLI C, CIARDIELLO F. COMBINED TARGETED THERAPIES IN NON-SMALL CELL LUNG CANCER: A WINNER STRATEGY? CURR OPIN ONCOL. 2007 MAR;19(2):98-102. REVIEW. PUBMED PMID: 17272980. IF 4.614 CIT. 30
243. MARTINELLI E, MORGILLO F, TROIANI T, TORTORA G, CIARDIELLO F. PANITUMUMAB: THE EVIDENCE OF ITS THERAPEUTIC POTENTIAL IN METASTATIC COLORECTAL CANCER CARE. CORE EVID. 2007 NOV 30;2(2):81-8. PUBMED PMID: 21221177; PUBMED CENTRAL PMCID: PMC3012427. IF 2.133 CIT.
244. BIANCO C, GIOVANNETTI E, CIARDIELLO F, MEY V, NANNIZZI S, TORTORA G, TROIANI T, PASQUALETTI F, ECKHARDT G, DE LIGUORO M, RICCIARDI S, DEL TACCA M, RABEN D, CIONINI L, DANESI R. SYNERGISTIC ANTITUMOR ACTIVITY OF ZD6474, AN INHIBITOR OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING, WITH GEMCITABINE AND IONIZING RADIATION AGAINST PANCREATIC CANCER. CLIN CANCER RES. 2006 DEC 1;12(23):7099-107. PUBMED PMID: 17145834. IF 8.738 CIT. 56
245. TROIANI T, LOCKERBIE O, MORROW M, CIARDIELLO F, ECKHARDT SG. SEQUENCE-DEPENDENT INHIBITION OF HUMAN COLON CANCER CELL GROWTH AND OF PROSURVIVAL PATHWAYS BY OXALIPLATIN IN COMBINATION WITH ZD6474 (ZACTIMA), AN INHIBITOR OF VEGFR AND EGFR TYROSINE KINASES. MOL CANCER THER. 2006 JUL;5(7):1883-94. PUBMED PMID: 16891475. IF 5.579 CIT. 42
246. ORDITURA M, MARTINELLI E, GALIZIA G, CARLOMAGNO C, AURILIO G, VECCHIONE L, LIETO E, DE PLACIDO S, CATALANO G, CIARDIELLO F, DE VITA F. WEEKLY DOCETAXEL AND CAPECITABINE IS NOT EFFECTIVE IN THE TREATMENT OF ADVANCED GASTRIC CANCER: A PHASE II STUDY. ANN ONCOL. 2006 OCT;17(10):1529-32. EPUB 2006 JUL 27. PUBMED PMID: 16873436. IF 9.269 CIT. 16
247. CIARDIELLO F, TROIANI T, BIANCO R, ORDITURA M, MORGILLO F, MARTINELLI E, MORELLI MP, CASCONI T, TORTORA G. INTERACTION BETWEEN THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND THE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) PATHWAYS: A RATIONAL APPROACH FOR MULTI-TARGET ANTICANCER THERAPY. ANN ONCOL. 2006 JUN;17 SUPPL 7: VII109-14. REVIEW. PUBMED PMID: 16760272. IF 9.269 CIT. 92
248. MORELLI MP, CASCONI T, TROIANI T, TUCCILLO C, BIANCO R, NORMANNO N, ROMANO M, VENEZIANI BM, FONTANINI G, ECKHARDT SG, DE PACIDO S, TORTORA G, CIARDIELLO F. ANTI-TUMOR ACTIVITY OF THE COMBINATION OF CETUXIMAB, AN ANTI-EGFR BLOCKING MONOCLONAL

- ANTIBODY AND ZD6474, AN INHIBITOR OF VEGFR AND EGFR TYROSINE KINASES. *J CELL PHYSIOL.* 2006 AUG;208(2):344-53. PUBMED PMID: 16688779. IF 4.155 CIT. 64
249. CIARDIELLO F, TROIANI T, CAPUTO F, DE LAURENTIIS M, TORTORA G, PALMIERI G, DE VITA F, DIADEMA MR, ORDITURA M, COLANTUONI G, GRIDELLI C, CATALANO G, DE PLACIDO S, BIANCO AR. PHASE II STUDY OF GEFITINIB IN COMBINATION WITH DOCETAXEL AS FIRST-LINE THERAPY IN METASTATIC BREAST CANCER. *BR J CANCER.* 2006 JUN 5;94(11):1604-9. PUBMED PMID: 16685276; PUBMED CENTRAL PMCID: PMC2361320. IF 5.569 CIT. 98
250. GALIZIA G, LIETO E, FERRARACCIO F, DE VITA F, CASTELLANO P, ORDITURA M, IMPERATORE V, LA MURA A, LA MANNA G, PINTO M, CATALANO G, PIGNATELLI C, CIARDIELLO F. PROGNOSTIC SIGNIFICANCE OF EPIDERMAL GROWTH FACTOR RECEPTOR EXPRESSION IN COLON CANCER PATIENTS UNDERGOING CURATIVE SURGERY. *ANN SURG ONCOL.* 2006 JUN;13(6):823-35. EPUB 2006 APR 18. PUBMED PMID: 16614884. IF 3.655 CIT. 127
251. CASCONI T, MORELLI MP, CIARDIELLO F. SMALL MOLECULE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN NON-SMALL CELL LUNG CANCER. *ANN ONCOL.* 2006 MAR;17 SUPPL 2: II46-48. REVIEW. PUBMED PMID: 16608981. 9.269 CIT. 24
252. CIARDIELLO F. EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN CANCER TREATMENT. *FUTURE ONCOL.* 2005 APR;1(2):221-34. REVIEW. PUBMED PMID: 16555994. IF 2.129 CIT. 67
253. CIARDIELLO F, DE VITA F, ORDITURA M, COMUNALE D, GALIZIA G. CETUXIMAB IN THE TREATMENT OF COLORECTAL CANCER. *FUTURE ONCOL.* 2005 APR;1(2):173-81. REVIEW. PUBMED PMID: 16555987. IF 2.129 CIT. 17
254. MAIONE P, GRIDELLI C, TROIANI T, CIARDIELLO F. COMBINING TARGETED THERAPIES AND DRUGS WITH MULTIPLE TARGETS IN THE TREATMENT OF NSCLC. *ONCOLOGIST.* 2006 MAR;11(3):274-84. REVIEW. PUBMED PMID: 16549812. IF 4.789 CIT. 89
255. GALIZIA G, FERRARACCIO F, LIETO E, ORDITURA M, CASTELLANO P, IMPERATORE V, LA MANNA G, PINTO M, CIARDIELLO F, LA MURA A, DE VITA F. P27 DOWNREGULATION AND METALLOTHIONEIN OVEREXPRESSION IN GASTRIC CANCER PATIENTS ARE ASSOCIATED WITH A POOR SURVIVAL RATE. *J SURG ONCOL.* 2006 MAR 1;93(3):241-52. PUBMED PMID: 16482605. IF 3.151 CIT. 49
256. CARLOMAGNO C, ORDITURA M, PEPE S, DE VITA F, ROMANO C, CIARDIELLO F, FERRARA C, MARTINELLI E, BIANCO R, AURILIO G, D'AGOSTINO D, TORTORA G, CATALANO G, DE PLACIDO S. CAPECITABINE PLUS WEEKLY OXALIPLATIN IN GASTROINTESTINAL TUMORS: A PHASE I STUDY. *AM J CLIN ONCOL.* 2006 FEB;29(1):85-9. PUBMED PMID: 16462509. IF 2.977 CIT. 3
257. CASCONI T, TROIANI T, MORELLI MP, GRIDELLI C, CIARDIELLO F. ANTIANGIOGENIC DRUGS IN NON-SMALL CELL LUNG CANCER TREATMENT. *CURR OPIN ONCOL.* 2006 MAR;18(2):151-5. REVIEW. PUBMED PMID: 16462184. IF 4.614 CIT. 24
258. DAMIANO V, CAPUTO R, BIANCO R, D'ARMIENTO FP, LEONARDI A, DE PLACIDO S, BIANCO AR, AGRAWAL S, CIARDIELLO F, TORTORA G. NOVEL TOLL-LIKE RECEPTOR 9 AGONIST INDUCES EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITION AND SYNERGISTIC ANTITUMOR ACTIVITY WITH EGFR INHIBITORS. *CLIN CANCER RES.* 2006 JAN 15;12(2):577-83. PUBMED PMID: 16428503. IF 8.738 CIT. 57
259. FREDERICK B, GUSTAFSON D, BIANCO C, CIARDIELLO F, DIMERY I, RABEN D. ZD6474, AN INHIBITOR OF VEGFR AND EGFR TYROSINE KINASE ACTIVITY IN COMBINATION WITH RADIOTHERAPY. *INT J RADIAT ONCOL BIOL PHYS.* 2006 JAN 1;64(1):33-7. PUBMED PMID: 16377413. IF 4.495 CIT. 40
260. BIANCO R, MELISI D, CIARDIELLO F, TORTORA G. KEY CANCER CELL SIGNAL TRANSDUCTION PATHWAYS AS THERAPEUTIC TARGETS. *EUR J CANCER.* 2006 FEB;42(3):290-4. EPUB 2006 JAN 11. REVIEW. PUBMED PMID: 16376541. IF 6.163 CIT. 131
261. MELISI D, CAPUTO R, DAMIANO V, BIANCO R, VENEZIANI BM, BIANCO AR, DE PLACIDO S, CIARDIELLO F, TORTORA G. ZOLEDRONIC ACID COOPERATES WITH A CYCLOOXYGENASE-2 INHIBITOR AND GEFITINIB IN INHIBITING BREAST AND PROSTATE CANCER. *ENDOCR RELAT CANCER.* 2005 DEC;12(4):1051-8. PUBMED PMID: 16322342. IF 4.472 CIT. 35
262. CIARDIELLO F, DE VITA F. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS IN CANCER THERAPY. *PROG DRUG RES.* 2005; 63:93-114. REVIEW. PUBMED PMID: 16265878. CIT. 143

263. CIARDIELLO F, MA B. [EGF RECEPTOR BLOCKADE WITH MONOCLONAL ANTIBODIS AND SO-CALLED "SMALL MOLECULES"]. ONKOLOGIE. 2005 OCT;28 SUPPL 4:18-24. EPUB 2005 OCT 3. GERMAN. PUBMED PMID: 16205101. IF 1.522 CIT. 1
264. TUCCILLO C, CUOMO A, ROCCO A, MARTINELLI E, STAIBANO S, MASCOLO M, GRAVINA AG, NARDONE G, RICCI V, CIARDIELLO F, DEL VECCHIO BLANCO C, ROMANO M. VASCULAR ENDOTHELIAL GROWTH FACTOR AND NEO-ANGIOGENESIS IN H. PYLORI GASTRITIS IN HUMANS. J PATHOL. 2005 NOV;207(3):277-84. PUBMED PMID: 16184519. IF 7.381 CIT. 42
265. BIANCO R, TROIANI T, TORTORA G, CIARDIELLO F. INTRINSIC AND ACQUIRED RESISTANCE TO EGFR INHIBITORS IN HUMAN CANCER THERAPY. ENDOCR RELAT CANCER. 2005 JUL;12 SUPPL 1: S159-71. REVIEW. PUBMED PMID: 16113092. IF 4.472 CIT. 99
266. GEE JM, HOWELL A, GULLICK WJ, BENZ CC, SUTHERLAND RL, SANTEN RJ, MARTIN LA, CIARDIELLO F, MILLER WR, DOWSETT M, BARRETT-LEE P, ROBERTSON JF, JOHNSTON SR, JONES HE, WAKELING AE, DUNCAN R, NICHOLSON RI. CONSENSUS STATEMENT. WORKSHOP ON THERAPEUTIC RESISTANCE IN BREAST CANCER: IMPACT OF GROWTH FACTOR SIGNALLING PATHWAYS AND IMPLICATIONS FOR FUTURE TREATMENT. ENDOCR RELAT CANCER. 2005 JUL; 12 SUPPL 1:S1-7. REVIEW. PUBMED PMID: 16113086. IF 4.472 CIT. 36
267. DAMIANO V, MELISI D, BIANCO C, RABEN D, CAPUTO R, FONTANINI G, BIANCO R, RYAN A, BIANCO AR, DE PLACIDO S, CIARDIELLO F, TORTORA G. COOPERATIVE ANTITUMOR EFFECT OF MULTITARGETED KINASE INHIBITOR ZD6474 AND IONIZING RADIATION IN GLIOBLASTOMA. CLIN CANCER RES. 2005 AUG 1;11(15):5639-44. PUBMED PMID: 16061883. IF 8.738 CIT. 86
268. DE LAURENTIIS M, ARPINO G, MASSARELLI E, RUGGIERO A, CARLOMAGNO C, CIARDIELLO F, TORTORA G, D'AGOSTINO D, CAPUTO F, CANCELLO G, MONTAGNA E, MALORNI L, ZINNO L, LAURIA R, BIANCO AR, DE PLACIDO S. A META-ANALYSIS ON THE INTERACTION BETWEEN HER-2 EXPRESSION AND RESPONSE TO ENDOCRINE TREATMENT IN ADVANCED BREAST CANCER. CLIN CANCER RES. 2005 JUL 1;11(13):4741-8. PUBMED PMID: 16000569. IF 8.738 CIT. 291
269. MORELLI MP, CASCONI T, TROIANI T, DE VITA F, ORDITURA M, LAUS G, ECKHARDT SG, PEPE S, TORTORA G, CIARDIELLO F. SEQUENCE-DEPENDENT ANTIPROLIFERATIVE EFFECTS OF CYTOTOXIC DRUGS AND EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS. ANN ONCOL. 2005 MAY;16 SUPPL 4: IV61-68. PUBMED PMID: 15923432. IF 9.269 CIT. 121
270. DE VITA F, ORDITURA M, CIARDIELLO F, CATALANO G. ADJUVANT CHEMOTHERAPY OF GASTRIC CANCER: WHICH REGIMENS? ANN ONCOL. 2005 MAY;16 SUPPL 4:IV102-105. REVIEW. PUBMED PMID: 15923408. IF 9.269 CIT. 5
271. DI MAIO M, GRIDELLI C, NORMANNO N, PERRONE F, CIARDIELLO F. TRYING TO COMPOSE THE PUZZLE WITH ALL THE PIECES: EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN NON-SMALL CELL LUNG CANCER. J CELL PHYSIOL. 2005 DEC;205(3):355-63. REVIEW. PUBMED PMID: 15895392. IF 4.155 CIT. 32
272. BIANCO R, DANIELE G, CIARDIELLO F, TORTORA G. MONOCLONAL ANTIBODIES TARGETING THE EPIDERMAL GROWTH FACTOR RECEPTOR. CURR DRUG TARGETS. 2005 MAY;6(3):275-87. REVIEW. PUBMED PMID: 15857288. IF 3.029 CIT. 44
273. DE VITA F, ORDITURA M, MATANO E, BIANCO R, CARLOMAGNO C, INFUSINO S, DAMIANO V, SIMEONE E, DIADEMA MR, LIETO E, CASTELLANO P, PEPE S, DE PLACIDO S, GALIZIA G, DI MARTINO N, CIARDIELLO F, CATALANO G, BIANCO AR. A PHASE II STUDY OF BIWEEKLY OXALIPLATIN PLUS INFUSIONAL 5-FLUOROURACIL AND FOLINIC ACID (FOLFOX-4) AS FIRST-LINE TREATMENT OF ADVANCED GASTRIC CANCER PATIENTS. BR J CANCER. 2005 MAY 9;92(9):1644-9. PUBMED PMID: 15856038; PUBMED CENTRAL PMCID: PMC2362040. IF 5.569 CIT. 282
274. GRIDELLI C, MAIONE P, ROSSI A, CIARDIELLO F, RABEN D. TREATMENT OF LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER IN THE ELDERLY. CURR OPIN ONCOL. 2005 MAR;17(2):130-4. REVIEW. PUBMED PMID: 15725917. IF 4.614 CIT. 11
275. BIANCO R, CIARDIELLO F, TORTORA G. CHEMOSENSITIZATION BY ANTISENSE OLIGONUCLEOTIDES TARGETING MDM2. CURR CANCER DRUG TARGETS. 2005 FEB;5(1):51-6. REVIEW. PUBMED PMID: 15720189. IF 3.707 CIT. 44

276. TUCCILLO C, ROMANO M, TROIANI T, MARTINELLI E, MORGILLO F, DE VITA F, BIANCO R, FONTANINI G, BIANCO RA, TORTORA G, CIARDIELLO F. ANTITUMOR ACTIVITY OF ZD6474, A VASCULAR ENDOTHELIAL GROWTH FACTOR-2 AND EPIDERMAL GROWTH FACTOR RECEPTOR SMALL MOLECULE TYROSINE KINASE INHIBITOR, IN COMBINATION WITH SC-236, A CYCLOOXYGENASE-2 INHIBITOR. *CLIN CANCER RES.* 2005 FEB 15;11(3):1268-76. PUBMED PMID: 15709198. IF 8.738 CIT. 45
277. RABEN D, HELFRICH B, CHAN DC, CIARDIELLO F, ZHAO L, FRANKLIN W, BARÓN AE, ZENG C, JOHNSON TK, BUNN PA JR. THE EFFECTS OF CETUXIMAB ALONE AND IN COMBINATION WITH RADIATION AND/OR CHEMOTHERAPY IN LUNG CANCER. *CLIN CANCER RES.* 2005 JAN 15;11(2 PT 1):795-805. PUBMED PMID: 15701870. IF 8.738 CIT. 252
278. BIANCO C, NORMANNO N, SALOMON DS, CIARDIELLO F. ROLE OF THE CRIPTO (EGF-CFC) FAMILY IN EMBRYOGENESIS AND CANCER. *GROWTH FACTORS.* 2004 SEP;22(3):133-9. REVIEW. PUBMED PMID: 15518236. IF 2.043 CIT. 35
279. GRIDELLI C, MASSARELLI E, MAIONE P, ROSSI A, HERBST RS, ONN A, CIARDIELLO F. POTENTIAL ROLE OF MOLECULARLY TARGETED THERAPY IN THE MANAGEMENT OF ADVANCED NONSMALL CELL LUNG CARCINOMA IN THE ELDERLY. *CANCER.* 2004 OCT 15;101(8):1733-44. REVIEW. PUBMED PMID: 15386339. IF 5.649 CIT. 16
280. NORMANNO N, DE LUCA A, MAIELLO MR, BIANCO C, MANCINO M, STRIZZI L, ARRA C, CIARDIELLO F, AGRAWAL S, SALOMON DS. CRIPTO-1: A NOVEL TARGET FOR THERAPEUTIC INTERVENTION IN HUMAN CARCINOMA. *INT J ONCOL.* 2004 OCT;25(4):1013-20. PUBMED PMID: 15375551. IF 3.018 CIT. 29
281. RABEN D, BIANCO C, DAMIANO V, BIANCO R, MELISI D, MIGNOGNA C, D'ARMIENTO FP, CIONINI L, BIANCO AR, TORTORA G, CIARDIELLO F, BUNN P. ANTITUMOR ACTIVITY OF ZD6126, A NOVEL VASCULAR-TARGETING AGENT, IS ENHANCED WHEN COMBINED WITH ZD1839, AN EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR, AND POTENTIATES THE EFFECTS OF RADIATION IN A HUMAN NON-SMALL CELL LUNG CANCER XENOGRAFT MODEL. *MOL CANCER THER.* 2004 AUG;3(8):977-83. PUBMED PMID: 15299080. IF 5.579 CIT. 59
282. ORDITURA M, QUAGLIA F, MORGILLO F, MARTINELLI E, LIETO E, DE ROSA G, COMUNALE D, DIADEMA MR, CIARDIELLO F, CATALANO G, DE VITA F. PEGYLATED LIPOSOMAL DOXORUBICIN: PHARMACOLOGIC AND CLINICAL EVIDENCE OF POTENT ANTITUMOR ACTIVITY WITH REDUCED ANTHRACYCLINE-INDUCED CARDIOTOXICITY (REVIEW). *ONCOL REP.* 2004 SEP;12(3):549-56. REVIEW. PUBMED PMID: 15289836. IF 2.486 CIT. 34
283. BIANCO R, CAPUTO R, CAPUTO R, DAMIANO V, DE PLACIDO S, FICORELLA C, AGRAWAL S, BIANCO AR, CIARDIELLO F, TORTORA G. COMBINED TARGETING OF EPIDERMAL GROWTH FACTOR RECEPTOR AND MDM2 BY GEFITINIB AND ANTISENSE MDM2 COOPERATIVELY INHIBIT HORMONE-INDEPENDENT PROSTATE CANCER. *CLIN CANCER RES.* 2004 JUL 15;10(14):4858-64. PUBMED PMID: 15269162. IF 8.738 CIT. 40
284. GALIZIA G, LIETO E, FERRARACCIO F, ORDITURA M, DE VITA F, CASTELLANO P, IMPERATORE V, ROMANO C, CIARDIELLO F, AGOSTINI B, PIGNATELLI C. DETERMINATION OF MOLECULAR MARKER EXPRESSION CAN PREDICT CLINICAL OUTCOME IN COLON CARCINOMAS. *CLIN CANCER RES.* 2004 MAY 15;10(10):3490-9. PUBMED PMID: 15161706. IF 8.738 CIT. 129
285. CIARDIELLO F, DE VITA F, ORDITURA M, TORTORA G. THE ROLE OF EGFR INHIBITORS IN NONSMALL CELL LUNG CANCER. *CURR OPIN ONCOL.* 2004 MAR;16(2):130-5. REVIEW. PUBMED PMID: 15075904. IF 4.614 CIT. 97
286. LORENZO GD, BIANCO R, TORTORA G, CIARDIELLO F. INVOLVEMENT OF GROWTH FACTOR RECEPTORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY IN PROSTATE CANCER DEVELOPMENT AND PROGRESSION TO ANDROGEN INDEPENDENCE. *CLIN PROSTATE CANCER.* 2003 JUN;2(1):50-7. REVIEW. PUBMED PMID: 15046685 CIT. 57
287. MELISI D, TROIANI T, DAMIANO V, TORTORA G, CIARDIELLO F. THERAPEUTIC INTEGRATION OF SIGNAL TRANSDUCTION TARGETING AGENTS AND CONVENTIONAL ANTI-CANCER TREATMENTS. *ENDOCR RELAT CANCER.* 2004 MAR;11(1):51-68. REVIEW. PUBMED PMID: 15027885. IF 4.472 CIT. 36
288. CIARDIELLO F, BIANCO R, CAPUTO R, CAPUTO R, DAMIANO V, TROIANI T, MELISI D, DE VITA F, DE PLACIDO S, BIANCO AR, TORTORA G. ANTITUMOR ACTIVITY OF ZD6474, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR, IN HUMAN CANCER CELLS WITH

- ACQUIRED RESISTANCE TO ANTIEPIDERMAL GROWTH FACTOR RECEPTOR THERAPY. CLIN CANCER RES. 2004 JAN 15;10(2):784-93. PUBMED PMID: 14760102. IF 8.738 CIT. 325
289. TORTORA G, MELISI D, CIARDIELLO F. ANGIOGENESIS: A TARGET FOR CANCER THERAPY. CURR PHARM DES. 2004;10(1):11-26. REVIEW. PUBMED PMID: 14754402. IF 3.052 CIT. 78
290. TORTORA G, CIARDIELLO F. ANTISENSE TARGETING PROTEIN KINASE A TYPE I AS A DRUG FOR INTEGRATED STRATEGIES OF CANCER THERAPY. ANN N Y ACAD SCI. 2003 DEC; 1002:236-43. REVIEW. PUBMED PMID: 14751838. IF 4.518 CIT. 25
291. DE VITA F, ORDITURA M, LIETO E, INFUSINO S, MORGILLO F, MARTINELLI E, CASTELLANO P, ROMANO C, CIARDIELLO F, CATALANO G, PIGNATELLI C, GALIZIA G. ELEVATED PERIOPERATIVE SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR LEVELS IN PATIENTS WITH COLON CARCINOMA. CANCER. 2004 JAN 15;100(2):270-8. PUBMED PMID: 14716760. IF 5.649 CIT.124
292. CIARDIELLO F, DE VITA F, ORDITURA M, DE PLACIDO S, TORTORA G. EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN LATE STAGE CLINICAL TRIALS. EXPERT OPIN EMERG DRUGS. 2003 NOV;8(2):501-14. REVIEW. PUBMED PMID: 14662002. IF 2.120 CIT. 34
293. TORTORA G, CIARDIELLO F. ANTISENSE STRATEGIES TARGETING PROTEIN KINASE C: PRECLINICAL AND CLINICAL DEVELOPMENT. SEMIN ONCOL. 2003 AUG;30(4 SUPPL 10):26-31. REVIEW. PUBMED PMID: 12917818. IF 3.954 CIT. 47
294. RABEN D, HELFRICH B, CIARDIELLO F, BUNN PA. UNDERSTANDING THE MECHANISMS OF ACTION OF EGFR INHIBITORS IN NSCLC: WHAT WE KNOW AND WHAT WE DO NOT KNOW. LUNG CANCER. 2003 AUG;41 SUPPL 1: S15-22. REVIEW. PUBMED PMID: 12867058. IF 3.767 CIT. 13
295. CIARDIELLO F, TORTORA G. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AS A TARGET IN CANCER THERAPY: UNDERSTANDING THE ROLE OF RECEPTOR EXPRESSION AND OTHER MOLECULAR DETERMINANTS THAT COULD INFLUENCE THE RESPONSE TO ANTI-EGFR DRUGS. EUR J CANCER. 2003 JUL;39(10):1348-54. REVIEW. PUBMED PMID: 12826036. IF 6.163 CIT. 203
296. CAPUTO R, TUCCILLO C, MANZO BA, ZARRILLI R, TORTORA G, BLANCO CDEL V, RICCI V, CIARDIELLO F, ROMANO M. HELICOBACTER PYLORI VACA TOXIN UP-REGULATES VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION IN MKN 28 GASTRIC CELLS THROUGH AN EPIDERMAL GROWTH FACTOR RECEPTOR-, CYCLOOXYGENASE-2-DEPENDENT MECHANISM. CLIN CANCER RES. 2003 JUN;9(6):2015-21. PUBMED PMID: 12796363. IF 8.738 CIT. 88
297. TORTORA G, CAPUTO R, DAMIANO V, MELISI D, BIANCO R, FONTANINI G, VENEZIANI BM, DE PLACIDO S, BIANCO AR, CIARDIELLO F. COMBINATION OF A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR WITH EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR ZD1839 AND PROTEIN KINASE A ANTISENSE CAUSES COOPERATIVE ANTITUMOR AND ANTIANGIOGENIC EFFECT. CLIN CANCER RES. 2003 APR;9(4):1566-72. PUBMED PMID: 12684433. IF 8.738 CIT. 172
298. CIARDIELLO F, CAPUTO R, DAMIANO V, CAPUTO R, TROIANI T, VITAGLIANO D, CARLOMAGNO F, VENEZIANI BM, FONTANINI G, BIANCO AR, TORTORA G. ANTITUMOR EFFECTS OF ZD6474, A SMALL MOLECULE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR, WITH ADDITIONAL ACTIVITY AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE. CLIN CANCER RES. 2003 APR;9(4):1546-56. PUBMED PMID: 12684431. IF 8.738 CIT. 368
299. RABEN D, BIANCO C, HELFRICH B, WENG E, CIARDIELLO F, HARARI P. INTERFERENCE WITH EGFR SIGNALING: PARADIGM FOR IMPROVING RADIATION RESPONSE IN CANCER TREATMENT. EXPERT REV ANTICANCER THER. 2002 AUG;2(4):461-71. REVIEW. PUBMED PMID: 12647989. IF 2.094 CIT. 19
300. TORTORA G, CIARDIELLO F. [RATIONALES FOR THE INTEGRATION OF MOLECULAR AND CONVENTIONAL THERAPIES]. TUMORI. 2002 NOV-DEC;88(6): A9-13. REVIEW. ITALIAN. PUBMED PMID: 12597159. IF 1.071
301. DI LORENZO G, AUTORINO R, CIARDIELLO F, RABEN D, BIANCO C, TROIANI T, PIZZA C, DE LAURENTIIS M, PENSABENE M, D'ARMIENTO M, BIANCO AR, DE PLACIDO S. EXTERNAL BEAM RADIOTHERAPY IN BONE METASTATIC PROSTATE CANCER: IMPACT ON PATIENTS' PAIN RELIEF AND QUALITY OF LIFE. ONCOL REP. 2003 MAR-APR;10(2):399-404. REVIEW. PUBMED PMID: 12579279. IF 2.486 CIT. 27

302. TORTORA G, CAPUTO R, DAMIANO V, CAPUTO R, TROIANI T, VENEZIANI BM, DE PLACIDO S, BIANCO AR, ZANGEMEISTER-WITTKE U, CIARDIELLO F. COMBINED TARGETED INHIBITION OF BCL-2, BCL-XL, EPIDERMAL GROWTH FACTOR RECEPTOR, AND PROTEIN KINASE A TYPE I CAUSES POTENT ANTITUMOR, APOPTOTIC, AND ANTIANGIOGENIC ACTIVITY. *CLIN CANCER RES.* 2003 FEB;9(2):866-71. PUBMED PMID: 12576461. IF 8.738 CIT. 64
303. CARLOMAGNO F, VITAGLIANO D, GUIDA T, CIARDIELLO F, TORTORA G, VECCHIO G, RYAN AJ, FONTANINI G, FUSCO A, SANTORO M. ZD6474, AN ORALLY AVAILABLE INHIBITOR OF KDR TYROSINE KINASE ACTIVITY, EFFICIENTLY BLOCKS ONCOGENIC RET KINASES. *CANCER RES.* 2002 DEC 15;62(24):7284-90. PUBMED PMID: 12499271. IF 8.556 CIT. 525
304. DI LORENZO G, TORTORA G, D'ARMIENTO FP, DE ROSA G, STAIBANO S, AUTORINO R, D'ARMIENTO M, DE LAURENTIIS M, DE PLACIDO S, CATALANO G, BIANCO AR, CIARDIELLO F. EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPENDENCE IN HUMAN PROSTATE CANCER. *CLIN CANCER RES.* 2002 NOV;8(11):3438-44. PUBMED PMID: 12429632. IF 8.738 CIT. 420
305. CIARDIELLO F. THE RATIONAL BASIS OF USING NOVEL TARGETED BIOLOGICAL AGENTS IN NON-SMALL CELL LUNG CANCER. *SUPPL TUMORI.* 2002 JUL-AUG;1(4): S31-3. REVIEW. PUBMED PMID: 12415813. CIT. 1
306. CIARDIELLO F. AN UPDATE OF NEW TARGETS FOR CANCER TREATMENT: RECEPTOR-MEDIATED SIGNALS. *ANN ONCOL.* 2002;13 SUPPL 4:29-38. REVIEW. PUBMED PMID: 12401663. IF 9.269 CIT. 21
307. BIANCO C, TORTORA G, BIANCO R, CAPUTO R, VENEZIANI BM, CAPUTO R, DAMIANO V, TROIANI T, FONTANINI G, RABEN D, PEPE S, BIANCO AR, CIARDIELLO F. ENHANCEMENT OF ANTITUMOR ACTIVITY OF IONIZING RADIATION BY COMBINED TREATMENT WITH THE SELECTIVE EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR ZD1839 (IRESSA). *CLIN CANCER RES.* 2002 OCT;8(10):3250-8. PUBMED PMID: 12374696. IF 8.738 CIT. 274
308. TORTORA G, CIARDIELLO F. PROTEIN KINASE A AS TARGET FOR NOVEL INTEGRATED STRATEGIES OF CANCER THERAPY. *ANN N Y ACAD SCI.* 2002 JUN; 968:139-47. REVIEW. PUBMED PMID: 12119273. IF 4.518 CIT. 97
309. CIARDIELLO F, TORTORA G. INHIBITION OF BCL-2 AS CANCER THERAPY. *ANN ONCOL.* 2002 APR;13(4):501-2. PUBMED PMID: 12056698. IF 9.269 CIT. 36
310. CIARDIELLO F, TORTORA G. ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR DRUGS IN CANCER THERAPY. *EXPERT OPIN INVESTIG DRUGS.* 2002 JUN;11(6):755-68. REVIEW. PUBMED PMID: 12036420. IF 4.408 CIT. 114
311. TORTORA G, CIARDIELLO F, DAMIANO V, DE LAURENTIIS M, MATANO E, PEPE S, PENSABENE M, CATALANO G, DE PLACIDO S, BIANCO AR. PRECLINICAL AND PHASE I STUDY OF OXALIPLATIN AND TOPOTECAN IN COMBINATION IN HUMAN CANCER. *ANN ONCOL.* 2002 MAR;13(3):392-8. PUBMED PMID: 11996469. IF 9.269 CIT. 13
312. CIARDIELLO F, TORTORA G, DE PLACIDO S, BIANCO AR. ZD1839 (IRESSA): PRECLINICAL STUDIES AND PHARMACOLOGY. *TUMORI.* 2002 JAN-FEB;88(1 SUPPL 1): S155-7. PUBMED PMID: 11989913. IF 1.071 CIT. 8
313. CIARDIELLO F, CAPUTO R, BORRIELLO G, DEL BUFALO D, BIROCCIO A, ZUPI G, BIANCO AR, TORTORA G. ZD1839 (IRESSA), AN EGFR-SELECTIVE TYROSINE KINASE INHIBITOR, ENHANCES TAXANE ACTIVITY IN BCL-2 OVEREXPRESSION, MULTIDRUG-RESISTANT MCF-7 ADR HUMAN BREAST CANCER CELLS. *INT J CANCER.* 2002 MAR 20;98(3):463-9. PUBMED PMID: 11920601. IF 5.531 CIT. 97
314. NORMANNO N, CAMPIGLIO M, DE LA, SOMENZI G, MAIELLO M, CIARDIELLO F, GIANNI L, SALOMON DS, MENARD S. COOPERATIVE INHIBITORY EFFECT OF ZD1839 (IRESSA) IN COMBINATION WITH TRASTUZUMAB (HERCEPTIN) ON HUMAN BREAST CANCER CELL GROWTH. *ANN ONCOL.* 2002 JAN;13(1):65-72. PUBMED PMID: 11863114. IF 9.269 CIT. 330
315. TORTORA G, CIARDIELLO F. PROTEIN KINASE A TYPE I: A TARGET FOR CANCER THERAPY. *CLIN CANCER RES.* 2002 FEB;8(2):303-4. PUBMED PMID: 11839645. IF 8.738 CIT. 22
316. TORTORA G, CAPUTO R, DAMIANO V, FONTANINI G, MELISI D, VENEZIANI BM, ZUNINO F, BIANCO AR, CIARDIELLO F. ORAL ADMINISTRATION OF A NOVEL TAXANE, AN ANTISENSE OLIGONUCLEOTIDE TARGETING PROTEIN KINASE A, AND THE EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR

- IRESSA CAUSES COOPERATIVE ANTITUMOR AND ANTIANGIOGENIC ACTIVITY. CLIN CANCER RES. 2001 DEC;7(12):4156-63. PUBMED PMID: 11751516. IF 8.738 CIT. 55
317. CIARDIELLO F, TORTORA G. A NOVEL APPROACH IN THE TREATMENT OF CANCER: TARGETING THE EPIDERMAL GROWTH FACTOR RECEPTOR. CLIN CANCER RES. 2001 OCT;7(10):2958-70. REVIEW. PUBMED PMID: 11595683. IF 8.738 CIT. 1080
 318. TORTORA G, CAPUTO R, DAMIANO V, BIANCO R, FONTANINI G, CUCCATO S, DE PLACIDO S, BIANCO AR, CIARDIELLO F. COMBINED BLOCKADE OF PROTEIN KINASE A AND BCL-2 BY ANTISENSE STRATEGY INDUCES APOPTOSIS AND INHIBITS TUMOR GROWTH AND ANGIOGENESIS. CLIN CANCER RES. 2001 AUG;7(8):2537-44. PUBMED PMID: 11489837. IF 8.738 CIT.42
 319. CIARDIELLO F, CAPUTO R, TROIANI T, BORRIELLO G, KANDIMALLA ER, AGRAWAL S, MENDELSON J, BIANCO AR, TORTORA G. ANTISENSE OLIGONUCLEOTIDES TARGETING THE EPIDERMAL GROWTH FACTOR RECEPTOR INHIBIT PROLIFERATION, INDUCE APOPTOSIS, AND COOPERATE WITH CYTOTOXIC DRUGS IN HUMAN CANCER CELL LINES. INT J CANCER. 2001 JUL 15;93(2):172-8. PUBMED PMID: 11410862. IF 5.531 CIT. 90
 320. CIARDIELLO F, CAPUTO R, BIANCO R, DAMIANO V, FONTANINI G, CUCCATO S, DE PLACIDO S, BIANCO AR, TORTORA G. INHIBITION OF GROWTH FACTOR PRODUCTION AND ANGIOGENESIS IN HUMAN CANCER CELLS BY ZD1839 (IRESSA), A SELECTIVE EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR. CLIN CANCER RES. 2001 MAY;7(5):1459-65. PUBMED PMID: 11350918. IF 8.738 CIT. 682
 321. CIARDIELLO F. EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS AS ANTICANCER AGENTS. DRUGS. 2000;60 SUPPL 1:25-32; DISCUSSION 41-2. REVIEW. PUBMED PMID: 11129169. IF 4.883 CIT. 236
 322. DE LUCA A, ARRA C, D'ANTONIO A, CASAMASSIMI A, LOSITO S, FERRARO P, CIARDIELLO F, SALOMON DS, NORMANNO N. SIMULTANEOUS BLOCKAGE OF DIFFERENT EGF-LIKE GROWTH FACTORS RESULTS IN EFFICIENT GROWTH INHIBITION OF HUMAN COLON CARCINOMA XENOGRAFTS. ONCOGENE. 2000 NOV 30;19(51):5863-71. PUBMED PMID: 11127817. IF 7.932 CIT. 79
 323. BIANCO C, BIANCO R, TORTORA G, DAMIANO V, GUERRIERI P, MONTEMAGGI P, MENDELSON J, DE PLACIDO S, BIANCO AR, CIARDIELLO F. ANTITUMOR ACTIVITY OF COMBINED TREATMENT OF HUMAN CANCER CELLS WITH IONIZING RADIATION AND ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY C225 PLUS TYPE I PROTEIN KINASE A ANTISENSE OLIGONUCLEOTIDE. CLIN CANCER RES. 2000 NOV;6(11):4343-50. PUBMED PMID: 11106252. IF 8.738 CIT. 145
 324. TORTORA G, CAPUTO R, DAMIANO V, BIANCO R, CHEN J, AGRAWAL S, BIANCO AR, CIARDIELLO F. A NOVEL MDM2 ANTI-SENSE OLIGONUCLEOTIDE HAS ANTI-TUMOR ACTIVITY AND POTENTIATES CYTOTOXIC DRUGS ACTING BY DIFFERENT MECHANISMS IN HUMAN COLON CANCER. INT J CANCER. 2000 DEC 1;88(5):804-9. PUBMED PMID: 11072252. IF 5.531 CIT. 77
 325. CIARDIELLO F, BIANCO R, DAMIANO V, FONTANINI G, CAPUTO R, POMATICO G, DE PLACIDO S, BIANCO AR, MENDELSON J, TORTORA G. ANTIANGIOGENIC AND ANTITUMOR ACTIVITY OF ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR C225 MONOCLONAL ANTIBODY IN COMBINATION WITH VASCULAR ENDOTHELIAL GROWTH FACTOR ANTISENSE OLIGONUCLEOTIDE IN HUMAN GEO COLON CANCER CELLS. CLIN CANCER RES. 2000 SEP;6(9):3739-47. PUBMED PMID: 10999768. IF 8.738 CIT. 446
 326. TORTORA G, CIARDIELLO F. TARGETING OF EPIDERMAL GROWTH FACTOR RECEPTOR AND PROTEIN KINASE A: MOLECULAR BASIS AND THERAPEUTIC APPLICATIONS. ANN ONCOL. 2000 JUL;11(7):777-83. REVIEW. PUBMED PMID: 10997803. 9.269 CIT. 682
 327. INDOLFI C, DI LORENZO E, RAPACCIUOLO A, STINGONE AM, STABILE E, LECCIA A, TORELLA D, CAPUTO R, CIARDIELLO F, TORTORA G, CHIARIELLO M. 8-CHLORO-CAMP INHIBITS SMOOTH MUSCLE CELL PROLIFERATION IN VITRO AND NEOINTIMA FORMATION INDUCED BY BALLOON INJURY IN VIVO. J AM COLL CARDIOL. 2000 JUL;36(1):288-93. PUBMED PMID: 10898448. IF 17.759 CIT. 61
 328. TORTORA G, BIANCO R, DAMIANO V, FONTANINI G, DE PLACIDO S, BIANCO AR, CIARDIELLO F. ORAL ANTISENSE THAT TARGETS PROTEIN KINASE A COOPERATES WITH TAXOL AND INHIBITS TUMOR GROWTH, ANGIOGENESIS, AND GROWTH FACTOR PRODUCTION. CLIN CANCER RES. 2000 JUN;6(6):2506-12. PUBMED PMID: 10873106. IF 8.738 CIT. 66

329. CIARDIELLO F, CAPUTO R, BIANCO R, DAMIANO V, POMATICO G, DE PLACIDO S, BIANCO AR, TORTORA G. ANTITUMOR EFFECT AND POTENTIATION OF CYTOTOXIC DRUGS ACTIVITY IN HUMAN CANCER CELLS BY ZD-1839 (IRESSA), AN EPIDERMAL GROWTH FACTOR RECEPTOR-SELECTIVE TYROSINE KINASE INHIBITOR. *CLIN CANCER RES.* 2000 MAY;6(5):2053-63. PUBMED PMID: 10815932. IF 8.738 CIT. 1062
330. CIARDIELLO F, CAPUTO R, POMATICO G, DE LAURENTIIS M, DE PLACIDO S, BIANCO AR, TORTORA G. RESISTANCE TO TAXANES IS INDUCED BY C-ERBB-2 OVEREXPRESSION IN HUMAN MCF-10A MAMMARY EPITHELIAL CELLS AND IS BLOCKED BY COMBINED TREATMENT WITH AN ANTISENSE OLIGONUCLEOTIDE TARGETING TYPE I PROTEIN KINASE A. *INT J CANCER.* 2000 MAR 1;85(5):710-5. PUBMED PMID: 10699953. IF 5.531 CIT. 74
331. DE PLACIDO S, CARLOMAGNO C, CIARDIELLO F, DE LAURENTIIS M, PEPE S, RUGGIERO A, TORTORA G, PANICO L, D'ANTONIO A, PETTINATO G, PETRELLA G, BIANCO AR. MEASUREMENT OF NEOVASCULARIZATION IS AN INDEPENDENT PROGNOSTICATOR OF SURVIVAL IN NODE-NEGATIVE BREAST CANCER PATIENTS WITH LONG-TERM FOLLOW-UP. *CLIN CANCER RES.* 1999 OCT;5(10):2854-9. PUBMED PMID: 10537353. IF 8.738 CIT. 21
332. NORMANNO N, TORTORA G, DE LUCA A, POMATICO G, CASAMASSIMI A, AGRAWAL S, MENDELSON J, BIANCO AR, CIARDIELLO F. SYNERGISTIC GROWTH INHIBITION AND INDUCTION OF APOPTOSIS BY A NOVEL MIXED BACKBONE ANTISENSE OLIGONUCLEOTIDE TARGETING CRIPTO IN COMBINATION WITH C225 ANTI-EGFR MONOCLONAL ANTIBODY AND 8-CL-CAMP IN HUMAN GEO COLON CANCER CELLS. *ONCOL REP.* 1999 SEP-OCT;6(5):1105-9. PUBMED PMID: 10425310. IF 2.486 CIT. 20
333. CIARDIELLO F, BIANCO R, DAMIANO V, DE LORENZO S, PEPE S, DE PLACIDO S, FAN Z, MENDELSON J, BIANCO AR, TORTORA G. ANTITUMOR ACTIVITY OF SEQUENTIAL TREATMENT WITH TOPOTECAN AND ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY C225. *CLIN CANCER RES.* 1999 APR;5(4):909-16. PUBMED PMID: 10213228. IF 8.738 CIT. 371
334. TORTORA G, CAPUTO R, POMATICO G, PEPE S, BIANCO AR, AGRAWAL S, MENDELSON J, CIARDIELLO F. COOPERATIVE INHIBITORY EFFECT OF NOVEL MIXED BACKBONE OLIGONUCLEOTIDE TARGETING PROTEIN KINASE A IN COMBINATION WITH DOCETAXEL AND ANTI-EPIDERMAL GROWTH FACTOR-RECEPTOR ANTIBODY ON HUMAN BREAST CANCER CELL GROWTH. *CLIN CANCER RES.* 1999 APR;5(4):875-81. PUBMED PMID: 10213224. IF 8.738 CIT. 73
335. DE LUCA A, CASAMASSIMI A, SELVAM MP, LOSITO S, CIARDIELLO F, AGRAWAL S, SALOMON DS, NORMANNO N. EGF-RELATED PEPTIDES ARE INVOLVED IN THE PROLIFERATION AND SURVIVAL OF MDA-MB-468 HUMAN BREAST CARCINOMA CELLS. *INT J CANCER.* 1999 FEB 9;80(4):589-94. PUBMED PMID: 9935161. IF 5.531 CIT. 44
336. CIARDIELLO F, CAPUTO R, BIANCO R, DAMIANO V, POMATICO G, PEPE S, BIANCO AR, AGRAWAL S, MENDELSON J, TORTORA G. COOPERATIVE INHIBITION OF RENAL CANCER GROWTH BY ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY AND PROTEIN KINASE A ANTISENSE OLIGONUCLEOTIDE. *J NATL CANCER INST.* 1998 JUL 15;90(14):1087-94. PUBMED PMID: 9672257. IF 14.697 CIT. 87
337. TORTORA G, CAPUTO R, DAMIANO V, BIANCO R, PEPE S, POMATICO G, BIANCO AR, JIANG Z, AGRAWAL S, CIARDIELLO F. COOPERATIVE ANTITUMOR EFFECT OF MIXED BACKBONE OLIGONUCLEOTIDES TARGETING PROTEIN KINASE A IN COMBINATION WITH CYTOTOXIC DRUGS OR BIOLOGIC AGENTS. *ANTISENSE NUCLEIC ACID DRUG DEV.* 1998 APR;8(2):141-5. REVIEW. PUBMED PMID: 9593054 CIT. 13
338. CIARDIELLO F, TORTORA G. INTERACTIONS BETWEEN THE EPIDERMAL GROWTH FACTOR RECEPTOR AND TYPE I PROTEIN KINASE A: BIOLOGICAL SIGNIFICANCE AND THERAPEUTIC IMPLICATIONS. *CLIN CANCER RES.* 1998 APR;4(4):821-8. REVIEW. PUBMED PMID: 9563874. IF 8.738 CIT. 104
339. FONTANINI G, DE LAURENTIIS M, VIGNATI S, CHINÈ S, LUCCHI M, SILVESTRI V, MUSSI A, DE PLACIDO S, TORTORA G, BIANCO AR, GULLICK W, ANGELETTI CA, BEVILACQUA G, CIARDIELLO F. EVALUATION OF EPIDERMAL GROWTH FACTOR-RELATED GROWTH FACTORS AND RECEPTORS AND OF NEOANGIOGENESIS IN COMPLETELY RESECTED STAGE I-IIIa NON-SMALL-CELL LUNG CANCER: AMPHIREGULIN AND MICROVESSEL COUNT ARE INDEPENDENT PROGNOSTIC INDICATORS OF SURVIVAL. *CLIN CANCER RES.* 1998 JAN;4(1):241-9. PUBMED PMID: 9516978. IF 8.738 CIT. 303
340. CIARDIELLO F, DIXIT M, DI ISERNIA G, DAMIANO V, BIANCO R, BIANCO AR, ARTEAGA CL, TORTORA G. DOWN-REGULATION OF TYPE I PROTEIN KINASE A BY TRANSFECTION OF HUMAN BREAST

- CANCER CELLS WITH AN EPIDERMAL GROWTH FACTOR RECEPTOR ANTISENSE EXPRESSION VECTOR. BREAST CANCER RES TREAT. 1998 JAN;47(1):57-62. PUBMED PMID: 9493976. IF 4.085 CIT. 8
341. NORMANNO N, DE LUCA A, SALOMON DS, CIARDIELLO F. EPIDERMAL GROWTH FACTOR-RELATED PEPTIDES AS TARGETS FOR EXPERIMENTAL THERAPY OF HUMAN COLON CARCINOMA. CANCER DETECT PREV. 1998;22(1):62-7. REVIEW. PUBMED PMID: 9466051. IF 2.522 CIT. 40
342. DI SIMONE D, GALIMBERTI S, BASOLO F, CIARDIELLO F, PETRINI M, SCHEPER RJ. C-HA-RAS TRANSFECTION AND EXPRESSION OF MDR-RELATED GENES IN MCF-10A HUMAN BREAST CELL LINE. ANTICANCER RES. 1997 SEP-OCT;17(5A):3587-92. PUBMED PMID: 9413207. IF 1.895 CIT. 9
343. TORTORA G, DI ISERNIA G, SANDOMENICO C, BIANCO R, POMATICO G, PEPE S, BIANCO AR, CIARDIELLO F. SYNERGISTIC INHIBITION OF GROWTH AND INDUCTION OF APOPTOSIS BY 8-CHLORO-CAMP AND PACLITAXEL OR CISPLATIN IN HUMAN CANCER CELLS. CANCER RES. 1997 NOV 15;57(22):5107-11. PUBMED PMID: 9371510. IF 8.556 CIT. 48
344. BUI TD, TORTORA G, CIARDIELLO F, HARRIS AL. EXPRESSION OF WNT5A IS DOWNREGULATED BY EXTRACELLULAR MATRIX AND MUTATED C-HA-RAS IN THE HUMAN MAMMARY EPITHELIAL CELL LINE MCF-10A. BIOCHEM BIOPHYS RES COMMUN. 1997 OCT 29;239(3):911-7. PUBMED PMID: 9367869. IF 2.371 CIT. 33
345. TORTORA G, CAPUTO R, DAMIANO V, BIANCO R, PEPE S, BIANCO AR, JIANG Z, AGRAWAL S, CIARDIELLO F. SYNERGISTIC INHIBITION OF HUMAN CANCER CELL GROWTH BY CYTOTOXIC DRUGS AND MIXED BACKBONE ANTISENSE OLIGONUCLEOTIDE TARGETING PROTEIN KINASE A. PROC NATL ACAD SCI U S A. 1997 NOV 11;94(23):12586-91. PUBMED PMID: 9356493; PUBMED CENTRAL PMCID: PMC25047. IF 9.674 CIT. 66
346. DE LUCA A, SELVAM MP, SANDOMENICO C, PEPE S, BIANCO AR, CIARDIELLO F, SALOMON DS, NORMANNO N. ANTI-SENSE OLIGONUCLEOTIDES DIRECTED AGAINST EGF-RELATED GROWTH FACTORS ENHANCE ANTI-PROLIFERATIVE EFFECT OF CONVENTIONAL ANTI-TUMOR DRUGS IN HUMAN COLON-CANCER CELLS. INT J CANCER. 1997 OCT 9;73(2):277-82. PUBMED PMID: 9335455. IF 5.531 CIT. 35
347. FONTANINI G, LUCCHI M, VIGNATI S, MUSSI A, CIARDIELLO F, DE LAURENTIIS M, DE PLACIDO S, BASOLO F, ANGELETTI CA, BEVILACQUA G. ANGIOGENESIS AS A PROGNOSTIC INDICATOR OF SURVIVAL IN NON-SMALL-CELL LUNG CARCINOMA: A PROSPECTIVE STUDY. J NATL CANCER INST. 1997 JUN 18;89(12):881-6. PUBMED PMID: 9196255. IF 14.697 CIT. 321
348. NORMANNO N, CIARDIELLO F. EGF-RELATED PEPTIDES IN THE PATHOPHYSIOLOGY OF THE MAMMARY GLAND. J MAMMARY GLAND BIOL NEOPLASIA. 1997 APR;2(2):143-51. REVIEW. PUBMED PMID: 10882300. IF 3.143 CIT. 65
349. BIANCO C, TORTORA G, BALDASSARRE G, CAPUTO R, FONTANINI G, CHINÈ S, BIANCO AR, CIARDIELLO F. 8-CHLORO-CYCLIC AMP INHIBITS AUTOCRINE AND ANGIOGENIC GROWTH FACTOR PRODUCTION IN HUMAN COLORECTAL AND BREAST CANCER. CLIN CANCER RES. 1997 MAR;3(3):439-48. PUBMED PMID: 9815703. IF 8.738 CIT. 35
350. TORTORA G, DAMIANO V, BIANCO C, BALDASSARRE G, BIANCO AR, LANFRANCONE L, PELICCI PG, CIARDIELLO F. THE RIALPHA SUBUNIT OF PROTEIN KINASE A (PKA) BINDS TO GRB2 AND ALLOWS PKA INTERACTION WITH THE ACTIVATED EGF-RECEPTOR. ONCOGENE. 1997 FEB 27;14(8):923-8. PUBMED PMID: 9050991. IF 7.932 CIT. 108
351. KANNAN S, DE SANTIS M, LOHMEYER M, RIESE DJ 2ND, SMITH GH, HYNES N, SENO M, BRANDT R, BIANCO C, PERSICO G, KENNEY N, NORMANNO N, MARTINEZ-LACACI I, CIARDIELLO F, STERN DF, GULLICK WJ, SALOMON DS. CRIPTO ENHANCES THE TYROSINE PHOSPHORYLATION OF SHC AND ACTIVATES MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) IN MAMMARY EPITHELIAL CELLS. J BIOL CHEM. 1997 FEB 7;272(6):3330-5. PUBMED PMID: 9013573. IF 4.258 CIT. 100
352. BIANCO AR, CARLOMAGNO C, DE LAURENTIIS M, DE PLACIDO S, TORTORA G, CIARDIELLO F. PROGNOSTIC FACTORS IN HUMAN COLORECTAL CANCER. TUMORI. 1997 JAN-FEB;83(1 SUPPL): S15-8. REVIEW. PUBMED PMID: 9154061. IF 1.071 CIT. 21
353. CIARDIELLO F, DAMIANO V, BIANCO R, BIANCO C, FONTANINI G, DE LAURENTIIS M, DE PLACIDO S, MENDELSON J, BIANCO AR, TORTORA G. ANTITUMOR ACTIVITY OF COMBINED BLOCKADE OF

- EPIDERMAL GROWTH FACTOR RECEPTOR AND PROTEIN KINASE A. J NATL CANCER INST. 1996 DEC 4;88(23):1770-6. PUBMED PMID: 8944008. IF 14.697 CIT. 158
354. DIISERNIA G, CIARDIELLO F, SANDOMENICO C, PEPE S, BIANCO A, TORTORA G. 8-CHLORO-CAMP ENHANCES THE GROWTH INHIBITORY EFFECT OF CYTOTOXIC DRUGS IN HUMAN COLON CANCER CELLS. INT J ONCOL. 1996 DEC;9(6):1233-7. PUBMED PMID: 21541633. IF 3.018 CIT. 7
355. TAGLIAFERRI P, CORREALE P, MOTTOLA M, DE SIMONE G, MONTESARCHIO V, MATANO E, REA A, MORABITO A, FAMIANI M, CIARDIELLO F, TORTORA G, CARAGLIA M, BARILE C, PALMIERI G, BIANCO AR. HIGH-DOSE RECOMBINANT INTERLEUKIN-2/VERAPAMIL COMBINATION IN ADVANCED CANCER. EUR J CANCER. 1996 JUL;32A(8):1436-7. PUBMED PMID: 8869114. IF 6.163 CIT. 6
356. BALDASSARRE G, BIANCO C, TORTORA G, RUGGIERO A, MOASSER M, DMITROVSKY E, BIANCO AR, CIARDIELLO F. TRANSFECTION WITH A CRIPTO ANTI-SENSE PLASMID SUPPRESSES ENDOGENOUS CRIPTO EXPRESSION AND INHIBITS TRANSFORMATION IN A HUMAN EMBRYONAL CARCINOMA CELL LINE. INT J CANCER. 1996 MAY 16;66(4):538-43. PUBMED PMID: 8635871. IF 5.531 CIT. 29
357. MINCIONE G, BIANCO C, KANNAN S, COLLETTA G, CIARDIELLO F, SLIWKOWSKI M, YARDEN Y, NORMANNO N, PRAMAGGIORE A, KIM N, SALOMON DS. ENHANCED EXPRESSION OF HEREGULIN IN C-ERB B-2 AND C-HA-RAS TRANSFORMED MOUSE AND HUMAN MAMMARY EPITHELIAL CELLS. J CELL BIOCHEM. 1996 MAR 15;60(4):437-46. PUBMED PMID: 8707884. IF 3.446 CIT. 33
358. NORMANNO N, BIANCO C, DAMIANO V, DE ANGELIS E, SELVAM MP, GRASSI M, MAGLIULO G, TORTORA G, BIANCO AR, MENDELSON J, SALOMON DS, CIARDIELLO F. GROWTH INHIBITION OF HUMAN COLON CARCINOMA CELLS BY COMBINATIONS OF ANTI-EPIDERMAL GROWTH FACTOR-RELATED GROWTH FACTOR ANTISENSE OLIGONUCLEOTIDES. CLIN CANCER RES. 1996 MAR;2(3):601-9. PUBMED PMID: 9816209. IF 8.738 CIT. 66
359. PANICO L, D'ANTONIO A, SALVATORE G, MEZZA E, TORTORA G, DE LAURENTIIS M, DE PLACIDO S, GIORDANO T, MERINO M, SALOMON DS, MULLICK WJ, PETTINATO G, SCHNITT SJ, BIANCO AR, CIARDIELLO F. DIFFERENTIAL IMMUNOHISTOCHEMICAL DETECTION OF TRANSFORMING GROWTH FACTOR ALPHA, AMPHIREGULIN AND CRIPTO IN HUMAN NORMAL AND MALIGNANT BREAST TISSUES. INT J CANCER. 1996 JAN 3;65(1):51-6. PUBMED PMID: 8543395. IF 5.531 CIT. 114
360. TAGLIAFERRI P, TORTORA G, GUARRASI R, DAMIANO V, RUGGIERO A, MORELLI D, CARAGLIA M, BIANCO R, DI ISERNIA G, PEPE S, ARTEAGA CL, LANGTON-WEBSTER BC, BIANCO AR, CIARDIELLO F. DIFFERENTIAL SENSITIVITY TO NON-MAJOR HISTOCOMPATIBILITY COMPLEX-RESTRICTED RECOMBINANT INTERLEUKIN 2-ACTIVATED LYMPHOCYTE KILLING OF HUMAN MAMMARY EPITHELIAL MCF-10A CELLS OVEREXPRESSING ONCOGENES OR PROTEIN KINASE A SUBUNITS. CLIN CANCER RES. 1996 JAN;2(1):207-14. PUBMED PMID: 9816108. IF 8.738 CIT. 2
361. GIUNCIUGLIO D, CULTY M, FASSINA G, MASIELLO L, MELCHIORI A, PAGLIALUNGA G, ARAND G, CIARDIELLO F, BASOLO F, THOMPSON EW, ET AL. INVASIVE PHENOTYPE OF MCF10A CELLS OVEREXPRESSING C-HA-RAS AND C-ERBB-2 ONCOGENES. INT J CANCER. 1995 DEC 11;63(6):815-22. PUBMED PMID: 8847140. IF 5.531 CIT. 93
362. NORMANNO N, SELVAM MP, BIANCO C, DAMIANO V, DE ANGELIS E, GRASSI M, MAGLIULO G, TORTORA G, SALOMON DS, CIARDIELLO F. AMPHIREGULIN ANTI-SENSE OLIGODEOXYNUCLEOTIDES INHIBIT GROWTH AND TRANSFORMATION OF A HUMAN COLON CARCINOMA CELL LINE. INT J CANCER. 1995 SEP 15;62(6):762-6. PUBMED PMID: 7558427. IF 5.531 CIT. 31
363. NORMANNO N, KIM N, WEN D, SMITH K, HARRIS AL, PLOWMAN G, COLLETTA G, CIARDIELLO F, SALOMON DS. EXPRESSION OF MESSENGER RNA FOR AMPHIREGULIN, HEREGULIN, AND CRIPTO-1, THREE NEW MEMBERS OF THE EPIDERMAL GROWTH FACTOR FAMILY, IN HUMAN BREAST CARCINOMAS. BREAST CANCER RES TREAT. 1995 SEP;35(3):293-7. PUBMED PMID: 7579500. IF 4.085 CIT. 81
364. DAMIANO V, DIISERNIA G, CIARDIELLO F, PEPE S, BIANCO A, BIANCO C, RUGGIERO A, BALDASSARRE G, MERLO G, TORTORA G. OVEREXPRESSION OF WILD-TYPE P53 OVERRIDES THE MITOGENIC EFFECT OF RI-ALPHA SUBUNIT OF PROTEIN-KINASE-A IN HUMAN BREAST CELLS. INT J ONCOL. 1995 AUG;7(2):331-6. PUBMED PMID: 21552843. IF 3.018
365. SALOMON DS, BRANDT R, CIARDIELLO F, NORMANNO N. EPIDERMAL GROWTH FACTOR-RELATED PEPTIDES AND THEIR RECEPTORS IN HUMAN MALIGNANCIES. CRIT REV ONCOL HEMATOL. 1995 JUL;19(3):183-232. REVIEW. PUBMED PMID: 7612182. IF 5.039 CIT. 2801

366. CARAGLIA M, LEARDI A, CORRADINO S, CIARDIELLO F, BUDILLON A, GUARRASI R, BIANCO AR, TAGLIAFERRI P. ALPHA-INTERFERON POTENTIATES EPIDERMAL GROWTH FACTOR RECEPTOR-MEDIATED EFFECTS ON HUMAN EPIDERMAL CARCINOMA KB CELLS. INT J CANCER. 1995 MAY 4;61(3):342-7. PUBMED PMID: 7729946. IF 5.531 CIT. 42
367. TAGLIAFERRI P, MATANO E, REA A, FAMIANI M, CIARDIELLO F, TORTORA G, MONTESARCHIO V, MORABITO A, CARAGLIA M, DELAURENTIIS M, DEPLACIDO S, PALMIERI G, BIANCO A. MITOXANTRONE, ETOPOSIDE AND BLEOMYCIN (MEB) CHEMOTHERAPY IN NON-HODGKINS-LYMPHOMA PATIENTS NON-ELEGIBLE FOR STANDARD CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) COMBINATION. ONCOL REP. 1995 MAY;2(3):365-8. PUBMED PMID: 21597742. IF 2.486
368. TORTORA G, CIARDIELLO F, PEPE S, TAGLIAFERRI P, RUGGIERO A, BIANCO C, GUARRASI R, MIKI K, BIANCO AR. PHASE I CLINICAL STUDY WITH 8-CHLORO-CAMP AND EVALUATION OF IMMUNOLOGICAL EFFECTS IN CANCER PATIENTS. CLIN CANCER RES. 1995 APR;1(4):377-84. PUBMED PMID: 9815994. IF 8.738 CIT. 72
369. CALIGO MA, CIPOLLINI G, FIORE L, CALVO S, BASOLO F, COLLECCHI P, CIARDIELLO F, PEPE S, PETRINI M, BEVILACQUA G. NM23 GENE EXPRESSION CORRELATES WITH CELL GROWTH RATE AND S-PHASE. INT J CANCER. 1995 MAR 16;60(6):837-42. PUBMED PMID: 7896455. IF 5.531 CIT. 85
370. CIARDIELLO F, DAMIANO V, BIANCO C, DI ISERNIA G, RUGGIERO A, CARAGLIA M, TAGLIAFERRI P, BASELGA J, MENDELSON J, BIANCO AR, ET AL. COOPERATIVE ANTIPROLIFERATIVE EFFECTS OF 8-CHLORO-CYCLIC AMP AND 528 ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR MONOCLONAL ANTIBODY ON HUMAN CANCER CELLS. CLIN CANCER RES. 1995 FEB;1(2):161-7. PUBMED PMID: 9815969. IF 8.738 CIT. 22
371. TORTORA G, CIARDIELLO F, DAMIANO V, PEPE S, BIANCO C, DI ISERNIA G, DAVIES SL, NORTH P, HARRIS AL, HICKSON ID, ET AL. CYCLIC AMP-DEPENDENT PROTEIN KINASE TYPE I IS INVOLVED IN HYPERSENSITIVITY OF HUMAN BREAST CELLS TO TOPOISOMERASE II INHIBITORS. CLIN CANCER RES. 1995 JAN;1(1):49-56. PUBMED PMID: 9815886. IF 8.738 CIT. 9
372. SALOMON DS, NORMANNO N, CIARDIELLO F, BRANDT R, SHOYAB M, TODARO GJ. THE ROLE OF AMPHIREGULIN IN BREAST CANCER. BREAST CANCER RES TREAT. 1995;33(2):103-14. REVIEW. PUBMED PMID: 7749138. IF 4.085 CIT. 66
373. TORTORA G, PEPE S, BIANCO C, DAMIANO V, RUGGIERO A, BALDASSARRE G, CORBO C, CHO-CHUNG YS, BIANCO AR, CIARDIELLO F. DIFFERENTIAL EFFECTS OF PROTEIN KINASE A SUB-UNITS ON CHINESE-HAMSTER-OVARY CELL CYCLE AND PROLIFERATION. INT J CANCER. 1994 DEC 1;59(5):712-6. PUBMED PMID: 7960245. IF 5.531 CIT. 36
374. TORTORA G, PEPE S, BIANCO C, BALDASSARRE G, BUDILLON A, CLAIR T, CHO-CHUNG YS, BIANCO AR, CIARDIELLO F. THE RI ALPHA SUBUNIT OF PROTEIN KINASE A CONTROLS SERUM DEPENDENCY AND ENTRY INTO CELL CYCLE OF HUMAN MAMMARY EPITHELIAL CELLS. ONCOGENE. 1994 NOV;9(11):3233-40. PUBMED PMID: 7936647. IF 7.932 CIT. 77
375. SABBATINI AR, BASOLO F, VALENTINI P, MATTII L, CALVO S, FIORE L, CIARDIELLO F, PETRINI M. INDUCTION OF MULTIDRUG RESISTANCE (MDR) BY TRANSFECTION OF MCF-10A CELL LINE WITH C-HA-RAS AND C-ERBB-2 ONCOGENES. INT J CANCER. 1994 OCT 15;59(2):208-11. PUBMED PMID: 7927921. IF 5.531 CIT. 27
376. NORTH PS, DAVIES SL, CIARDIELLO F, DAMIANO V, BIANCO C, PEPE S, BIANCO AR, HARRIS AL, HICKSON ID, TORTORA G. OVEREXPRESSION OF THE RI ALPHA SUBUNIT OF PROTEIN KINASE A CONFERS HYPERSENSITIVITY TO TOPOISOMERASE II INHIBITORS AND 8-CHLORO-CYCLIC ADENOSINE 3'5'-MONOPHOSPHATE IN CHINESE HAMSTER OVARY CELLS. CANCER RES. 1994 AUG 1;54(15):4123-8. PUBMED PMID: 7518350. IF 8.556 CIT. 13
377. BRANDT R, NORMANNO N, GULLICK WJ, LIN JH, HARKINS R, SCHNEIDER D, JONES BW, CIARDIELLO F, PERSICO MG, ARMENANTE F, ET AL. IDENTIFICATION AND BIOLOGICAL CHARACTERIZATION OF AN EPIDERMAL GROWTH FACTOR-RELATED PROTEIN: CRIPTO-1. J BIOL CHEM. 1994 JUN 24;269(25):17320-8. PUBMED PMID: 8006041. IF 4.258 CIT. 103
378. BASOLO F, VENESIO T, CALVO S, FIORE L, FONTANINI G, CIARDIELLO F, TONIOLO A, LISCIA D, MERLO G. THE EFFECT OF FGF-3 INT-2 ON GROWTH AND TRANSFORMATION OF MCF-10A NORMAL

- HUMAN MAMMARY EPITHELIAL-CELLS IS DISTINCT FROM FGF-1 AND FGF-2. INT J ONCOL. 1994 JUN;4(6):1365-70. PUBMED PMID: 21567063. IF 3.018 CIT. 3
379. BIANCO C, TORTORA G, BASOLO F, FIORE L, FONTANINI G, MERLO G, SALOMON D, BIANCO A, CIARDIELLO F. EFFECTS OF MUTANT P53 GENES ON TRANSFORMATION OF HUMAN MAMMARY EPITHELIAL-CELLS. INT J ONCOL. 1994 MAY;4(5):1077-82. PUBMED PMID: 21567022. IF 3.018 CIT. 7
380. QI CF, LISCIA DS, NORMANNO N, MERLO G, JOHNSON GR, GULLICK WJ, CIARDIELLO F, SAEKI T, BRANDT R, KIM N, ET AL. EXPRESSION OF TRANSFORMING GROWTH FACTOR ALPHA, AMPHIREGULIN AND CRIPTO-1 IN HUMAN BREAST CARCINOMAS. BR J CANCER. 1994 MAY;69(5):903-10. PUBMED PMID: 8180021; PUBMED CENTRAL PMCID: PMC1968887. IF 5.569 CIT. 132
381. NORMANNO N, SELVAM MP, QI CF, SAEKI T, JOHNSON G, KIM N, CIARDIELLO F, SHOYAB M, PLOWMAN G, BRANDT R, ET AL. AMPHIREGULIN AS AN AUTOCRINE GROWTH FACTOR FOR C-HA-RAS- AND C-ERBB-2-TRANSFORMED HUMAN MAMMARY EPITHELIAL CELLS. PROC NATL ACAD SCI U S A. 1994 MAR 29;91(7):2790-4. PUBMED PMID: 7908443; PUBMED CENTRAL PMCID: PMC43456. IF 9.674 CIT. 99
382. TAGLIAFERRI P, CORREALE P, MOTTOLA M, DESIMONE G, REA A, ASCIONE R, MORABITO A, MATANO E, MONTESARCHIO V, CARAGLIA M, TORTORA G, CIARDIELLO F, BARILE C, PALMIERI G, BIANCO A. CARDIOVASCULAR MONITORING OF DRUG-RESISTANT LYMPHOMA PATIENTS TREATED WITH EPOCH CHEMOTHERAPY PLUS HIGH-DOSE VERAPAMIL IN CONTINUOUS-INFUSION. ONCOL REP. 1994 MAR;1(2):341-4. PUBMED PMID: 21607361. IF 2.486 CIT. 2
383. BASOLO F, FIORE L, CIARDIELLO F, CALVO S, FONTANINI G, CONALDI PG, TONIOLO A. RESPONSE OF NORMAL AND ONCOGENE-TRANSFORMED HUMAN MAMMARY EPITHELIAL CELLS TO TRANSFORMING GROWTH FACTOR BETA 1 (TGF-BETA 1): LACK OF GROWTH-INHIBITORY EFFECT ON CELLS EXPRESSING THE SIMIAN VIRUS 40 LARGE-T ANTIGEN. INT J CANCER. 1994 MAR 1;56(5):736-42. PUBMED PMID: 8314352. IF 5.531 CIT. 28
384. CIARDIELLO F, TORTORA G, BIANCO C, SELVAM MP, BASOLO F, FONTANINI G, PACIFICO F, NORMANNO N, BRANDT R, PERSICO MG, ET AL. INHIBITION OF CRIPTO EXPRESSION AND TUMORIGENICITY IN HUMAN COLON CANCER CELLS BY ANTISENSE RNA AND OLIGODEOXYNUCLEOTIDES. ONCOGENE. 1994 JAN;9(1):291-8. PUBMED PMID: 8302592. IF 7.932 CIT. 76
385. PEPE S, RUGGIERO A, TORTORA G, CIARDIELLO F, GARBI C, YOKOZAKI H, CHO-CHUNG YS, CLAIR T, SKALHEGG BS, BIANCO AR. FLOW-CYTOMETRIC DETECTION OF THE RI ALPHA SUBUNIT OF TYPE I CAMP-DEPENDENT PROTEIN KINASE IN HUMAN CELLS. CYTOMETRY. 1994 JAN 1;15(1):73-9. PUBMED PMID: 8162827. IF 3.181 CIT. 104
386. NORMANNO N, CIARDIELLO F, BRANDT R, SALOMON DS. EPIDERMAL GROWTH FACTOR-RELATED PEPTIDES IN THE PATHOGENESIS OF HUMAN BREAST CANCER. BREAST CANCER RES TREAT. 1994 JAN;29(1):11-27. REVIEW. PUBMED PMID: 7912564. IF 4.085 CIT. 109
387. CIARDIELLO F, TORTORA G, PEPE S, BIANCO C, BALDASSARRE G, RUGGIERO A, BIANCO C, SELVAM MP, BIANCO AR. REDUCTION OF RI ALPHA SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE EXPRESSION INDUCES GROWTH INHIBITION OF HUMAN MAMMARY EPITHELIAL CELLS TRANSFORMED BY TGF-ALPHA, C-HA-RAS, AND C-ERBB-2 GENES. ANN N Y ACAD SCI. 1993 NOV 30; 698:102-7. PUBMED PMID: 7904135. IF 4.518 CIT. 5
388. MINCIONE G, CIRAFICI AM, LAZZARESCHI D, PEPE S, CIARDIELLO F, COLLETTA G. LOSS OF THYROTROPIN REGULATION AND TRANSFORMING GROWTH FACTOR BETA-INDUCED GROWTH ARREST IN ERBB-2 OVEREXPRESSIONING RAT THYROID CELLS. CANCER RES. 1993 NOV 15;53(22):5548-53. PUBMED PMID: 8106149. IF 8.556 CIT. 13
389. KENNEY NJ, SAEKI T, GOTTARDIS M, KIM N, GARCIA-MORALES P, MARTIN MB, NORMANNO N, CIARDIELLO F, DAY A, CUTLER ML, ET AL. EXPRESSION OF TRANSFORMING GROWTH FACTOR ALPHA ANTISENSE MRNA INHIBITS THE ESTROGEN-INDUCED PRODUCTION OF TGF ALPHA AND ESTROGEN-INDUCED PROLIFERATION OF ESTROGEN-RESPONSIVE HUMAN BREAST CANCER CELLS. J CELL PHYSIOL. 1993 SEP;156(3):497-514. PUBMED PMID: 8360257. IF 4.155 CIT. 66
390. CIARDIELLO F, BIANCO C, NORMANNO N, BALDASSARRE G, PEPE S, TORTORA G, BIANCO AR, SALOMON DS. INFECTION WITH A TRANSFORMING GROWTH FACTOR ALPHA ANTI-SENSE RETROVIRAL EXPRESSION VECTOR REDUCES THE IN VITRO GROWTH AND TRANSFORMATION OF A

HUMAN COLON CANCER CELL LINE. INT J CANCER. 1993 JUL 30;54(6):952-8. PUBMED PMID: 8335403. IF 5.531 CIT. 31

391. TORTORA G, PEPE S, CIRAFICI AM, CIARDIELLO F, PORCELLINI A, CLAIR T, COLLETTA G, CHO-CHUNG YS, BIANCO AR. THYROID-STIMULATING HORMONE-REGULATED GROWTH AND CELL CYCLE DISTRIBUTION OF THYROID CELLS INVOLVE TYPE I ISOZYME OF CYCLIC AMP-DEPENDENT PROTEIN KINASE. CELL GROWTH DIFFER. 1993 MAY;4(5):359-65. PUBMED PMID: 8518230. IF 3.620 CIT. 25
392. CIARDIELLO F, PEPE S, BIANCO C, BALDASSARRE G, RUGGIERO A, BIANCO C, SELVAM MP, BIANCO AR, TORTORA G. DOWN-REGULATION OF RI ALPHA SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE INDUCES GROWTH INHIBITION OF HUMAN MAMMARY EPITHELIAL CELLS TRANSFORMED BY C-HA-RAS AND C-ERBB-2 PROTO-ONCOGENES. INT J CANCER. 1993 FEB 1;53(3):438-43. PUBMED PMID: 8094073. IF 5.531 CIT. 52
393. BASOLO F, SERRA C, CIARDIELLO F, FIORE L, RUSSO J, CAMPANI D, DOLEI A, SQUARTINI F, TONIOLO A. REGULATION OF SURFACE-DIFFERENTIATION MOLECULES BY EPIDERMAL GROWTH FACTOR, TRANSFORMING GROWTH FACTOR ALPHA, AND HYDROCORTISONE IN HUMAN MAMMARY EPITHELIAL CELLS TRANSFORMED BY AN ACTIVATED C-HA-RAS PROTO-ONCOGENE. INT J CANCER. 1992 JUN 19;51(4):634-40. PUBMED PMID: 1601524. IF 5.531 CIT. 18
394. SAEKI T, STROMBERG K, QI CF, GULLICK WJ, TAHARA E, NORMANNO N, CIARDIELLO F, KENNEY N, JOHNSON GR, SALOMON DS. DIFFERENTIAL IMMUNOHISTOCHEMICAL DETECTION OF AMPHIREGULIN AND CRIPTO IN HUMAN NORMAL COLON AND COLORECTAL TUMORS. CANCER RES. 1992 JUN 15;52(12):3467-73. PUBMED PMID: 1596904. IF 8.556 CIT. 134
395. VENESIO T, TAVERNA D, HYNES NE, DEED R, MACALLAN D, CIARDIELLO F, VALVERIUS EM, SALOMON DS, CALLAHAN R, MERLO G. THE INT-2 GENE PRODUCT ACTS AS A GROWTH FACTOR AND SUBSTITUTES FOR BASIC FIBROBLAST GROWTH FACTOR IN PROMOTING THE DIFFERENTIATION OF A NORMAL MOUSE MAMMARY EPITHELIAL CELL LINE. CELL GROWTH DIFFER. 1992 JAN;3(1):63-71. PUBMED PMID: 1376141. IF 3.620 CIT. 15
396. CIARDIELLO F, GOTTARDIS M, BASOLO F, PEPE S, NORMANNO N, DICKSON RB, BIANCO AR, SALOMON DS. ADDITIVE EFFECTS OF C-ERBB-2, C-HA-RAS, AND TRANSFORMING GROWTH FACTOR-ALPHA GENES ON IN VITRO TRANSFORMATION OF HUMAN MAMMARY EPITHELIAL CELLS. MOL CARCINOGEN. 1992;6(1):43-52. PUBMED PMID: 1354442. IF 4.722 CIT. 80
397. SAEKI T, CRISTIANO A, LYNCH MJ, BRATTAIN M, KIM N, NORMANNO N, KENNEY N, CIARDIELLO F, SALOMON DS. REGULATION BY ESTROGEN THROUGH THE 5'-FLANKING REGION OF THE TRANSFORMING GROWTH FACTOR ALPHA GENE. MOL ENDOCRINOL. 1991 DEC;5(12):1955-63. PUBMED PMID: 1791840. IF 3.432 CIT. 82
398. KUNIYASU H, YOSHIDA K, YOKOZAKI H, YASUI W, ITO H, TOGE T, CIARDIELLO F, PERSICO MG, SAEKI T, SALOMON DS, ET AL. EXPRESSION OF CRIPTO, A NOVEL GENE OF THE EPIDERMAL GROWTH FACTOR FAMILY, IN HUMAN GASTROINTESTINAL CARCINOMAS. JPN J CANCER RES. 1991 SEP;82(9):969-73. PUBMED PMID: 1938601. IF 1.580 CIT. 116
399. CIARDIELLO F, KIM N, SAEKI T, DONO R, PERSICO MG, PLOWMAN GD, GARRIGUES J, RADKE S, TODARO GJ, SALOMON DS. DIFFERENTIAL EXPRESSION OF EPIDERMAL GROWTH FACTOR-RELATED PROTEINS IN HUMAN COLORECTAL TUMORS. PROC NATL ACAD SCI U S A. 1991 SEP 1;88(17):7792-6. PUBMED PMID: 1715580; PUBMED CENTRAL PMCID: PMC52389. IF 9.674 CIT. 248
400. COLLETTA G, CIRAFICI AM, DI CARLO A, CIARDIELLO F, SALOMON DS, VECCHIO G. CONSTITUTIVE EXPRESSION OF TRANSFORMING GROWTH FACTOR ALPHA DOES NOT TRANSFORM RAT THYROID EPITHELIAL CELLS. ONCOGENE. 1991 APR;6(4):583-7. PUBMED PMID: 1709483. IF 7.932 CIT. 12
401. CIARDIELLO F, KIM N, MCGEADY ML, LISCIA DS, SAEKI T, BIANCO C, SALOMON DS. EXPRESSION OF TRANSFORMING GROWTH FACTOR ALPHA (TGF ALPHA) IN BREAST CANCER. ANN ONCOL. 1991 MAR;2(3):169-82. REVIEW. PUBMED PMID: 2043488. IF 9.269 CIT. 132
402. CIARDIELLO F, DONO R, KIM N, PERSICO MG, SALOMON DS. EXPRESSION OF CRIPTO, A NOVEL GENE OF THE EPIDERMAL GROWTH FACTOR GENE FAMILY, LEADS TO IN VITRO TRANSFORMATION OF A NORMAL MOUSE MAMMARY EPITHELIAL CELL LINE. CANCER RES. 1991 FEB 1;51(3):1051-4. PUBMED PMID: 1846316. IF 8.556 CIT. 116

403. SALOMON DS, CIARDIELLO F, VALVERIUS EM, KIM N. THE ROLE OF RAS GENE EXPRESSION AND TRANSFORMING GROWTH FACTOR ALPHA PRODUCTION IN THE ETIOLOGY AND PROGRESSION OF RODENT AND HUMAN BREAST CANCER. *CANCER TREAT RES.* 1991; 53:107-57. REVIEW. PUBMED PMID: 1672074. IF 7.983 CIT. 9
404. SALOMON DS, KIM N, SAEKI T, CIARDIELLO F. TRANSFORMING GROWTH FACTOR-ALPHA: AN ONCODEVELOPMENTAL GROWTH FACTOR. *CANCER CELLS.* 1990 DEC;2(12):389-97. REVIEW. PUBMED PMID: 2088454. IF 23.214 CIT. 117
405. VALVERIUS EM, CIARDIELLO F, HELDIN NE, BLONDEL B, MERLO G, SMITH G, STAMPFER MR, LIPPMAN ME, DICKSON RB, SALOMON DS. STROMAL INFLUENCES ON TRANSFORMATION OF HUMAN MAMMARY EPITHELIAL CELLS OVEREXPRESSING C-MYC AND SV40T. *J CELL PHYSIOL.* 1990 NOV;145(2):207-16. PUBMED PMID: 2174061. IF 4.155 CIT. 58
406. VALVERIUS EM, VELU T, SHANKAR V, CIARDIELLO F, KIM N, SALOMON DS. OVER-EXPRESSION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN HUMAN BREAST CANCER CELLS FAILS TO INDUCE AN ESTROGEN-INDEPENDENT PHENOTYPE. *INT J CANCER.* 1990 OCT 15;46(4):712-8. PUBMED PMID: 1698733. IF 5.531 CIT. 33
407. MERLO GR, BLONDEL BJ, DEED R, MACALLAN D, PETERS G, DICKSON C, LISCIA DS, CIARDIELLO F, VALVERIUS EM, SALOMON DS, ET AL. THE MOUSE INT-2 GENE EXHIBITS BASIC FIBROBLAST GROWTH FACTOR ACTIVITY IN A BASIC FIBROBLAST GROWTH FACTOR-RESPONSIVE CELL LINE. *CELL GROWTH DIFFER.* 1990 OCT;1(10):463-72. PUBMED PMID: 2278877. IF 3.620 CIT. 17
408. CIARDIELLO F, MCGEADY ML, KIM N, BASOLO F, HYNES N, LANGTON BC, YOKOZAKI H, SAEKI T, ELLIOTT JW, MASUI H, ET AL. TRANSFORMING GROWTH FACTOR-ALPHA EXPRESSION IS ENHANCED IN HUMAN MAMMARY EPITHELIAL CELLS TRANSFORMED BY AN ACTIVATED C-HA-RAS PROTOONCOGENE BUT NOT BY THE C-NEU PROTOONCOGENE, AND OVEREXPRESSION OF THE TRANSFORMING GROWTH FACTOR-ALPHA COMPLEMENTARY DNA LEADS TO TRANSFORMATION. *CELL GROWTH DIFFER.* 1990 SEP;1(9):407-20. PUBMED PMID: 1981145. IF 3.620 CIT. 100
409. YANAGIHARA K, CIARDIELLO F, TALBOT N, MCGEADY ML, COOPER H, BENADE L, SALOMON DS, BASSIN RH. ISOLATION OF A NEW CLASS OF 'FLAT' REVERTANTS FROM RAS-TRANSFORMED NIH3T3 CELLS USING CIS-4-HYDROXY-L-PROLINE. *ONCOGENE.* 1990 AUG;5(8):1179-86. PUBMED PMID: 2202950. IF 7.932 CIT. 17
410. HYNES NE, TAVERNA D, HARWERTH IM, CIARDIELLO F, SALOMON DS, YAMAMOTO T, GRONER B. EPIDERMAL GROWTH FACTOR RECEPTOR, BUT NOT C-ERBB-2, ACTIVATION PREVENTS LACTOGENIC HORMONE INDUCTION OF THE BETA-CASEIN GENE IN MOUSE MAMMARY EPITHELIAL CELLS. *MOL CELL BIOL.* 1990 AUG;10(8):4027-34. PUBMED PMID: 2196443; PUBMED CENTRAL PMCID: PMC360913. IF 4.427 CIT. 134
411. LISCIA DS, MERLO G, CIARDIELLO F, KIM N, SMITH GH, CALLAHAN R, SALOMON DS. TRANSFORMING GROWTH FACTOR-ALPHA MESSENGER RNA LOCALIZATION IN THE DEVELOPING ADULT RAT AND HUMAN MAMMARY GLAND BY IN SITU HYBRIDIZATION. *DEV BIOL.* 1990 JUL;140(1):123-31. PUBMED PMID: 2358112. IF 3.155 CIT. 86
412. CIARDIELLO F, TORTORA G, KIM N, CLAIR T, ALLY S, SALOMON DS, CHO-CHUNG YS. 8-CHLORO-CAMP INHIBITS TRANSFORMING GROWTH FACTOR ALPHA TRANSFORMATION OF MAMMARY EPITHELIAL CELLS BY RESTORATION OF THE NORMAL MRNA PATTERNS FOR CAMP-DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT ISOFORMS WHICH SHOW DISRUPTION UPON TRANSFORMATION. *J BIOL CHEM.* 1990 JAN 15;265(2):1016-20. PUBMED PMID: 1688548. IF 4.258 CIT. 69
413. CIARDIELLO F, VALVERIUS EM, COLUCCI-D'AMATO GL, KIM N, BASSIN RH, SALOMON DS. DIFFERENTIAL GROWTH FACTOR EXPRESSION IN TRANSFORMED MOUSE NIH-3T3 CELLS. *J CELL BIOCHEM.* 1990 JAN;42(1):45-57. PUBMED PMID: 1967612. IF 3.446 CIT. 31
414. MCGEADY ML, KERBY S, SHANKAR V, CIARDIELLO F, SALOMON D, SEIDMAN M. INFECTION WITH A TGF-ALPHA RETROVIRAL VECTOR TRANSFORMS NORMAL MOUSE MAMMARY EPITHELIAL CELLS BUT NOT NORMAL RAT FIBROBLASTS. *ONCOGENE.* 1989 NOV;4(11):1375-82. PUBMED PMID: 2812779. IF 7.932 CIT. 75
415. CIARDIELLO F, KIM N, LISCIA DS, BIANCO C, LIDEREAU R, MERLO G, CALLAHAN R, GREINER J, SZPAK C, KIDWELL W, ET AL. MRNA EXPRESSION OF TRANSFORMING GROWTH FACTOR ALPHA IN HUMAN

BREAST CARCINOMAS AND ITS ACTIVITY IN EFFUSIONS OF BREAST CANCER PATIENTS. J NATL CANCER INST. 1989 AUG 2;81(15):1165-71. PUBMED PMID: 2545892. IF 12.583 CIT. 31

416. CIARDIELLO F, HYNES N, KIM N, VALVERIUS EM, LIPPMAN ME, SALOMON DS. TRANSFORMATION OF MOUSE MAMMARY EPITHELIAL CELLS WITH THE HA-RAS BUT NOT WITH THE NEU ONCOGENE RESULTS IN A GENE DOSAGE-DEPENDENT INCREASE IN TRANSFORMING GROWTH FACTOR-ALPHA PRODUCTION. FEBS LETT. 1989 JUL 3;250(2):474-8. PUBMED PMID: 2568949. IF 3.519 CIT. 21
417. TORTORA G, CIARDIELLO F, ALLY S, CLAIR T, SALOMON DS, CHO-CHUNG YS. SITE-SELECTIVE 8-CHLOROADENOSINE 3',5'-CYCLIC MONOPHOSPHATE INHIBITS TRANSFORMATION AND TRANSFORMING GROWTH FACTOR ALPHA PRODUCTION IN KI-RAS-TRANSFORMED RAT FIBROBLASTS. FEBS LETT. 1989 JAN 2;242(2):363-7. PUBMED PMID: 2536620. IF 3.519 CIT. 57
418. SHANKAR V, CIARDIELLO F, KIM N, DERYNCK R, LISCIA DS, MERLO G, LANGTON BC, SHEER D, CALLAHAN R, BASSIN RH, ET AL. TRANSFORMATION OF AN ESTABLISHED MOUSE MAMMARY EPITHELIAL CELL LINE FOLLOWING TRANSFECTION WITH A HUMAN TRANSFORMING GROWTH FACTOR ALPHA CDNA. MOL CARCINOG. 1989;2(1):1-11. PUBMED PMID: 2786419. IF 4.722 CIT. 77
419. SALOMON DS, KIDWELL WR, KIM N, CIARDIELLO F, BATES SE, VALVERIUS E, LIPPMAN ME, DICKSON RB, STAMPFER M. MODULATION BY ESTROGEN AND GROWTH FACTORS OF TRANSFORMING GROWTH FACTOR-ALPHA AND EPIDERMAL GROWTH FACTOR RECEPTOR EXPRESSION IN NORMAL AND MALIGNANT HUMAN MAMMARY EPITHELIAL CELLS. RECENT RESULTS CANCER RES. 1989; 113:57-69. PUBMED PMID: 2756237. IF 12.798 CIT. 39
420. SALOMON DS, CIARDIELLO F, VALVERIUS E, SAEKI T, KIM N. TRANSFORMING GROWTH FACTORS IN HUMAN BREAST CANCER. BIOMED PHARMACOTHER. 1989;43(9):661-7. PUBMED PMID: 2624883. IF 2.326 CIT. 109
421. CIARDIELLO F, KIM N, HYNES N, JAGGI R, REDMOND S, LISCIA DS, SANFILIPPO B, MERLO G, CALLAHAN R, KIDWELL WR, ET AL. INDUCTION OF TRANSFORMING GROWTH FACTOR ALPHA EXPRESSION IN MOUSE MAMMARY EPITHELIAL CELLS AFTER TRANSFORMATION WITH A POINT-MUTATED C-HA-RAS PROTOONCOGENE. MOL ENDOCRINOL. 1988 DEC;2(12):1202-16. PUBMED PMID: 3063955. IF 3.432 CIT. 56
422. CIARDIELLO F, SANFILIPPO B, YANAGIHARA K, KIM N, TORTORA G, BASSIN RH, KIDWELL WR, SALOMON DS. DIFFERENTIAL GROWTH SENSITIVITY TO 4-CIS-HYDROXY-L-PROLINE OF TRANSFORMED RODENT CELL LINES. CANCER RES. 1988 MAY 1;48(9):2483-91. PUBMED PMID: 2833347. IF 8.556 CIT. 12
423. SANFILIPPO B, CIARDIELLO F, SALOMON DS, KIDWELL WR. GROWTH OF CELLS ON A PERFLUOROCARBON-MEDIUM INTERPHASE: A QUANTITATIVE ASSAY FOR ANCHORAGE-INDEPENDENT CELL GROWTH. IN VITRO CELL DEV BIOL. 1988 JAN;24(1):71-8. PUBMED PMID: 3422228. IF 1.385 CIT. 14
424. IAFFAIOLI RV, FRASCI G, TORTORA G, CIARDIELLO F, NUZZO F, SCALA S, PACELLI R, BIANCO AR. EFFECT OF THYMIC EXTRACT 'THYMOSTIMULIN' ON THE INCIDENCE OF INFECTIONS AND MYELOTOKICITY DURING ADJUVANT CHEMOTHERAPY FOR BREAST CANCER. THYMUS. 1988-1989;12(2):69-75. PUBMED PMID: 3150630. CIT. 17
425. BHATTACHARYA B, CIARDIELLO F, SALOMON DS, COOPER HL. DISORDERED METABOLISM OF MICROFILAMENT PROTEINS, TROPOMYOSIN AND ACTIN, IN MOUSE MAMMARY EPITHELIAL CELLS EXPRESSING THE HA-RAS ONCOGENE. ONCOGENE RES. 1988;3(1):51-65. PUBMED PMID: 3060798. IF 7.932 CIT. 15
426. TAGLIAFERRI P, YANAGIHARA K, CIARDIELLO F, TALBOT N, FLATOW U, BENADE L, BASSIN RH. EFFECTS OF OUABAIN ON NIH/3T3 CELLS TRANSFORMED WITH RETROVIRAL ONCOGENES AND ON HUMAN TUMOR CELL LINES. INT J CANCER. 1987 NOV 15;40(5):653-8. PUBMED PMID: 3679592. IF 5.531 CIT. 10

Autorizzo il trattamento dei miei dati personali in accordo con il DI 196/2003 e successivi aggiornamenti.

Fortunato Ciardiello

A handwritten signature in black ink, appearing to read 'Fortunato Ciardiello', written in a cursive style.